<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="1121"><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy</ProtocolTitle><Sponsor>Kitov Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="199314"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>152</Patients><Biomarkers>Creatinine; Diastolic blood pressure; Systolic blood pressure</Biomarkers><Condition>Hypertension</Condition><Controls>amlodipine; celecoxib</Controls><EnrollmentCount>152</EnrollmentCount><Interventions>KIT-302</Interventions><Reference>2013-005381-19; KIT-302-03-01; NCT02172040</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Shinbaro Capsule</ProtocolTitle><Sponsor>GC Pharma</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85152"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>198</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>198</EnrollmentCount><Interventions>Sinbaro</Interventions><Reference>GCSB_P3; NCT01535417</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple Dose Study of LY-3031207 in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="89267"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Prostacyclin I; Prostaglandin E; Thromboxane A</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>LY-3031207; LY-3031207; simvastatin</Interventions><Reference>14284; I5W-EW-LBCB; NCT01632566</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-Dental Surgery Pain, Compared to Both Placebo and Celecoxib</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12720"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>364</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>364</EnrollmentCount><Interventions>lumiracoxib</Interventions><Reference>CCOX189A2474; NCT00348491</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I</ProtocolTitle><Sponsor>Wyeth</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="19977"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>650</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>650</EnrollmentCount><Interventions>TDS-943</Interventions><Reference>NCT00546507; TD-06-13</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>FACT OA2</ProtocolAcronym><ProtocolTitle>Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="315360"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1650</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; diclofenac</Controls><EnrollmentCount>1650</EnrollmentCount><Interventions>fasinumab</Interventions><Reference>2017-001702-15; FACT OA2; NCT03304379; R475-OA-1688</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial of YYC-301 for Treatment of Osteoarthritis of the Knee</ProtocolTitle><Sponsor>YooYoung Pharmaceuticals Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="371129"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>252</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>YYC-301; celecoxib</Controls><EnrollmentCount>252</EnrollmentCount><Interventions>YYC-301</Interventions><Reference>NCT03850587; YYPCT_YYC301_P2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of LY-3023703 Testing Pain Relief After Wisdom Teeth Removal</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="138174"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>124</Patients><Biomarkers>Prostaglandin E</Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>124</EnrollmentCount><Interventions>LY-3023703</Interventions><Reference>14852; I6H-MC-MCBC; NCT01872910</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="171349"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Epstein-Barr virus (EBV) transformed lymphocytes (B cells); T regulatory cells</Biomarkers><Condition>Esophagus tumor</Condition><Controls>H-1299</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>H-1299; celecoxib; cyclophosphamide</Interventions><Reference>14-C-0053; 140053; NCT02054104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="171349"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Epstein-Barr virus (EBV) transformed lymphocytes (B cells); T regulatory cells</Biomarkers><Condition>Mesothelioma</Condition><Controls>H-1299</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>H-1299; celecoxib; cyclophosphamide</Interventions><Reference>14-C-0053; 140053; NCT02054104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="171349"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Epstein-Barr virus (EBV) transformed lymphocytes (B cells); T regulatory cells</Biomarkers><Condition>Sarcoma</Condition><Controls>H-1299</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>H-1299; celecoxib; cyclophosphamide</Interventions><Reference>14-C-0053; 140053; NCT02054104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="171349"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Epstein-Barr virus (EBV) transformed lymphocytes (B cells); T regulatory cells</Biomarkers><Condition>Melanoma</Condition><Controls>H-1299</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>H-1299; celecoxib; cyclophosphamide</Interventions><Reference>14-C-0053; 140053; NCT02054104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="171349"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Epstein-Barr virus (EBV) transformed lymphocytes (B cells); T regulatory cells</Biomarkers><Condition>Thymus neoplasm</Condition><Controls>H-1299</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>H-1299; celecoxib; cyclophosphamide</Interventions><Reference>14-C-0053; 140053; NCT02054104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="171349"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Epstein-Barr virus (EBV) transformed lymphocytes (B cells); T regulatory cells</Biomarkers><Condition>Lung tumor</Condition><Controls>H-1299</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>H-1299; celecoxib; cyclophosphamide</Interventions><Reference>14-C-0053; 140053; NCT02054104</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness and Safety of Different Doses of BI-1026706 in Patients With Postoperative Dental Pain</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="177530"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>80</EnrollmentCount><Interventions>BI-1026706</Interventions><Reference>1320.13; 2013-003580-62; NCT02084511</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Two Dosages of Diractin in Osteoarthritis (OA)</ProtocolTitle><Sponsor>IDEA AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22297"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1395</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>1399</EnrollmentCount><Interventions>Diractin</Interventions><Reference>CL-033-III-03; NCT00716547</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA)</ProtocolTitle><Sponsor>Heron Therapeutics Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="383452"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>HTX-011; acetaminophen; celecoxib; ibuprofen; luer lock applicator</Interventions><Reference>HTX-011-306; NCT03974932</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of LY-3127760 in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="158669"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>13</Patients><Biomarkers>Potassium; Prostacyclin receptor; Prostaglandin E; Prostaglandin E2 receptor EP4 subtype; Sodium; Thromboxane A2; Tumor necrosis factor</Biomarkers><Condition>Unidentified indication</Condition><Controls>celecoxib</Controls><EnrollmentCount>80</EnrollmentCount><Interventions>LY-3127760</Interventions><Reference>15181; I7A-MC-EACA; NCT01968070</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Two Different Doses of BI-1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="167667"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>BI-1026706; celecoxib; pregabalin</Interventions><Reference>1320.3; 2012-005691-33; NCT02037165</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Single-Dose Study of LY-3023703 in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="89268"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Creatinine; Prostaglandin E; Prostaglandin E2; Thromboxane; Thromboxane A</Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>LY-3023703</Interventions><Reference>14707; I6H-MC-MCBA; NCT01632579</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Lumiracoxib in Patients With Primary Knee Osteoarthritis (OA)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21847"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1551</Patients><Biomarkers>C-reactive protein</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>1684</EnrollmentCount><Interventions>lumiracoxib</Interventions><Reference>CCOX189A2361; NCT00367315</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of ARRY-371797 in subjects undergoing third molar extraction</ProtocolTitle><Sponsor>Array BioPharma Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12698"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>253</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>250</EnrollmentCount><Interventions>ARRY-371797</Interventions><Reference>ARRAY-797-222; NCT00663767</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Alpha-DC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="192666"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Peritoneal tumor</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>alpha DC1 cells; celecoxib; interferon alfa-2b; rintatolimod</Interventions><Reference>12-110; 5P01CA132714-05; NCT02151448</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Type-1 Polarized Dendritic Cell (alpha-DC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-alfa-2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="247079"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers>Cytotoxic T-Lymphocytes; GTPase KRas; HLA class I histocompatibility antigen, A alpha chain; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>alpha-type-1 polarized dendritic cell vaccine (peritoneal cancer), University of Pittsburgh; celecoxib; interferon alfa-2b; rintatolimod</Interventions><Reference>15-023; NCT02615574</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial of the Efficacy and Safety of Subcutaneous Tetrodotoxin (Tectin) for Moderate to Severe Inadequately Controlled Cancer-Related Pain</ProtocolTitle><Sponsor>WEX Pharmaceuticals Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="143220"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>126</Patients><Biomarkers></Biomarkers><Condition>Cancer pain</Condition><Controls></Controls><EnrollmentCount>146</EnrollmentCount><Interventions>Tetrodin; acetaminophen; celecoxib; dexamethasone</Interventions><Reference>ISRCTN75684296; WEX-014</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Effect on Gastroduodenal Mucosa of PA-32540, PA-32540 and Celecoxib, and Aspirin With Celecoxib</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="17964"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Cardiovascular disease</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>PA-32540; PA-32540; aspirin; celecoxib</Interventions><Reference>NCT00700687; PA32540-109</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Study 2</ProtocolAcronym><ProtocolTitle>A Study of MK-0663 and an Approved Drug in the Treatment of Osteoarthritis</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="57118"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>608</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>etoricoxib</Interventions><Reference>2004_058; MK0663-077; NCT00092781; Study 2</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Of CP-195543 And Celecoxib Dual Therapy In Subjects With Rheumatoid Arthritis (RA)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="2344"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers>Alanine transaminase; Albumin; Alkaline phosphatase; Aspartate aminotransferase; Basophils; Bicarbonates; Bilirubin; Blood platelets; C-reactive protein; C-reactive protein; Calcium; Chlorides; Creatine kinase; Creatinine; Diastolic blood pressure; Eosinophils; Erythrocytes; Glucose; Heart rate; Hematocrit; Hemoglobin; Joint swelling; Joint tenderness; Lactate dehydrogenase; Leukocyte count; Lymphocytes; Monocytes; Neutrophils; Oxalic acid; Phosphate; Potassium; Sodium; Systolic blood pressure; Total protein; Urea nitrogen; Uric acid</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>CP-195543; celecoxib; celecoxib</Interventions><Reference>A7701005; NCT00424294</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SUCCESS-VI</ProtocolAcronym><ProtocolTitle>A 6-week, randomized, double-blind, parallel trial, to compare the safety and efficacy of celecoxib and rofecoxib in hypertensive patients with osteoarthritis (OA)</ProtocolTitle><Sponsor>GD Searle &amp; Co, Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="30230"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>810</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>rofecoxib</Controls><EnrollmentCount>810</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>N49-99-02-149; SUCCESS-VI</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip</ProtocolTitle><Sponsor>Regeneron Pharmaceuticals Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="380618"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Celebrex; REG-N475; Zorvolex; naproxen</Interventions><Reference>2018-001618-13; NCT03949673; R475-OA-1816</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoarthritis or Rheumatoid Arthritis After 12 Weeks of Treatment With L-001069957 (21 mg) Plus Low-Dose Aspirin, L- 01069957 (42 mg) Plus Low-Dose Aspirin, Celecoxib (400 mg) Plus Low-Dose Aspirin, or Low-Dose Aspirin Alone</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="138539"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1360</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>aspirin</Controls><EnrollmentCount>1360</EnrollmentCount><Interventions>aspirin; celecoxib; rofecoxib</Interventions><Reference>0782-003; EudraCT 2004-000612-54</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study Conducted Under In-House Blinding Conditions to Determine the Incidence of Gastroduodenal Ulcers in Patients With Osteoarthritis or Rheumatoid Arthritis After 12 Weeks of Treatment With L-001069957 (21 mg) Plus Low-Dose Aspirin, L- 01069957 (42 mg) Plus Low-Dose Aspirin, Celecoxib (400 mg) Plus Low-Dose Aspirin, or Low-Dose Aspirin Alone</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="138539"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1360</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>aspirin</Controls><EnrollmentCount>1360</EnrollmentCount><Interventions>aspirin; celecoxib; rofecoxib</Interventions><Reference>0782-003; EudraCT 2004-000612-54</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GRC-27864 First-in-man, Single-ascending Dose Study in Healthy Subjects</ProtocolTitle><Sponsor>Glenmark Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="201801"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>76</Patients><Biomarkers>15-Keto-13,14-dihydroprostaglandin E2; Dinoprostone; Prostaglandins</Biomarkers><Condition>Inflammatory disease</Condition><Controls>celecoxib</Controls><EnrollmentCount>76</EnrollmentCount><Interventions>GRC-27864</Interventions><Reference>GRC 27864-101; NCT02179645</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>GRC-27864 First-in-man, Single-ascending Dose Study in Healthy Subjects</ProtocolTitle><Sponsor>Glenmark Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="201801"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>76</Patients><Biomarkers>15-Keto-13,14-dihydroprostaglandin E2; Dinoprostone; Prostaglandins</Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>76</EnrollmentCount><Interventions>GRC-27864</Interventions><Reference>GRC 27864-101; NCT02179645</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 52-Week, International, Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg Once Daily, Lumiracoxib 100 mg Twice Daily and Celecoxib 200 mg Once-Daily in Patients With Primary OA of Hip, Knee, Hand or Spine</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21471"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3032</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>3036</EnrollmentCount><Interventions>lumiracoxib</Interventions><Reference>CCOX189A2369; NCT00145301</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Ketoprofen in Transfersome Compared to Oral Celecoxib and Placebo for Pain Associated With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>IDEA AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21762"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>397</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>360</EnrollmentCount><Interventions>ketoprofen</Interventions><Reference>CL-033-II-03; CR012214; NCT00317733; NCT01309464</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Exploratory, Double-Blind, Randomized, Placebo and Active-Controlled Study to Assess the Safety and Efficacy of RGH-478 for the Treatment of Moderate to Severe Pain in Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Gedeon Richter Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="132024"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>250</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>250</EnrollmentCount><Interventions>RGH-478; celecoxib</Interventions><Reference>EudraCT 2011-000931-10; RGH-478-004</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of LY-2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="204690"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>266</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>268</EnrollmentCount><Interventions>galcanezumab</Interventions><Reference>15515; I5Q-MC-CGAF; NCT02192190</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Trial of YH-23537 in Patients With Knee Osteoarthritis</ProtocolTitle><Sponsor>Yuhan Corp</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259967"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>435</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>435</EnrollmentCount><Interventions>YH-23537</Interventions><Reference>NCT02759198; YH23537-202</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple Dose Study of LY-3023703 in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="129630"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Blood pressure; Dinoprostone; Epoprostenol; Transaminases</Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>LY-3023703</Interventions><Reference>14708; I6H-MC-MCBB; NCT01849055</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multiple Dose Study of LY-3023703 in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="129630"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Blood pressure; Dinoprostone; Epoprostenol; Transaminases</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>LY-3023703</Interventions><Reference>14708; I6H-MC-MCBB; NCT01849055</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of MK-0663 and an Approved Drug in the Treatment of Osteoarthritis</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21409"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>599</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>etoricoxib</Interventions><Reference>0663-076; 2004_057; MK0663-076; NCT00092768</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21479"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1262</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>1200</EnrollmentCount><Interventions>lumiracoxib</Interventions><Reference>CCOX189A2367; NCT00154219</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy of PN-400 bid and Celebrex qd in Patients With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22096"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>619</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>614</EnrollmentCount><Interventions>esomeprazole; naproxen; naproxen/esomeprazole</Interventions><Reference>NCT00664560; PN400-307</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of LY-3031207 in Healthy Subjects</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="81621"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>42</Patients><Biomarkers>PGE; PGEM; PGIM; TXAM</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>42</EnrollmentCount><Interventions>LY-3031207</Interventions><Reference>14283; I5W-EW-LBCA; NCT01449630</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Experimental Biomarker Study for Pain Thresholds</ProtocolTitle><Sponsor>Purdue Pharma LP</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="254746"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Blood flow; Body temperature</Biomarkers><Condition>Pain</Condition><Controls>capsaicin; capsaicin; celecoxib</Controls><EnrollmentCount>37</EnrollmentCount><Interventions>V-116517; capsaicin</Interventions><Reference>2011-002399-18; NCT02695745; VND1004</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Experimental Biomarker Study for Pain Thresholds</ProtocolTitle><Sponsor>Purdue Pharma LP</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="254746"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Blood flow; Body temperature</Biomarkers><Condition>Postherpetic neuralgia</Condition><Controls>capsaicin; capsaicin; celecoxib</Controls><EnrollmentCount>37</EnrollmentCount><Interventions>V-116517; capsaicin</Interventions><Reference>2011-002399-18; NCT02695745; VND1004</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>VAPER</ProtocolAcronym><ProtocolTitle>Vaccination with peptides (molecules) and other ingredients which stimulate the anticancer immune system in patients with advanced cancers</ProtocolTitle><Sponsor>Guy's &amp; St Thomas' Hospital NHS Trust, King's College London, University of Nottingham</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="213433"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>CD4/CD8 ratio; Cytotoxic T-Lymphocytes; Cytotoxic T-lymphocyte protein 4; Forkhead box protein P3; Programmed cell death protein 1; Regulatory T-Lymphocytes; T-lymphocytes; Tumor mass</Biomarkers><Condition>Advanced solid tumor</Condition><Controls>celecoxib</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>cyclophosphamide; hTERT multipeptide vaccine; imiquimod; montanide ISA-51 VG</Interventions><Reference>01; 117895; 2014-003025-18; ISRCTN07292674; VAPER; VAPER</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Study of PN-400 (Vimovo) Twice-Daily and Celebrex Once-Daily in Patients With Osteoarthritis</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22095"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>615</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>610</EnrollmentCount><Interventions>naproxen/esomeprazole</Interventions><Reference>NCT00665431; PN400-309</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of celecoxib in patients with osteoarthritis</ProtocolTitle><Sponsor>GD Searle &amp; Co, Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="76830"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>686</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>686</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191252; N49-96-02-060</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIb, randomized, parallel, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of etoricoxib versus celecoxib, ibuprofen on cardiac biomarkers in patients with osteoarthritis</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="76962"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>433</Patients><Biomarkers>CRP; LDL-C; fibrinogen; homocysteine</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; ibuprofen</Controls><EnrollmentCount>433</EnrollmentCount><Interventions>etoricoxib</Interventions><Reference>065</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study Assessing the Treatment Responsiveness of a Novel Osteoarthritis Stiffness Scale</ProtocolTitle><Sponsor>Bayer AG</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="344505"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>41</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>41</EnrollmentCount><Interventions>Aleve; acetaminophen; celecoxib; naproxen</Interventions><Reference>19783; NCT03570554</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>RESILIENCE</ProtocolAcronym><ProtocolTitle>Evaluation of Superiority of Valsartan + Celecoxib + Metformin Over Metformin Alone in Type 2 Diabetes Patients</ProtocolTitle><Sponsor>Arkay Therapeutics LLC</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="354704"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>115</Patients><Biomarkers>Adiponectin; Adiponectin/Leptin ratio; Glucose; Glycosylated serum albumin; Hemoglobin A, glycosylated; Homeostasis model assessment Beta cell function; Homeostasis model assessment insulin resistance; Insulin; Leptin; Total body mass</Biomarkers><Condition>Non-insulin dependent diabetes</Condition><Controls>Glucophage XR</Controls><EnrollmentCount>115</EnrollmentCount><Interventions>Glucophage XR; RK-01; celecoxib; valsartan</Interventions><Reference>NCT03686657; RESILIENCE; RK-01 PROTOTYPE</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="376708"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>47</Patients><Biomarkers>Standardized uptake value</Biomarkers><Condition>Myositis</Condition><Controls></Controls><EnrollmentCount>47</EnrollmentCount><Interventions>11C-ER-176; 11C-MC-1; PET scan; celecoxib</Interventions><Reference>19-M-0079; 190079; NCT03912428</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="376708"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>47</Patients><Biomarkers>Standardized uptake value</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>47</EnrollmentCount><Interventions>11C-ER-176; 11C-MC-1; PET scan; celecoxib</Interventions><Reference>19-M-0079; 190079; NCT03912428</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="376708"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>47</Patients><Biomarkers>Standardized uptake value</Biomarkers><Condition>Myopathy</Condition><Controls></Controls><EnrollmentCount>47</EnrollmentCount><Interventions>11C-ER-176; 11C-MC-1; PET scan; celecoxib</Interventions><Reference>19-M-0079; 190079; NCT03912428</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the Efficacy and Safety of Entelon Tablet 150 mg in Patients With Osteoarthritis of Knee</ProtocolTitle><Sponsor>Hanlim Pharmaceutical Co Ltd, St.Antonius Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="104784"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>338</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>338</EnrollmentCount><Interventions>Entelon</Interventions><Reference>HL_ENTR_302; KCT0000629; NCT01768520</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Trial II</ProtocolAcronym><ProtocolTitle>Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II</ProtocolTitle><Sponsor>Wyeth</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="19979"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>650</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>650</EnrollmentCount><Interventions>TDS-943</Interventions><Reference>NCT00546832; TD-07-14; Trial II</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Co-crystal E-58425 Versus Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial</ProtocolTitle><Sponsor>Laboratorios Dr Esteve SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="294235"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>637</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib; tramadol</Controls><EnrollmentCount>637</EnrollmentCount><Interventions>E-58425</Interventions><Reference>ESTEVE-SUSA-301; NCT03108482</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assessment of a Combination Therapy With Candesartan And Celecoxib For Patients With Advanced Hepatocellular Carcinoma After Transhepatic Arterial Chemoembolization</ProtocolTitle><Sponsor>Kurume University School of Medicine</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="132758"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>candesartan; celecoxib</Interventions><Reference>JPRN-UMIN000002435</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>CLASS</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, comparative trial to study the tolerability of celecoxib, diclofenac and ibuprofen in osteoarthritis and rheumatoid arthritis: The CLASS (Celecoxib Long-term Arthritis Safety Study)</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="111791"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib; diclofenac; ibuprofen</Interventions><Reference>CLASS</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>CLASS</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, comparative trial to study the tolerability of celecoxib, diclofenac and ibuprofen in osteoarthritis and rheumatoid arthritis: The CLASS (Celecoxib Long-term Arthritis Safety Study)</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="111791"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib; diclofenac; ibuprofen</Interventions><Reference>CLASS</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>The COMMAND Trial</ProtocolAcronym><ProtocolTitle>Parecoxib, Celecoxib and Paracetamol for Pain Management Following Cesarean Delivery</ProtocolTitle><Sponsor>King Edward Memorial Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="133320"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>111</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; paracetamol; parecoxib; pethidine; pethidine</Interventions><Reference>ACTRN12609001041246; ANZCTR320810; The COMMAND Trial</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on the effect of fluconazole on the pharmacokinetics of imrecoxib tablets in healthy subjects (single-center, single-arm, open, self-control)</ProtocolTitle><Sponsor>School of Pharmaceutical Sciences, Central South University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="249284"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Arthritis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib; fluconazole; imrecoxib</Interventions><Reference>ChiCTR-OIB-15007606</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex Total Knee Arthroplasty Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="20872"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>22</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191225; NCT00359151</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of herbal composition colchicum autumnale, saffon and ginger with celecoxib on clinical symptoms in aged 60 to 70 years with osteoarthritis of the knee in Bushehr</ProtocolTitle><Sponsor>Bushehr University of Medical Science</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="236823"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>Herbal capsules (colchicum autumnale, saffon and ginger); celecoxib</Interventions><Reference>IRCT2015053022466N1; bpums.rec.1394.4</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With Juvenille Rheumatoid Arthritis (JRA)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9668"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>242</Patients><Biomarkers></Biomarkers><Condition>Juvenile rheumatoid arthritis</Condition><Controls>naproxen</Controls><EnrollmentCount>225</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191127; N49-01-02-195; NCT00652925</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multicenter Clinical Control Study Of Noncytotoxic Drug - Gastric Carcinoma D2 Radical Correction - Capecitabine Combined Therapy In Gastric Carcinoma</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="136071"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Stomach tumor</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>capecitabine; celecoxib; lanreotide</Interventions><Reference>ChiCTR-TNRC-00000052</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="45499"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>celecoxib; docetaxel</Interventions><Reference>NCT00494338; XRP6976J_2504</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28589"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>106</Patients><Biomarkers>E1; E1S; E2; SHBG</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>celecoxib; exemestane; exemestane; exemestane + celecoxib</Interventions><Reference>A3191139; NCT00038103; NQ8-01-02-013</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Antiangiogenetic Therapy for Pediatric Malignancies with no Conventional Treatment Modalities Left</ProtocolTitle><Sponsor>University Hospital for Children and Adolescents</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="199731"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Cancer</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; etoposide phosphate; thalidomide</Interventions><Reference>2008-006989-28; extended2008</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preemptive Analgesia in Total Knee Arthroplasty</ProtocolTitle><Sponsor>Faculty of Medicine, University of Indonesia</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="339415"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Knee motion</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>bupivacaine; celecoxib; pregabaline</Interventions><Reference>FAKULTASKUI; NCT03523832</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>S-Adenosyl Methionine (SAMe) Versus Celecoxib for the Treatment of Osteoarthritis Symptoms: A Double-Blind, Crossover Trial</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="149750"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>61</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>61</EnrollmentCount><Interventions>S-adenosyl methionine; celecoxib</Interventions><Reference>HS#2000-1046; ISRCTN36233495</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib for Pediatric Adenotonsillectomy</ProtocolTitle><Sponsor>Childrens Hospital of Eastern Ontario (CHEO)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47087"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>195</Patients><Biomarkers>CYP2C9</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>282</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>#09/10E; NCT00849966</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Bladder Cancer</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="26950"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>146</Patients><Biomarkers></Biomarkers><Condition>Bladder cancer</Condition><Controls></Controls><EnrollmentCount>152</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ID99-368; N01CN85186; NCI-2009-00869; NCT00006124</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Fundamental Research on Peri-operative Immune Regulation to Prevent Post-operative Recurrance of Rectal Cancer</ProtocolTitle><Sponsor>Science &amp; Technology Department of Sichuan Province, Sichuan University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="98812"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>110</Patients><Biomarkers>COX-2; CRP; IL-6</Biomarkers><Condition>Rectal tumor</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ChiCTR-TRC-10000866</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="371877"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>OxyContin; acetaminophen; ibuprofen</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Celebrex; OxyContin; acetaminophen; bupivacaine; dexamethasone; gabapentin; ibuprofen</Interventions><Reference>IRB-300002992; NCT03859024</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety And Efficacy Of Celecoxib Versus Sodium Diclofenac In The Treatment Of Acute Low Back Pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12845"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>244</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>diclofenac</Controls><EnrollmentCount>244</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191064; NCT00640432</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Arthroplasty Inflammation Prophylaxis With Celecoxib</ProtocolTitle><Sponsor>Vancouver Coastal Health Authority</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="13059"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Celecoxib</Interventions><Reference>NCT00533247; PAC01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer Who Have Undergone Surgery</ProtocolTitle><Sponsor>Case Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67972"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>17</Patients><Biomarkers>COX-2</Biomarkers><Condition>Renal tumor</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>celecoxib; recombinant interferon alfa-2b</Interventions><Reference>CASE8805; NCI-2010-01390; NCT01158534</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Epirubicin and Celecoxib in Treating Patients With Hepatocellular Carcinoma</ProtocolTitle><Sponsor>National Cancer Institute, Northwestern University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29179"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>8</Patients><Biomarkers>COX-2; Vascular endothelial growth factor</Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls></Controls><EnrollmentCount>8</EnrollmentCount><Interventions>celecoxib; epirubicin</Interventions><Reference>NCT00057980; NU 02I6; NU-02I6</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of various oral analgesic effects for post-operative pain following minor oral surgery</ProtocolTitle><Sponsor>Tokyo Dental College</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="243577"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>acetaminophen; celecoxib; diclofenac sodium; fentanyl</Interventions><Reference>UMIN000019431</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>PROMET</ProtocolAcronym><ProtocolTitle>Pilot Study Of Metronomic Chemotherapy With Cyclophosphamide, Celecoxib And Dexamethasone In Patients With Diagnosis Of Prostate Cancer Of The Refractory Hormone In Advanced Stage Appraisal Pharmacodynamics</ProtocolTitle><Sponsor>Azienda USL 6 Livorno</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="138846"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>27</Patients><Biomarkers>CYP 5; CYP2B6; CYP2C19; CYP2C9; Prostate specific antigen; Tsp-1; VEGF; mRNA; sVEGFR-2</Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; dexamethasone</Interventions><Reference>ASL605LIOM03 PROMET; EudraCT 2005-005967-27; PROMET</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Selenium and celecoxib, alone or in combination, in preventing cancer in patients with esophageal dysplasia</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="27177"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>267</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls>selenium</Controls><EnrollmentCount>600</EnrollmentCount><Interventions>celecoxib; selenium</Interventions><Reference>CDR0000067930; NCI-OH95-C-N026; NCI-P00-0157; NCT00005885</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22169"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>375</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>380</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191069; NCT00640627</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CI(R)CA</ProtocolAcronym><ProtocolTitle>CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen</ProtocolTitle><Sponsor>Hospital Universitario Pedro Ernesto</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="104136"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>22</Patients><Biomarkers></Biomarkers><Condition>Antiphospholipid syndrome</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>Coumadin; acetaminophen (Tylenol); celecoxib; rofecoxib</Interventions><Reference>32323232; CI(R)CA; NCT01762891; Pfizer</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Active Drug Comparative, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of PG-201 in Osteoarthritis Patients</ProtocolTitle><Sponsor>PMG Pharm Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="86468"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>309</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>309</EnrollmentCount><Interventions>PG-201</Interventions><Reference>NCT01576419; PG201-P3</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex In Acute Gouty Arthritis Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="16553"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>402</Patients><Biomarkers>Serum creatinine</Biomarkers><Condition>Gout</Condition><Controls>indomethacin</Controls><EnrollmentCount>402</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2007-005912-23; A3191219; NCT00549549</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the Effects of celecoxib, celecoxib - caffeine and Ibuprofen on pain control after Surgery</ProtocolTitle><Sponsor>Babol University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="155041"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib; ibuprofen</Controls><EnrollmentCount>45</EnrollmentCount><Interventions>caffeine; celecoxib</Interventions><Reference>302,159 / n / c; IRCT201305253813N2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="43189"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Rectal tumor</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>capecitabine; celecoxib</Interventions><Reference>CDR0000360666; NCCTG-N0346; NCI-2012-02582; NCT00081224</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Metronomic Study for Head and Neck Cancer</ProtocolTitle><Sponsor>Tata Memorial Center, Tata Memorial Hospital &amp; Cancer Research Inst</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="247194"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>422</Patients><Biomarkers></Biomarkers><Condition>Metastatic head and neck cancer</Condition><Controls></Controls><EnrollmentCount>422</EnrollmentCount><Interventions>celecoxib; cisplatin; methotrexate</Interventions><Reference>159; CTRI/2015/11/006388</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="245430"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; duloxetine; oxycodone; pregabalin; tramadol + paracetamol (oral), Johnson &amp; Johnson</Interventions><Reference>DULOXETINE; NCT02600247</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of High-Risk Oral Cavity Cancer</ProtocolTitle><Sponsor>National Health Research Institutes</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="58614"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Mouth tumor</Condition><Controls>cyclophosphamide; dexamethasone</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; thalidomide</Interventions><Reference>NCT00934739; T1306</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, randomized, cross-over, 4 sequences, 4 periods, pharmacokinetic interaction and comparative bioavailability study of medicinal products for oral administration of Celecoxib / Metocarbamol in capsules with 200 mg / 215 mg (Test) and Celecoxib in capsules with 200 mg (Reference) and Metocarbamol in capsules with 215 mg (Reference) in healthy subjects under fasting conditions</ProtocolTitle><Sponsor>AXIS Clinicals AMERICA SA DE CV</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="341944"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>celecoxib; metocarbamol</Controls><EnrollmentCount>48</EnrollmentCount><Interventions>Celecoxib/Metocarbamol</Interventions><Reference>ACL17-PC072</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparison of the Efficacy of Analgesia and Functional Outcome Between Local Infiltration Analgesia and Adductor Canal Block After Total Knee Replacement: a Randomized Clinical Trial</ProtocolTitle><Sponsor>Chulalongkorn University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="235243"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>58</Patients><Biomarkers>Knee motion; Muscle strength</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>adductor canal block; celecoxib; esomeprazole; levobupivacaine; local infiltration analgesia; pregabalin; tramadol + paracetamol (oral), Johnson &amp; Johnson; tramadol hydrochloride</Interventions><Reference>TCTR20150720003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study for Estimation of Predictive Factors Which Are Related with Drug Response Variability of COX-2 Selective Inhibitor in Korean Healthy Subjects</ProtocolTitle><Sponsor>Dong-A University Hospital</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="381368"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>15-031; KCT0003958</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical study to evaluate the bioequivalence of celecoxib in healthy male and female volunteers, 200 mg capsules</ProtocolTitle><Sponsor>Ultra Laboratories, SA de CV</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="164493"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>BQ-2013-08-CLC-E</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo-controlled study of celecoxib or diclofenac to enhance gastrointestinal recovery and reduce post-operative ileus</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="61879"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>210</Patients><Biomarkers></Biomarkers><Condition>Gastrointestinal disease</Condition><Controls></Controls><EnrollmentCount>282</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>ACTRNO1265000299606</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>FLUVABREX</ProtocolAcronym><ProtocolTitle>Safety of Fluvastatin-Celebrex Association in Low and High Grade Optico-chiasmatic Gliomas</ProtocolTitle><Sponsor>Centre Oscar Lambret</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="182055"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Creatine kinase</Biomarkers><Condition>Glioma</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>Celebrex; fluvastatin</Interventions><Reference>FLUVABREX; FLUVABREX-1208; NCT02115074</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer</ProtocolTitle><Sponsor>University of Southern California</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="43717"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>celecoxib; cisplatin; irinotecan</Interventions><Reference>3E-02-1; NCT00183807</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="26553"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>M-protein; Serum beta microglobulin</Biomarkers><Condition>Multiple myeloma</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CCF-IRB-7029; CDR0000393514; MAYO-206904; N01CN25140; NCI-2009-00866; NCT00099047; UARK-18697</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer</ProtocolTitle><Sponsor>Roswell Park Comprehensive Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="347632"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>6</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Leukocyte common antigen; Programmed cell death 1 ligand 1; Programmed cell death protein 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>celecoxib; interferon alfa-2b; pembrolizumab; rintatolimod</Interventions><Reference>I 62218; NCT03599453</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Dysmenorrhea</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Keratosis</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Gout</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Alzheimers disease</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Renal cell carcinoma</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Periarthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Tenosynovitis</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Pancreas tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Prostate tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Non-Hodgkin lymphoma</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Back pain</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Bladder tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Cachexia</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Uterine cervix tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of the drugs Selex, 200 mg capsules, the manufacturer "Tamar A.V.E. Antusa plant", Greece for the Actavis Group, Iceland and Celebrex, capsules of 200 mg, the manufacturer "Pfizer Manufacturing Deutschland GmbH", Germany</ProtocolTitle><Sponsor>Actavis Group HF</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="245943"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Breast tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Selex), Actavis</Interventions><Reference>BE-07-2014-ACT-CEL</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="159469"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib; fluorouracil; leucovorin calcium</Interventions><Reference>CDR0000367335; EORTC-40023; NCT00085163; PETACC-5</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 5-peptide vaccine with immune modulators for patients with metastatic colorectal cancer</ProtocolTitle><Sponsor>Kindai University Faculty of Medicine</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="291383"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>HLA class I histocompatibility antigen, A alpha chain</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>5-peptide cocktail vaccine; celecoxib; cimetidine; cyclophosphamide; metformin hydrochloride</Interventions><Reference>UMIN000026163</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of preemptive analgesia on pain</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="192697"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>acetaminophen; celecoxib; gabapentin</Interventions><Reference>1920452606; IRCT2014051417681N1</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of preemptive analgesia on pain</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="192697"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Anxiety disorder</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>acetaminophen; celecoxib; gabapentin</Interventions><Reference>1920452606; IRCT2014051417681N1</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NICHE</ProtocolAcronym><ProtocolTitle>Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity</ProtocolTitle><Sponsor>Netherlands Cancer Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="285932"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>14</Patients><Biomarkers>CD4/CD8 ratio; Cytotoxic T-Lymphocytes; Interferon gamma; Memory T-Lymphocytes; Prostaglandin G/H synthase 2</Biomarkers><Condition>Colon tumor</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Celebrex; Opdivo; Yervoy</Interventions><Reference>2016-002940-17; N16NCI; NCT03026140; NICHE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, multicenter, multiple-dose, open-label study to evaluate the safety and pharmacokinetics of celecoxib for the treatment of patients with osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80162"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>11</Patients><Biomarkers>11-dehydro- TxB2; 6-keto-PGF1-alfa; PGE2; TxB2</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>I49-98-02-097</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients</ProtocolTitle><Sponsor>Chong Kun Dang Pharmaceutical Corp</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="289539"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>266HOA16008; NCT03067194</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>PCTKA</ProtocolAcronym><ProtocolTitle>Pregabalin, Celecoxib, Total Knee Arthroplasty and Intrathecal Morphine</ProtocolTitle><Sponsor>Chulalongkorn University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76990"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; celecoxib; pregabalin; pregabalin</Interventions><Reference>NCT01344213; PCTKA; anesTKA08</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43993"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>155</Patients><Biomarkers></Biomarkers><Condition>Glioblastoma</Condition><Controls></Controls><EnrollmentCount>178</EnrollmentCount><Interventions>celecoxib; isotretinoin; temozolomide; thalidomide, Celgene</Interventions><Reference>2004-0662; CDR0000432954; MDA-2004-0662; MDA-ID-02586; NCI-2009-00076; NCI-6636; NCT00112502</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Trial of Dendritic Cell Vaccination and Celecoxib With Postoperative Radiotherapy and Temozolomide for Treatment of Malignant Glioma</ProtocolTitle><Sponsor>Queensland Institute of Medical Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="136781"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Glioma</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; dendritic cell vaccine; temozolomide</Interventions><Reference>ACTRN12609000736246; P984</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot, Open-Label, Cross-over, Bioavailability Study of Celecoxib in Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="39339"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>16</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191354; NCT00813241</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study To Evaluate The Effects Of Celecoxib (Celebrex) Or Naproxen On Blood Pressure In Pediatric Patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="38481"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>201</Patients><Biomarkers>Blood pressure; Diastolic blood pressure; Heart rate; Systolic blood pressure</Biomarkers><Condition>Juvenile rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>201</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>2014-003737-26; A3191342; NCT00807846</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Protocol for Women at Increased Risk of Developing Breast Cancer</ProtocolTitle><Sponsor>University of Kansas Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="48373"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>Breast; Estradiol; Insulin-like growth factor 1; Insulin-like growth factor binding protein 2; Insulin-like growth factor binding protein 3; Ki-67; Sex hormone-binding globulin</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>9118; NCT00291694</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="286222"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Blood pressure; Body temperature; Head circumference; Heart rate; Occipital lobe; Respiratory frequency</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; diclofenac; naproxen; tanezumab</Interventions><Reference>2013-002548-10; A4091065; INFANT SAFETY FOLLOW-UP #2; NCT03031938; NEONATAL MONITORING STUDY #2</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="286222"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Blood pressure; Body temperature; Head circumference; Heart rate; Occipital lobe; Respiratory frequency</Biomarkers><Condition>Cancer pain</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; diclofenac; naproxen; tanezumab</Interventions><Reference>2013-002548-10; A4091065; INFANT SAFETY FOLLOW-UP #2; NCT03031938; NEONATAL MONITORING STUDY #2</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="286222"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>10</Patients><Biomarkers>Blood pressure; Body temperature; Head circumference; Heart rate; Occipital lobe; Respiratory frequency</Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; diclofenac; naproxen; tanezumab</Interventions><Reference>2013-002548-10; A4091065; INFANT SAFETY FOLLOW-UP #2; NCT03031938; NEONATAL MONITORING STUDY #2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Epicutaneously Applied Ketoprofen Transfersome Version Gel With or Without Combination With Oral Celecoxib for the Treatment of Muscle Pain Induced by Eccentric Exercise</ProtocolTitle><Sponsor>X-pert Med GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62243"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>82</Patients><Biomarkers></Biomarkers><Condition>Musculoskeletal pain</Condition><Controls>ketoprofen</Controls><EnrollmentCount>82</EnrollmentCount><Interventions>celecoxib; ketoprofen</Interventions><Reference>NCT01020279; XPM-023</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Post-Procedure Administration of Celecoxib Following Shoulder Surgery</ProtocolTitle><Sponsor>St. Louis Joint Replacement Institute</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="315119"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>BI177194; NCT03305068</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children: A Randomized, Controlled, Single-center Trial</ProtocolTitle><Sponsor>Childrens Hospital of Eastern Ontario Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="175051"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Hematological neoplasm</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>18/08SE; ISRCTN07429476</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Of Celecoxib In Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="61059"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>189</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>loxoprofen</Controls><EnrollmentCount>190</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191345; JapicCTI-101026; NCT00994461</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, double-blind, placebo-controlled, randomized clinical trial to compare the efficacy and safety of celecoxib and diclofenac for the treatment of patients with signs and symptoms of osteoarthritis of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80131"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>600</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>600</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191314; N49-98-02-118</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib as a Post-Tonsillectomy Pain Medication</ProtocolTitle><Sponsor>University of Iowa</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13065"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>200703765; NCT00583453</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PECS Block versus Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="294923"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>Pectoral Nerve block I; Pectoral Nerve block II; acetaminophen; bupivacaine; celecoxib; dexamethasone; fentanyl; gabapentin; midazolam</Interventions><Reference>16-X409; 201703053; NCT03084536</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in the treatment of depression</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="197435"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Major depressive disorder</Condition><Controls>diclofenac</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>24350; IRCT201405271556N58</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>CLASS</ProtocolAcronym><ProtocolTitle>A Randomized, Controlled Trial of Gastrointestinal Toxicity With Celecoxib versus Nonsteroidal Anti-Inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: Celecoxib Long-Term Arthritis Safety Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="153473"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>8059</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>8059</EnrollmentCount><Interventions>aspirin; celecoxib; celecoxib; diclofenac; diclofenac; ibuprofen; ibuprofen</Interventions><Reference>CLASS</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>CLASS</ProtocolAcronym><ProtocolTitle>A Randomized, Controlled Trial of Gastrointestinal Toxicity With Celecoxib versus Nonsteroidal Anti-Inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: Celecoxib Long-Term Arthritis Safety Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="153473"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>8059</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>8059</EnrollmentCount><Interventions>aspirin; celecoxib; celecoxib; diclofenac; diclofenac; ibuprofen; ibuprofen</Interventions><Reference>CLASS</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62261"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>84</Patients><Biomarkers>5,8,11,14-Eicosatetraenoic acid; Creatinine; LTE-4 (leukotriene E4); PGE-M (prostaglandin E metabolite)</Biomarkers><Condition>Nicotine dependence</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>celecoxib; zileuton; zileuton</Interventions><Reference>2009-0804; MDA09-13-01; N01CN35159; NCI-2011-02301; NCI-2013-00730; NCT01021215</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of celecoxib on early postoperative cognitive dysfunction in elderly patients undergoing Lower limb arthroplasty</ProtocolTitle><Sponsor>Xuzhou Central Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="257406"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>130</Patients><Biomarkers>Cytokines</Biomarkers><Condition>Cognitive disorder</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ChiCTR-IOR-16008168</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radial Extracorporeal Shock Wave Therapy for Chronic Non-specific Low Back Pain</ProtocolTitle><Sponsor>Zhejiang University School of Medicine</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="319015"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; eperisone; radial extracorporeal shock wave therapy (rESWT)</Interventions><Reference>FENGDOLORCLASTLOWBACKPAIN; NCT03337607</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of long-term effects on knee joint function between selective cox-2 inhibitor and naproxen + esomeprazole combination regimen after arthroscopic meniscectomy</ProtocolTitle><Sponsor>Yonsei University Health System</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="377782"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>36</EnrollmentCount><Interventions>esomeprazole magnesium; naproxen</Interventions><Reference>4-2018-1109; KCT0003790</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-week, randomized, placebo-controlled, double-blind, multicenter clinical trial to evaluate the safety and efficacy of celecoxib and rofecoxib for the treatment of patients with osteoarthritis (OA)</ProtocolTitle><Sponsor>Pfizer Inc, Weill Medical College of Cornell University</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="72381"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>475</Patients><Biomarkers>BUN; creatinine</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>477</EnrollmentCount><Interventions>celecoxib; rofecoxib</Interventions><Reference>635-IFL-0508-003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, 12-week, randomized, double-blind, placebo-controlled, multicenter clinical trial to study the analgesic efficacy of celecoxib compared to placebo in patients with chronic low back pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80176"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>360</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>360</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191156; COXA-0508-244</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, multicenter, active-controlled, parallel-group study to evaluate the efficacy and safety of celecoxib compared to loxoprofen for the treatment of patients with low back pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80196"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>822</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls>loxoprofen</Controls><EnrollmentCount>846</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191115; J49-01-02-217</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan</ProtocolTitle><Sponsor>New Approaches to Neuroblastoma Therapy Consortium</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="166990"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Neuroblastoma</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Celebrex; Hycamtin; cyclophosphamide (Cytoxan); eflornithine</Interventions><Reference>N2012-01; NCT02030964; P01CA081403</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Influence of the Home-Based Excercise of the Patient With Knee Osteoarthritis by Cox2-Inhibitor and Home-Based Exercise Combination Therapy</ProtocolTitle><Sponsor>Juntendo University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="122807"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Home-based excercise</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>JPRN-UMIN000006619</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>One-center, open, randomized, two-period, with two consecutive methods, crossover study of the relative bioavailability and bioequivalence of Celecoxib, 200 mg capsules (Velfarm, Russia) compared to Celebrex, 200 mg capsules (Pfizer, USA) when taken on an empty stomach by healthy volunteers</ProtocolTitle><Sponsor>Velfarm LLC</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="375058"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>Celebrex; celecoxib, Velfarm</Interventions><Reference>RDPh_18_05</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-label, two-periods, two-treatments, two-strings, crossover, randomized, single-dose study to assess the bioequivalence of celecoxib 200 mg capsules: Celecoxib versus Celebrex under fasted conditions</ProtocolTitle><Sponsor>Novag Infancia, S.A. de C.V</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="210516"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib, Novag Infancia</Interventions><Reference>BE14013</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PRESAP</ProtocolAcronym><ProtocolTitle>Prevention of Colorectal Sporadic Adenomatous Polyps</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23661"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1500</Patients><Biomarkers></Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>1561</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191107; EQ4-00-02-018; NCT00141193; PRESAP</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>PRESAP</ProtocolAcronym><ProtocolTitle>Prevention of Colorectal Sporadic Adenomatous Polyps</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23661"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1500</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>1561</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191107; EQ4-00-02-018; NCT00141193; PRESAP</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, placebo controlled study to evaluate the efficacy and safety of celecoxib versus placebo for the treatment of patients with osteoarthritis (OA) of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79833"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>402</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>402</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191302; N49-96-02-047</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>STARDOM2</ProtocolAcronym><ProtocolTitle>Efficacy and Safety in a Randomized Acute Pain Study of MR-308</ProtocolTitle><Sponsor>Mundipharma Research GmbH &amp; Co. KG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="289134"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1138</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib; tramadol</Controls><EnrollmentCount>1138</EnrollmentCount><Interventions>MR-308</Interventions><Reference>2016-000593-38; MR308-3502; NCT03062644; STARDOM2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, randomized, placebo-controlled, open-label, site-specific clinical trial to compare the efficacy of long-term treatment with celecoxib plus vitamin E to placebo plus vitamin E for the treatment of patients with Alzheimer’s disease</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="80135"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Alzheimers disease</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191296; EQ5-98-02-002</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="289192"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>258</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>258</EnrollmentCount><Interventions>celecoxib; oxycodone; parecoxib</Interventions><Reference>2016-FXY-099; NCT03059238</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>COMET-GI</ProtocolAcronym><ProtocolTitle>Metronomic Chemotherapy With Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in Pretreated Patients With Advanced Gastrointestinal Malignancies: A Pilot Clinical Study With Pharmacokinetic And Pharmacodynamic Evaluations</ProtocolTitle><Sponsor>Azienda USL 6 Livorno</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="141837"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Biliary cancer</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; tegafur; uracil</Interventions><Reference>ASL607LIOM01 COMET-GI; COMET-GI; EudraCT 2007-000065-38</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>COMET-GI</ProtocolAcronym><ProtocolTitle>Metronomic Chemotherapy With Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in Pretreated Patients With Advanced Gastrointestinal Malignancies: A Pilot Clinical Study With Pharmacokinetic And Pharmacodynamic Evaluations</ProtocolTitle><Sponsor>Azienda USL 6 Livorno</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="141837"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; tegafur; uracil</Interventions><Reference>ASL607LIOM01 COMET-GI; COMET-GI; EudraCT 2007-000065-38</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>COMET-GI</ProtocolAcronym><ProtocolTitle>Metronomic Chemotherapy With Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in Pretreated Patients With Advanced Gastrointestinal Malignancies: A Pilot Clinical Study With Pharmacokinetic And Pharmacodynamic Evaluations</ProtocolTitle><Sponsor>Azienda USL 6 Livorno</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="141837"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; tegafur; uracil</Interventions><Reference>ASL607LIOM01 COMET-GI; COMET-GI; EudraCT 2007-000065-38</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>COMET-GI</ProtocolAcronym><ProtocolTitle>Metronomic Chemotherapy With Uracil/Tegafur (UFT), Cyclophosphamide (CTX) and Celecoxib in Pretreated Patients With Advanced Gastrointestinal Malignancies: A Pilot Clinical Study With Pharmacokinetic And Pharmacodynamic Evaluations</ProtocolTitle><Sponsor>Azienda USL 6 Livorno</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="141837"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Metastatic pancreas cancer</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; tegafur; uracil</Interventions><Reference>ASL607LIOM01 COMET-GI; COMET-GI; EudraCT 2007-000065-38</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib on Post-Operative Pain</ProtocolTitle><Sponsor>Zahedan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="132714"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>83-1241; IRCT201010284947N2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="30004"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>39</Patients><Biomarkers></Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CALGB-40105; CDR0000256905; NCT00045591; U10CA031946</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on the Pharmacokinetics (PK) of DFN-15 versus Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="312694"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Migraine</Condition><Controls>Celebrex</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>DFN-15</Interventions><Reference>DFN-15-CD-008; NCT03282838</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I/II Study of Preoperative Chemoradiotherapy With S-1, Celecoxib and Radiation for Locally Advanced Rectal Cancer</ProtocolTitle><Sponsor>Chiba University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="167552"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Prostaglandin G/H synthase 2</Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Cefesone; celecoxib</Interventions><Reference>JPRN-UMIN000012818</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study of the Bone Protection Effect of Biqi Capsule for Treatment of Rheumatoid Arthritis</ProtocolTitle><Sponsor>Guangdong Provincial Hospital of Chinese Medicine</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="268327"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Alanine transaminase; Bone mineral density; C-reactive protein; Erythrocyte sedimentation rate; Matrix metalloproteinase 3/Tissue inhibitor of metalloproteinase 2 ratio; RANKL/OPG; Rheumatoid factor; Urea nitrogen</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>calcitriol; celecoxib; leflunomide; methotrexate</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>BiQi capsule; celecoxib; methotrexate</Interventions><Reference>ChiCTR-IPR-16009029</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>IPACK Nerve Block for Total Knee Arthroplasty</ProtocolTitle><Sponsor>Ochsner Health System</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="377397"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Anesthesia</Condition><Controls>acetaminophen; celecoxib; dexamethasone; fentanyl; gabapentin; ketamine; mepivacaine; midazolam; pregabalin; propofol</Controls><EnrollmentCount>72</EnrollmentCount><Interventions>acetaminophen; celecoxib; dexamethasone; fentanyl; gabapentin; ketamine; mepivacaine; midazolam; pregabalin; propofol; ropivacaine</Interventions><Reference>2016.307.C; NCT03921034</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>IPACK Nerve Block for Total Knee Arthroplasty</ProtocolTitle><Sponsor>Ochsner Health System</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="377397"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>acetaminophen; celecoxib; dexamethasone; fentanyl; gabapentin; ketamine; mepivacaine; midazolam; pregabalin; propofol</Controls><EnrollmentCount>72</EnrollmentCount><Interventions>acetaminophen; celecoxib; dexamethasone; fentanyl; gabapentin; ketamine; mepivacaine; midazolam; pregabalin; propofol; ropivacaine</Interventions><Reference>2016.307.C; NCT03921034</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing the effect of acupuncture and medical treatment on subjective symptoms and neuromuscular electrophysiologic changes in patients with cervical disk herniation</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="246427"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>90</Patients><Biomarkers>F wave</Biomarkers><Condition>Degenerative disc disease</Condition><Controls>celecoxib</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>acupuncture</Interventions><Reference>IR.MUMS.REC.1392.21; IRCT2015070311912N4</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The evaluation of celecoxib against skin toxicity caused by radiotherapy in patients with breast cancer</ProtocolTitle><Sponsor>Mazandaran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="220567"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Dermatitis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>1276; IRCT2014100619423N1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans</ProtocolTitle><Sponsor>University of Calgary</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="190274"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood pressure; Cerebral blood flow</Biomarkers><Condition>Hypertension</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Celecoxib; indomethacin</Interventions><Reference>NCT01280006; UC-MMHAP-COX-IH-2010001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans</ProtocolTitle><Sponsor>University of Calgary</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="190274"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood pressure; Cerebral blood flow</Biomarkers><Condition>Obstructive sleep apnea</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Celecoxib; indomethacin</Interventions><Reference>NCT01280006; UC-MMHAP-COX-IH-2010001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans</ProtocolTitle><Sponsor>University of Calgary</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="190274"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood pressure; Cerebral blood flow</Biomarkers><Condition>Cardiovascular disease</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Celecoxib; indomethacin</Interventions><Reference>NCT01280006; UC-MMHAP-COX-IH-2010001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Selective and Nonselective Cyclooxygenase Enzyme Inhibition on Arterial Blood Pressure and Cerebral Blood Flow With Exposure to Intermittent Hypoxia in Humans</ProtocolTitle><Sponsor>University of Calgary</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="190274"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood pressure; Cerebral blood flow</Biomarkers><Condition>Stroke</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Celecoxib; indomethacin</Interventions><Reference>NCT01280006; UC-MMHAP-COX-IH-2010001</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Different Kinds of Acupuncture Treatment for Knee Osteoarthritis</ProtocolTitle><Sponsor>Zhejiang Chinese Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="343589"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients>360</Patients><Biomarkers>Joint swelling; Knee circumference</Biomarkers><Condition>Osteoarthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>360</EnrollmentCount><Interventions>acupuncture; electro-acupuncture; moxibustion treatment; warm-needling treatment</Interventions><Reference>2018ZY008-KOA; NCT03563690</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low-Dose/Metronomic (LDM) Chemotherapy for Metastatic Breast Cancer</ProtocolTitle><Sponsor>HaEmek Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="64151"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers>HER2</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>capecitabine; celecoxib; cyclophosphamide; methotrexate; pamidronate; zoledronate</Interventions><Reference>0078-09-EMC; NCT01067989</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Add-on Therapy Compared to Haloperidol Alone in Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial</ProtocolTitle><Sponsor>Mazandaran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="137060"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Schizophrenia</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib; haloperidol; haloperidol</Interventions><Reference>108-82; IRCT138809201457N6</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Liposome Bupivacaine in Interscalene Block for Rotator Cuff Repair</ProtocolTitle><Sponsor>University of Minnesota - Clinical and Translational Science Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="346436"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Heart rate; Systolic blood pressure</Biomarkers><Condition>Pain</Condition><Controls>Celebrex; acetaminophen; bupivacaine; dexamethasone; fentanyl; gabapentin; hydromorphone; ibuprofen; ketamine; midazolam; ondansetron; oxycodone; propofol</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Celebrex; acetaminophen; dexamethasone; fentanyl; gabapentin; hydromorphone; ibuprofen; ketamine; liposomal bupivacaine; midazolam; ondansetron; oxycodone; propofol</Interventions><Reference>NCT03587584; STUDY00003350</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67283"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD25+; CD4+; Fox P3+; Regulatory T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>10-C-0138; 100138; NCT01143545</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67283"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD25+; CD4+; Fox P3+; Regulatory T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Mesothelioma</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>10-C-0138; 100138; NCT01143545</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67283"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD25+; CD4+; Fox P3+; Regulatory T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>10-C-0138; 100138; NCT01143545</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67283"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD25+; CD4+; Fox P3+; Regulatory T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>10-C-0138; 100138; NCT01143545</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67283"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD25+; CD4+; Fox P3+; Regulatory T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>10-C-0138; 100138; NCT01143545</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67283"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD25+; CD4+; Fox P3+; Regulatory T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Thymus neoplasm</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>10-C-0138; 100138; NCT01143545</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67283"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers>CD25+; CD4+; Fox P3+; Regulatory T-Lymphocytes; T-Helper Lymphocytes</Biomarkers><Condition>Thymoma</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>10-C-0138; 100138; NCT01143545</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide, Cyclophosphamide, Thalidomide, Celecoxib and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25703"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>97</Patients><Biomarkers>Thrombospondins</Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>celecoxib; celecoxib + cyclophosphamide + thalidomide, Celgene + fenofibrate + etoposide phosphate; cyclophosphamide; etoposide phosphate; fenofibrate; thalidomide, Celgene</Interventions><Reference>CDR0000487628; DFCI-04343; NCT00165321; NCT00357500</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide, Cyclophosphamide, Thalidomide, Celecoxib and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25703"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>97</Patients><Biomarkers>Thrombospondins</Biomarkers><Condition>Leukemia</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>celecoxib; celecoxib + cyclophosphamide + thalidomide, Celgene + fenofibrate + etoposide phosphate; cyclophosphamide; etoposide phosphate; fenofibrate; thalidomide, Celgene</Interventions><Reference>CDR0000487628; DFCI-04343; NCT00165321; NCT00357500</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide, Cyclophosphamide, Thalidomide, Celecoxib and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25703"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>97</Patients><Biomarkers>Thrombospondins</Biomarkers><Condition>Lymphoma</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>celecoxib; celecoxib + cyclophosphamide + thalidomide, Celgene + fenofibrate + etoposide phosphate; cyclophosphamide; etoposide phosphate; fenofibrate; thalidomide, Celgene</Interventions><Reference>CDR0000487628; DFCI-04343; NCT00165321; NCT00357500</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide, Cyclophosphamide, Thalidomide, Celecoxib and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25703"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>97</Patients><Biomarkers>Thrombospondins</Biomarkers><Condition>Neuroblastoma</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>celecoxib; celecoxib + cyclophosphamide + thalidomide, Celgene + fenofibrate + etoposide phosphate; cyclophosphamide; etoposide phosphate; fenofibrate; thalidomide, Celgene</Interventions><Reference>CDR0000487628; DFCI-04343; NCT00165321; NCT00357500</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide, Cyclophosphamide, Thalidomide, Celecoxib and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25703"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>97</Patients><Biomarkers>Thrombospondins</Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>celecoxib; celecoxib + cyclophosphamide + thalidomide, Celgene + fenofibrate + etoposide phosphate; cyclophosphamide; etoposide phosphate; fenofibrate; thalidomide, Celgene</Interventions><Reference>CDR0000487628; DFCI-04343; NCT00165321; NCT00357500</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide, Cyclophosphamide, Thalidomide, Celecoxib and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25703"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>97</Patients><Biomarkers>Thrombospondins</Biomarkers><Condition>Central nervous system tumor</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>celecoxib; celecoxib + cyclophosphamide + thalidomide, Celgene + fenofibrate + etoposide phosphate; cyclophosphamide; etoposide phosphate; fenofibrate; thalidomide, Celgene</Interventions><Reference>CDR0000487628; DFCI-04343; NCT00165321; NCT00357500</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide, Cyclophosphamide, Thalidomide, Celecoxib and Fenofibrate in Treating Young Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25703"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>97</Patients><Biomarkers>Thrombospondins</Biomarkers><Condition>Brain tumor</Condition><Controls></Controls><EnrollmentCount>101</EnrollmentCount><Interventions>celecoxib; celecoxib + cyclophosphamide + thalidomide, Celgene + fenofibrate + etoposide phosphate; cyclophosphamide; etoposide phosphate; fenofibrate; thalidomide, Celgene</Interventions><Reference>CDR0000487628; DFCI-04343; NCT00165321; NCT00357500</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin</ProtocolTitle><Sponsor>Universita Degli Studi G D`Annunzio Chieti</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21134"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>27</Patients><Biomarkers>11-dehydro-TXB2; PGE2; TXB2</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen</Interventions><Reference>635-IFL-0508-017; N49-98-71-900; NCT00565500</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin</ProtocolTitle><Sponsor>Universita Degli Studi G D`Annunzio Chieti</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21134"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>27</Patients><Biomarkers>11-dehydro-TXB2; PGE2; TXB2</Biomarkers><Condition>Ischemic heart disease</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen</Interventions><Reference>635-IFL-0508-017; N49-98-71-900; NCT00565500</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of transcranial direct current stimulation on low back pain</ProtocolTitle><Sponsor>AJA University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="303478"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>celecoxib; transcranial direct current stimulation</Interventions><Reference>IR.AJAUMS.REC.1394.28; IRCT2015113025314N1</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NEO-EXCEL</ProtocolAcronym><ProtocolTitle>Neoadjuvant Trial of Pre-Operative Exemestane or Letrozole +/- Celecoxib in the Treatment of Estrogen Receptor-Positive Early Breast Cancer</ProtocolTitle><Sponsor>University Hospital Birmingham NHS Foundation Trust</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="120851"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>266</Patients><Biomarkers>Estrogen receptor</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>266</EnrollmentCount><Interventions>celecoxib; exemestane; letrozole</Interventions><Reference>2006-000436-27; BR3031; ISRCTN09768535; MREC N: 06/MRE07/31; NEO-EXCEL; UKCRN ID: 1729</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>POP</ProtocolAcronym><ProtocolTitle>Toradol versus Celecoxib for Post-operative Pain</ProtocolTitle><Sponsor>University of Tennessee Health Science Center (US)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="318223"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>138</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Tora-Dol</Controls><EnrollmentCount>170</EnrollmentCount><Interventions>Celebrex; Dilaudid; Lortab; Tylenol</Interventions><Reference>12-02041-FB; NCT03331315; POP</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind, randomized, placebo-controlled, multicenter, parallel-group, comparative clinical trial to evaluate the safety and efficacy of celecoxib for the treatment of patients with Rheumatoid arthritis (RA)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="78986"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>330</Patients><Biomarkers>CRP</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>330</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191288; N49-96-02-012</Reference></Row><Row><ArmCount>7</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty</ProtocolTitle><Sponsor>Duke University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="266165"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Hip motion</Biomarkers><Condition>Pain</Condition><Controls>acetaminophen</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Ofirmev</Interventions><Reference>NCT02839876; PRO00072610</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multimodal Analgesic Using Morphine and COX-2 With or Without Dexmedetomidine for Colorectal Surgery</ProtocolTitle><Sponsor>The University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77370"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Blood pressure; Heart rate; Serum sCD40L</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>Diprivan; atracurium; atropine; celecoxib; dexmedetomidine; dologesic; ephedrine; fentanyl; hydralazine; isoflurane; labetalol; morphine sulphate; neostigmine; pethidine; phenylephrine</Interventions><Reference>200907176018; HKUCTR-68; NCT01353456; UW 06-009 T/1034</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="94686"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>14</Patients><Biomarkers>CYP2C9</Biomarkers><Condition>Neuroendocrine tumor</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>capecitabine; celecoxib</Interventions><Reference>12-1318; NCI-2012-01704; NCT01705106</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="94686"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>14</Patients><Biomarkers>CYP2C9</Biomarkers><Condition>Thymus neoplasm</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>capecitabine; celecoxib</Interventions><Reference>12-1318; NCI-2012-01704; NCT01705106</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="94686"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>14</Patients><Biomarkers>CYP2C9</Biomarkers><Condition>Thymoma</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>capecitabine; celecoxib</Interventions><Reference>12-1318; NCI-2012-01704; NCT01705106</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies</ProtocolTitle><Sponsor>University of Chicago</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="94686"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>14</Patients><Biomarkers>CYP2C9</Biomarkers><Condition>Advanced solid tumor</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>capecitabine; celecoxib</Interventions><Reference>12-1318; NCI-2012-01704; NCT01705106</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of Celecoxib After Surgical Sperm Retrieval</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="75804"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>78</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>1010011319; NCT01323595</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Vanderbilt-Ingram Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44030"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers>Cyclo-oxygenase-2; MMP; PEG2; PGE-M; Proangiogenic parameters; VEGF; microvessel density</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000584732; NCT00653250; P30CA068485; P50CA090949; VICC THO0055; VU-VICC-000724; VU-VICC-THO-0055</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, double-blind, randomized, three arm, two-period, crossover study to compare celecoxib, acetaminophen, and placebo for the treatment of patients with osteoarthritis of the hip or knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80127"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>524</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>524</EnrollmentCount><Interventions>acetaminophen; celecoxib</Interventions><Reference>635-IFL-0508-010</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib as a Chemopreventive Agent in Current and Former Smokers</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60530"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>219</Patients><Biomarkers></Biomarkers><Condition>Nicotine dependence</Condition><Controls></Controls><EnrollmentCount>219</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ID00-230; NCT00981201</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines and Iscomatrix With Chemotherapy After Tumor Removal</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="187809"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>41</Patients><Biomarkers></Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>41</EnrollmentCount><Interventions>Epigenetically modified autologous tumor cells; Iscomatrix; Thoracic metastasectomy; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0148; 110148; NCT01341496</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines and Iscomatrix With Chemotherapy After Tumor Removal</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="187809"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>41</Patients><Biomarkers></Biomarkers><Condition>Melanoma</Condition><Controls></Controls><EnrollmentCount>41</EnrollmentCount><Interventions>Epigenetically modified autologous tumor cells; Iscomatrix; Thoracic metastasectomy; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0148; 110148; NCT01341496</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines and Iscomatrix With Chemotherapy After Tumor Removal</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="187809"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>41</Patients><Biomarkers></Biomarkers><Condition>Metastatic lung cancer</Condition><Controls></Controls><EnrollmentCount>41</EnrollmentCount><Interventions>Epigenetically modified autologous tumor cells; Iscomatrix; Thoracic metastasectomy; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0148; 110148; NCT01341496</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CITICOX</ProtocolAcronym><ProtocolTitle>Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib (CITICOX)</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="141426"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>51</Patients><Biomarkers>CRP; IL-1; IL-17; IL-1Ra; IL-6; Kynurenine; MIF; PGE-2; RNA monocyte; TGF-beta; TNF-R1; TNF-R2; TNF-a; Tryptophan</Biomarkers><Condition>Depression</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>celecoxib; sertraline</Interventions><Reference>AFX02; AT::AFX02; CITICOX; DE::AFX02; EudraCT 2009-011990-34</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Tramadol Versus Oral Celecoxib for Post-perineal Repair Analgesia</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="355353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Celebrex; tramadol (Tramaw, Global Napi, Giza,Egypt)</Interventions><Reference>NCT03694873</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib on Transitional Pain After Outpatient Surgery</ProtocolTitle><Sponsor>Lawson Health Research Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="12724"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celebrex</Interventions><Reference>10457; NCT00664690; R-04-309</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>University of Michigan Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44347"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>15</Patients><Biomarkers></Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>capecitabine; celecoxib; irinotecan</Interventions><Reference>C-2424; NCT00230399; UMCC 3-24</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial Of Pregabalin And COX2 In Spinal Stenosis</ProtocolTitle><Sponsor>Seoul National University Bundang Hospital, South Korea</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="346084"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Spinal stenosis</Condition><Controls>Celebrex</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Celebrex; pregabalin</Interventions><Reference>NCT03584074; PRECOX2</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PreDuoFAP</ProtocolAcronym><ProtocolTitle>Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis</ProtocolTitle><Sponsor>Radboud University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="38779"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Adenomatous polyposis coli protein; Beta-catenin; Blood pressure; Caspase-3; Cyclin D1; Cyclooxygenase-2 (COX-2); E-cadherin; Glutathione S-transferase A1; Glutathione S-transferase P1; KIAA1199; Peroxisome proliferative activated receptor delta</Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls>celecoxib</Controls><EnrollmentCount>53</EnrollmentCount><Interventions>Urso; celecoxib; celecoxib + Urso</Interventions><Reference>ABR nr.: NL23569.091.08; CMO: 2008/148; EudraCT: 2008-003696-43; NCT00808743; PreDuoFAP; RUN 2008-4198</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PreDuoFAP</ProtocolAcronym><ProtocolTitle>Prevention of Progression of Duodenal Adenomas in Patients With Familial Adenomatous Polyposis</ProtocolTitle><Sponsor>Radboud University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="38779"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Adenomatous polyposis coli protein; Beta-catenin; Blood pressure; Caspase-3; Cyclin D1; Cyclooxygenase-2 (COX-2); E-cadherin; Glutathione S-transferase A1; Glutathione S-transferase P1; KIAA1199; Peroxisome proliferative activated receptor delta</Biomarkers><Condition>Adenoma</Condition><Controls>celecoxib</Controls><EnrollmentCount>53</EnrollmentCount><Interventions>Urso; celecoxib; celecoxib + Urso</Interventions><Reference>ABR nr.: NL23569.091.08; CMO: 2008/148; EudraCT: 2008-003696-43; NCT00808743; PreDuoFAP; RUN 2008-4198</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Individual Medication Effectiveness Tests Comparing Celecoxib (Encapsulated Celebrex) With Panadol Extend for Relief of Osteoarthritis</ProtocolTitle><Sponsor>University of Queensland</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="152798"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>59</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>59</EnrollmentCount><Interventions>celecoxib; paracetamol</Interventions><Reference>ACTRN12605000476639</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib Versus Placebo Before and After Knee Surgery on Overall Use of Analgesics After Surgery</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43263"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>204</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>204</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191067; NCT00633438</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Depression</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="125106"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>37</Patients><Biomarkers></Biomarkers><Condition>Major depressive disorder</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; fluoxetine; fluoxetine; fluoxetine + celecoxib</Interventions><Reference>5402; IRCT138711141556N5</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Celecoxib Vs Placebo to Prevent Pain in a Paced Walk</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="13921"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>06-04-41; NCT00194090</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Of Celecoxib In The Treatment Of Bipolar Disorder</ProtocolTitle><Sponsor>Kurdistan University of Medical Sciences, Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="241692"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>46</Patients><Biomarkers></Biomarkers><Condition>Mania</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib; valproic acid</Interventions><Reference>22216; IRCT201307171556N53</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Of Celecoxib In The Treatment Of Bipolar Disorder</ProtocolTitle><Sponsor>Kurdistan University of Medical Sciences, Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="241692"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>46</Patients><Biomarkers></Biomarkers><Condition>Bipolar disorder</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib; valproic acid</Interventions><Reference>22216; IRCT201307171556N53</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>SUCCESS-VII</ProtocolAcronym><ProtocolTitle>A phase IV, double-blind, randomized, parallel-group comparative clinical trial to evaluate the safety of celecoxib versus rofecoxib in treating hypertensive patients with osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80084"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1092</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>1092</EnrollmentCount><Interventions>celecoxib; rofecoxib</Interventions><Reference>A3191118; N49-00-02-181; SUCCESS-VII</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of decreasing pain of impacted wisdom teeth</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="219723"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>180</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>acetaminophen; celecoxib; codeine; ibuprofen</Interventions><Reference>4693; IRCT2014113020158N1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single oral dose, randomized, balanced, open, two-treatment, two sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="223495"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib (Senosiain Laboratories)</Interventions><Reference>AS/AA/NOV-14/0024</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty</ProtocolTitle><Sponsor>Hanyang University Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="217563"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>168</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib; naproxen + esomeprazole (oral fixed-dose combination, inflammatory pain), AstraZeneca/Aralez; oxycodone (formulated with abuse-deterrent naloxone, prolonged release tablet, pain), Mundipharma; tramadol + paracetamol (oral extended-release, pain), Janssen Korea</Controls><EnrollmentCount>168</EnrollmentCount><Interventions>celecoxib; duloxetine; naproxen + esomeprazole (oral fixed-dose combination, inflammatory pain), AstraZeneca/POZEN; oxycodone (formulated with abuse-deterrent naloxone, prolonged release tablet, pain), Mundipharma; tramadol + paracetamol (oral extended-release, pain), Janssen Korea</Interventions><Reference>CYMBALTATKR; NCT02307305</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="41957"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>ceramide; sphingosine-1-phosphate</Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>bortezomib; bortezomib + celecoxib; celecoxib</Interventions><Reference>CDR0000454922; MILLENNIUM-100825; MUSC-I065-341-03; NCT00290680</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in the treatment of obsessive-compulsive disorder</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="165956"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Obsessive compulsive disorder</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib; fluvoxamine</Interventions><Reference>23218; IRCT201312181556N56</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>NSKO</ProtocolAcronym><ProtocolTitle>NSAID Treatment in Knee Osteoarthritis</ProtocolTitle><Sponsor>University of Cantanzaro</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="134043"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Cytokine; IL-6; IL-8; TNF-alpha; VEGF</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>Celecoxib; diclofenac, Novartis; ibuprofen</Interventions><Reference>LGOG1; NCT01860833; NSKO</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia</ProtocolTitle><Sponsor>Fox Chase Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29324"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000393574; FCCC-02028; NCT00101335</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Prospective, Randomized, Multicenter Trial of Pregabalin and Celecoxib for Lumbar Spinal Stenosis</ProtocolTitle><Sponsor>Kobe University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="138427"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib; pregabalin</Interventions><Reference>JPRN-UMIN000007419</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Women With an Early Diagnosis of Breast Cancer, Taking Celecoxib Between the Biopsy and Lumpectomy/Mastectomy</ProtocolTitle><Sponsor>University of Kansas</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47957"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Her-2/neu; Ki-67; MAP kinase; angiogenesis associated proteins; pAKT; pERK1; pERK2</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>9061; NCT00328432</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib on Markers of Vascular Inflammation</ProtocolTitle><Sponsor>University of Florida</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="20846"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>75</Patients><Biomarkers>C-reactive protein (CRP); IL-6; TNF-alpha</Biomarkers><Condition>Hypertension</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>219-2001; NCT00471341</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib on Markers of Vascular Inflammation</ProtocolTitle><Sponsor>University of Florida</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="20846"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>75</Patients><Biomarkers>C-reactive protein (CRP); IL-6; TNF-alpha</Biomarkers><Condition>Coronary artery disease</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>219-2001; NCT00471341</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An open, randomized, two-step, crossover study of comparative pharmacokinetics (bioequivalence) of Celecoxib, 200 mg capsules, manufactured by Pharmproekt, Russia, and Celebrex, 200 mg capsules, produced by Pfizer Inc, USA, in two groups of healthy volunteers after a single fasting dose</ProtocolTitle><Sponsor>Farmproekt</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="381003"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>58</EnrollmentCount><Interventions>celecoxib, Farmproekt</Interventions><Reference>FP-CE-BE-01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="23663"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>51</Patients><Biomarkers>13-S-HODE; 15-LOX-1; Adenomatous polyposis coli protein  ; Cholesterol; GATA-6; HDL; LDL; Transcription factor GATA-6; Triglyceride</Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>1R01CA106577-01A1; DM02-592; NCI-2012-01522; NCT00258219; NCT00503035</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial of Transcathether Arterial Chemoembolization Combined With Non-Cytotoxic Drugs in Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="133742"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; lanreotide</Interventions><Reference>ChiCTR-TRC-00000173</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>Lesions2</ProtocolAcronym><ProtocolTitle>Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers</ProtocolTitle><Sponsor>Research Associates of New York, LLP</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="31690"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Stomach ulcer</Condition><Controls></Controls><EnrollmentCount>125</EnrollmentCount><Interventions>aspirin; celecoxib; clopidogrel; naproxen</Interventions><Reference>GA319181; Healing Study; Lesions2; NCT00778193</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>Lesions2</ProtocolAcronym><ProtocolTitle>Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers</ProtocolTitle><Sponsor>Research Associates of New York, LLP</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="31690"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Duodenal ulcer</Condition><Controls></Controls><EnrollmentCount>125</EnrollmentCount><Interventions>aspirin; celecoxib; clopidogrel; naproxen</Interventions><Reference>GA319181; Healing Study; Lesions2; NCT00778193</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effects of celecoxib plus risperidone on psychopathology, cognition and cytokine levels in chronic schizophrenia: a double-blind, randomized and placebo-controlled trial</ProtocolTitle><Sponsor>Jingzhou Mental Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="380594"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>90</Patients><Biomarkers>C-reactive protein; Cytokines; Interleukin 1; Interleukin-4; Interleukin-6; Tumor necrosis factor</Biomarkers><Condition>Schizophrenia</Condition><Controls>risperidone</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>celecoxib; risperidone</Interventions><Reference>ChiCTR1900023058</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of oral chemotherapy after completion of radiation and chemotherapy versus observation in carcinoma esophagus</ProtocolTitle><Sponsor>Tata Memorial Center, Tata Memorial Hospital &amp; Cancer Research Inst</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="241408"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>CTRT; celecoxib; methotrexate</Interventions><Reference>CTRI/2015/09/006204</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma</ProtocolTitle><Sponsor>China Medical University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="258313"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>270</Patients><Biomarkers></Biomarkers><Condition>Mouth tumor</Condition><Controls></Controls><EnrollmentCount>270</EnrollmentCount><Interventions>celecoxib; cisplatin; radiotherapy</Interventions><Reference>CMUH102-REC1-071; NCT02739204</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, double-blind, randomized, parallel-group clinical trial to compare celecoxib and diclofenac for antiarthritic efficacy and tolerability in patients with osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80091"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>617</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>617</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191309; I49-96-02-042</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Capsule endoscopy: Celecoxib Versus Loxoprofen/Lansoprazole</ProtocolTitle><Sponsor>Medical Co LTA Sumida Hospital, Nippon Medical School Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220776"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>150</Patients><Biomarkers>Hemoglobin</Biomarkers><Condition>Intestine injury</Condition><Controls>lansoprazole; loxoprofen</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UMIN000007936</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Traditional Chinese And Anti-rheumatic Drugs For The Treatment Of Rheumatoid Arthritis</ProtocolTitle><Sponsor>The Affiliated Hospital of Chengdu University of Traditional Chinese Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="103386"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Anti-cyclic citrullinated peptide; C-reactive protein</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Ginger-partitioned moxibustion of the Zusanli acupoint; Shanhuang Wuji decoction; celecoxib; esomeprazole</Interventions><Reference>ChiCTR-TCC-12002824</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preoperative Non-steroidal Anti-inflammatory Drugs (NSAID) to Colorectal Cancer Patients</ProtocolTitle><Sponsor>University of Gothenburg</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="49335"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>celecoxib; indomethacin</Interventions><Reference>NCT00473980; kl4501122</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1234</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>1234</EnrollmentCount><Interventions>celecoxib; loxoprofen</Interventions><Reference>A3191174; JapicCTI-050166; NCT00141154</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder</ProtocolTitle><Sponsor>Fox Chase Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="41678"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers>COX-1; peroxisome proliferator-activated receptor-gamma (PPAR-gamma)</Biomarkers><Condition>Bladder cancer</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib; rosiglitazone</Interventions><Reference>CDR0000365460; FCCC-03018; NCT00084578</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Post tonsillectomy pain control – a double-blinded, randomized, prospective study</ProtocolTitle><Sponsor>Frankston Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="150695"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib; oxycodone; paracetamol; penicillin</Interventions><Reference>ACTRN12613000600741; ANZCTR364153; HREC/12/PH/55; U1111-1142-4978</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Protocol for the Treatment of Metastatic Ewing Sarcoma</ProtocolTitle><Sponsor>Italian Sarcoma Group</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="257454"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>adriamycin; busulfan; celecoxib; cyclophosphamide; etoposide phosphate; ifosfamide; irinotecan; melphalan; peripheral blood stem cells transplantation; radiotherapy (42 to 54 Gy); temozolomide; vincristine</Interventions><Reference>ISG/AIEOP EW-2; NCT02727387</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Protocol for the Treatment of Metastatic Ewing Sarcoma</ProtocolTitle><Sponsor>Italian Sarcoma Group</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="257454"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Ewing sarcoma</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>adriamycin; busulfan; celecoxib; cyclophosphamide; etoposide phosphate; ifosfamide; irinotecan; melphalan; peripheral blood stem cells transplantation; radiotherapy (42 to 54 Gy); temozolomide; vincristine</Interventions><Reference>ISG/AIEOP EW-2; NCT02727387</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison the Effect of Celecoxib and Ibuprofen on the Treatment of Primary Dysmenorrhea on Students of Ilam Univercity of Medical Sciences</ProtocolTitle><Sponsor>Ilam University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="149935"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Dysmenorrhea</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib; ibuprofen</Interventions><Reference>162/52/22; IRCT201304096790N4</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Diclofenac Capsules to Treat Dental Pain</ProtocolTitle><Sponsor>Iroko Pharmaceuticals LLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="73693"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>202</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>202</EnrollmentCount><Interventions>diclofenac (SoluMatrix/capsule, dental pain), Iroko/iCeutica</Interventions><Reference>DIC2-08-03; NCT00985439</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Nephroblastoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Osteosarcoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Rhabdomyosarcoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Neuroblastoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Ewing sarcoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Soft tissue sarcoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Central nervous system tumor</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243234"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Brain tumor</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>AflacST1502; IRB00082488; NCT02574728</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study Between Two Medications For Oral Administration Of Celecoxib 200 mg Capsules With Food In Healthy Male Volunteers</ProtocolTitle><Sponsor>Not Assigned</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="163571"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CE-PEC.13104</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, multicenter, active and placebo-controlled, parallel group study to evaluate the efficacy and safety of celecoxib compared to loxoprofen for the treatment of patients with osteoarthritis (OA) of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79887"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>950</Patients><Biomarkers>BUN; CPK; Cholesterol; LDH; Total protein</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>950</EnrollmentCount><Interventions>celecoxib; loxoprofen</Interventions><Reference>A3191114; J49-01-02-216</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Selective COX-2 Inhibition on Neuroinflammation in Parkinson's Disease</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="137139"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Neuritis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>16901; EudraCT: 2007-001206-24; ISRCTN59798735</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Indomethacin Capsules to Treat Dental Pain</ProtocolTitle><Sponsor>Iroko Pharmaceuticals LLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="73656"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>203</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>203</EnrollmentCount><Interventions>indomethacin (SoluMatrix/capsule, dental pain), Iroko/iCeutica</Interventions><Reference>IND2-08-03; NCT00964431</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Heterotopic Ossification (HO) Celebrex Study</ProtocolTitle><Sponsor>US Naval Medical Research Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="88857"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Heterotopic ossification</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>110587; 352511; NCT01631669</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in preventing breast cancer in at-risk pre-menopausal women</ProtocolTitle><Sponsor>University of Kansas Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29731"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>110</Patients><Biomarkers>Breast; Breast cancer type 1 susceptibility protein; Breast cancer type 2 susceptibility protein; COX-2; E3 ubiquitin-protein ligase MIB1; Estrogen receptor; Insulin-like growth factor 1/Insulin-like growth factor binding protein-3 ratio; Ki-67 (MIB 1) antibody</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000271935; KUMC-HSC-8919-02; N01CN15135; NCT00056082</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-small-cell Lung Cancer</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29478"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>celecoxib; erlotinib</Interventions><Reference>4939-04-6R2; CDR0000377689; NCI-2009-00886; NCT00088959; U01CA096123</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cox-2 Inhibition in Radiation-Induced Oral Mucositis</ProtocolTitle><Sponsor>University of Connecticut</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="18920"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Oral mucositis</Condition><Controls></Controls><EnrollmentCount>43</EnrollmentCount><Interventions>celecoxib; radiation therapy</Interventions><Reference>COXAON-0509-150; GCRC 487; IRB 03 -157- 2; K23DE016946-05; NCT00698204</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Efficacy and Safety of Celecoxib Topical Administration Cream 1 and 2% to Reduce Pain in Patients with Acute Soft Tissue Injury</ProtocolTitle><Sponsor>Maver Products, SA de CV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="209060"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>111</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>111</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UIM-IICO/MAV/CEL-13.02</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot study to evaluate the bioequivalence of Celecoxib 200 mg capsules, Celecoxib (Landsteiner Scientific, SA de CV) versus Celebrex (Pfizer, Inc) in healthy volunteers</ProtocolTitle><Sponsor>Landsteiner Scientific Sa De Cv</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="229071"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>8</Patients><Biomarkers>Body height; Total body mass</Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>8</EnrollmentCount><Interventions>celecoxib (Landsteiner)</Interventions><Reference>15-006CEL</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-term, Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="252559"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>250</Patients><Biomarkers>Joint stiffness; Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>250</EnrollmentCount><Interventions>celecoxib; diclofenac; naproxen; tanezumab</Interventions><Reference>2013-002549-12; 2015-CT0304; A4091064; NCT02674386; PHRR160322-001198; TJR FOLLOW-UP</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SFCE METRO 01</ProtocolAcronym><ProtocolTitle>A Clinical Trial Using Metronomic Oral Low-dose Cyclophosphamide Alternating With Low-dose Oral Methotrexate With Continuous Celecoxib and Weekly Vinblastine in Children and Adolescents With Relapsed or Progressing solid Tumors</ProtocolTitle><Sponsor>Assistance Publique Hopitaux De Marseille</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="74268"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Circulating endothelial cells [CEC]; Endothelial precursor cells [CEP]</Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; methotrexate; vinblastine</Interventions><Reference>2010-021792-81; 2010-12; NCT01285817; SFCE METRO 01</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Multimodal Analgesia Following Hip Arthroscopy</ProtocolTitle><Sponsor>University of Western Ontario</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="320396"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Naprosyn; Percocet</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>Naprosyn; Percocet; bupivacaine; celecoxib; gabapentin; zopiclone</Interventions><Reference>110350; NCT03351439</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of efficacy of platelet-rich plasma injection plus oral celecoxib to treat knee osteoarthritis</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="315183"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; platelet-rich plasma</Interventions><Reference>1910095603; IRCT201301167274N6</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness of taping in knee osteoarthritis</ProtocolTitle><Sponsor>Isfahan University of medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="230023"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; exercise</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib; exercise; knee taping</Interventions><Reference>393450; IRCT2015041021673N1</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Photodynamic Therapy-Induced Immune Modulation: Part III</ProtocolTitle><Sponsor>Wright State Physicians</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="350929"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Actinic keratosis</Condition><Controls>celecoxib</Controls><EnrollmentCount>48</EnrollmentCount><Interventions>celecoxib; photodynamic therapy</Interventions><Reference>NCT03643744; PDT PART III</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the effect celecoxib against radiotherapy induced acute toxicities in the patients with prostate cancer compared with placebo group</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="303051"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Alanine transaminase; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatinine; Urea</Biomarkers><Condition>Urinary tract disease</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; external beam radiotherapy (70 Gy)</Interventions><Reference>IRCT2016020626401N1; SBMU.REC.1393.731</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the effect celecoxib against radiotherapy induced acute toxicities in the patients with prostate cancer compared with placebo group</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="303051"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Alanine transaminase; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatinine; Urea</Biomarkers><Condition>Intestine disease</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; external beam radiotherapy (70 Gy)</Interventions><Reference>IRCT2016020626401N1; SBMU.REC.1393.731</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the effect celecoxib against radiotherapy induced acute toxicities in the patients with prostate cancer compared with placebo group</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="303051"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Alanine transaminase; Alkaline phosphatase; Aspartate aminotransferase; Bilirubin; Blood cells; Creatinine; Urea</Biomarkers><Condition>Toxicity</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; external beam radiotherapy (70 Gy)</Interventions><Reference>IRCT2016020626401N1; SBMU.REC.1393.731</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="258296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Knee motion; Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>Celebrex; dexamethasone; manipulation under anesthesia</Interventions><Reference>15-009075; NCT02739035</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of low dose alpha-IFN combined celecoxib in reducing the metastasis of HCC after radiotherapy</ProtocolTitle><Sponsor>Fudan University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="92033"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>166</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls></Controls><EnrollmentCount>166</EnrollmentCount><Interventions>celecoxib; interferon-alpha</Interventions><Reference>ChiCTR-TRC-10000900</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib affecting inflammation following thoracic and abdominal surgery (Phase II study)</ProtocolTitle><Sponsor>Peter MacCallum Cancer Centre</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220402"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>Creatinine; Interleukin 1; Interleukin-10; Interleukin-6; Prostaglandins</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>32</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>13/06; ACTRN12615000041550; ANZCTR367658</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effectiveness and safety of celecoxib combined with diacerein in the treatment of senile degenerative knee osteoarthritis</ProtocolTitle><Sponsor>Second Affiliated Hospital Nanjing Medical University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="323129"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>celecoxib; celecoxib; diacerein; diacerein</Interventions><Reference>ChiCTR-IOR-17013867</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib After Tonsillectomy</ProtocolTitle><Sponsor>Childrens Hospital of Philadelphia</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="275525"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>172</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>acetaminophen; oxycodone</Controls><EnrollmentCount>172</EnrollmentCount><Interventions>Celebrex; acetaminophen; oxycodone</Interventions><Reference>15-011707; NCT02934191</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Different Doses of Celecoxib on Pain Control After Leg Fracture Surgery</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="133367"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>4291; IRCT201010194969N1</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer</ProtocolTitle><Sponsor>UNC Lineberger Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44958"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>14</Patients><Biomarkers>COX-2; PGE2</Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>14</EnrollmentCount><Interventions>celecoxib; cisplatin; irinotecan</Interventions><Reference>CDR0000561610; LCCC 0203; NCT00280124; NCT00520091</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma</ProtocolTitle><Sponsor>Tel Aviv Sourasky Medical Center</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="88549"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Acute lung injury</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; celecoxib; rosuvastatin; rosuvastatin</Interventions><Reference>NCT01623921; TASMC-08-WAA-026911-TLV</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of celecoxib 200 mg capsule (Liomont, SA de CV) versus Celebrex 200 mg capsule (Pfizer, SA de CV) in healthy subjects of both genders under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Liomont Sa De Cv</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="224981"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib (Liomont, SA de CV)</Interventions><Reference>P546S034V006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dendritic Cells in Lung Cancer</ProtocolTitle><Sponsor>Region Hovedstaden V/Herlev Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37685"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>MelCancerVac; celecoxib</Interventions><Reference>NCT00442754</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>City of Hope Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44048"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>107</Patients><Biomarkers>15-Keto-13,14-dihydroprostaglandin E2; COX-2; E-cadherin; EGFR; Prostaglandin E-metabolite</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>107</EnrollmentCount><Interventions>Celebrex; Tarceva; Tarceva</Interventions><Reference>06254; CDR0000549751; NCI-2010-00353; NCT00499655</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chronic Pain After Breast Cancer Surgery</ProtocolTitle><Sponsor>Radboud University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="134164"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>110</Patients><Biomarkers></Biomarkers><Condition>Cancer pain</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>celecoxib; midazolam; parecoxib</Interventions><Reference>CMO-nr. 2004/239; NTR1793</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Evaluation of Transversus Abdominis Plane Block and Celecoxib After Laparoscopic Gastrectomy</ProtocolTitle><Sponsor>Kansai Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="127577"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>Transversus abdominis plane block; celecoxib; fentanyl</Interventions><Reference>JPRN-UMIN000007457</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of Gabapentin, Celecoxib and Their Combination on Pain and Systemic Symptoms After Laminectomy</ProtocolTitle><Sponsor>Ilam University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="240870"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>152</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>152</EnrollmentCount><Interventions>celecoxib; celecoxib; gabapentin; gabapentin</Interventions><Reference>IR.MEDILAM. EC/94/H/269; IRCT2015071222870N3</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Variability in Response to Non-Steroidal Anti-Inflammatory Drugs</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="235070"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>288</Patients><Biomarkers>Aldosterone; Blood pressure; Creatinine; Estimated glomerular filtration rate; Fatty acids, omega-6; Fractional excretion of potassium; Fractional excretion of sodium; Omega-3 Fatty acids; Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2; Renin; Urea nitrogen; omega-3 Fatty acids/omega-6 fatty acids ratio</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>288</EnrollmentCount><Interventions>Celebrex; Naprosyn</Interventions><Reference>5U54HL117798; 820715; NCT02502006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of bioequivalence between Celecoxib 200 mg capsules (Siegfried Rhein, SA de CV) and Celebrex 200 mg capsules (Pfizer, Inc)</ProtocolTitle><Sponsor>Siegfried Rhein Sa De Cv</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="208929"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>28</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>28</EnrollmentCount><Interventions>Celecoxib (Siegfried Rhein)</Interventions><Reference>BE-CXB-007/0514</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="2419"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>138</Patients><Biomarkers></Biomarkers><Condition>Alzheimers disease</Condition><Controls></Controls><EnrollmentCount>138</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>DSIR AT-GP; NCT00065169; R01 MH58156; R01MH058156</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="2419"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>138</Patients><Biomarkers></Biomarkers><Condition>Dementia</Condition><Controls></Controls><EnrollmentCount>138</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>DSIR AT-GP; NCT00065169; R01 MH58156; R01MH058156</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="33155"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Age related macular degeneration</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>02-EI-0257; 020257; NCT00043680</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, double-blind, placebo-controlled, randomized study to evaluate the short-term efficacy and safety of celecoxib and ketoprofen for the treatment of patients with ankylosing spondylitis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="80173"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>246</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>246</EnrollmentCount><Interventions>celecoxib; ketoprofen</Interventions><Reference>A3191188; F49-98-02-137</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors</ProtocolTitle><Sponsor>Hartford Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="80692"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>15-PGDH; COX-2; PGE2; Transforming growth factor beta 1; Transforming growth factor beta-2; Vitamin D-binding protein</Biomarkers><Condition>Breast tumor</Condition><Controls>cholecalciferol</Controls><EnrollmentCount>45</EnrollmentCount><Interventions>celecoxib; cholecalciferol</Interventions><Reference>200806; NCT01425476</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, parallel group study comparing the incidence of gastrodudenal ulcer associated with celecoxib with that of diclofenac and ibuprofen  for the treatment of patients with osteoarthritis or rheumatoid arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79808"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>1099</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>1099</EnrollmentCount><Interventions>SC-58635; diclofenac; ibuprofen</Interventions><Reference>N49-97-02-071</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, double-blind, parallel group study comparing the incidence of gastrodudenal ulcer associated with celecoxib with that of diclofenac and ibuprofen  for the treatment of patients with osteoarthritis or rheumatoid arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79808"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>1099</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>1099</EnrollmentCount><Interventions>SC-58635; diclofenac; ibuprofen</Interventions><Reference>N49-97-02-071</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Barbara Ann Karmanos Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43132"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>55</Patients><Biomarkers>COX-2</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>capecitabine; celecoxib; irinotecan</Interventions><Reference>CDR0000445439; NCT00258232; WSU-C-2424</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="42798"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>PSA</Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>celecoxib; epirubicin; estramustine</Interventions><Reference>K-EPIRU-0030-280-US; NCT00218205</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Colorectal Cancer in Young Patients With a Genetic Predisposition for Familial Adenomatous Polyposis</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29503"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers>Adenomatous polyposis coli protein; Adenomatous polyposis coli protein  </Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000596468; ID02-090; MDA-ID-02090; NCT00685568</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV clinical trial to eveluate the safety and efficacy of celecoxib versus naproxen for the treatment of Hispanic patients with osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80121"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>315</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>315</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>A3191053</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Factors Affecting the Speed of Recovery After ACL Reconstruction</ProtocolTitle><Sponsor>University of Washington</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="363898"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Knee motion; Muscle strength; Thigh muscle</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>Celebrex; Oxycontin TR; Tylenol; dexamethasone; ropivacaine; standard ultrasound-guided adductor nerve block; standard ultrasound-guided femoral nerve block</Interventions><Reference>51788; NCT03770806</Reference></Row><Row><ArmCount>5+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Two Multimodal Analgesia Regimens in Total Knee Arthroplasty</ProtocolTitle><Sponsor>Ciusss de L'Est de l'Ile de Montreal</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="384951"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Knee motion</Biomarkers><Condition>Pain</Condition><Controls>acetaminophen; adductor canal block; celecoxib; dexamethasone; periarticular infiltration; pregabalin; ropivacaine</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Hydromorph Contin; acetaminophen; adductor canal block; celecoxib; dexamethasone; periarticular infiltration; pregabalin; ropivacaine</Interventions><Reference>MULTIMODALTKA; NCT03990038</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Irinotecan in Combination With Three Methods of Administration of Fluoropyrimidine</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="42930"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>547</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>547</EnrollmentCount><Interventions>5-FU; CapeIri; FOLFIRI; FOLFIRI+bev; bevacizumab; capecitabine; celecoxib; irinotecan; leucovorin; m-IFL; mIFL+bev</Interventions><Reference>A5961021; CPTAIV-0020-411; NCT00101686</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Early Diuresis Following Colorectal Surgery</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="221638"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>123</Patients><Biomarkers>Potassium</Biomarkers><Condition>Diuresis</Condition><Controls>ERAS; acetaminophen; celecoxib; gabapentin; tramadol</Controls><EnrollmentCount>123</EnrollmentCount><Interventions>ERAS; acetaminophen; celecoxib; furosemide; gabapentin; tramadol</Interventions><Reference>14-008292; NCT02351934; UL1TR000135</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Head and Neck Cancer That Can Be Removed By Surgery</ProtocolTitle><Sponsor>Centre Hospitalier Universitaire Vaudois</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="31196"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Angiopoietin like-2; Caspase 6; ErbB2; Interleukin-8 (IL-8); MAPK-4; MMP-13; MMP-9; N-CAM; PAI-1; PGE2; VEGF; c-IAP-2; integrin alpha V; sFlt-1</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000490047; CHUV-CEPO-161-05; EU-20627; NCT00357617</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22170"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>385</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>388</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191082; NCT00638807</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NVALT-4</ProtocolAcronym><ProtocolTitle>A Randomized, Placebo-Controlled, Phase II/III with Celecoxib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Academic Hospital Maastricht</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="144523"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>561</Patients><Biomarkers></Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>540</EnrollmentCount><Interventions>carboplatin; celecoxib; docetaxel</Interventions><Reference>2003/086; 2003/086 METC UMC Maastricht; NTR1703; NVALT-4</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect Comparison of Oral Medicine to Herpetic Pain</ProtocolTitle><Sponsor>Higashi Omiya General Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="138518"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>acetaminophen; celecoxib; gabapentin; pregabalin; tramadol hydrochloride</Interventions><Reference>JPRN-UMIN000009234</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>METRO-NB2012</ProtocolAcronym><ProtocolTitle>Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma</ProtocolTitle><Sponsor>University of Cologne</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="249840"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers></Biomarkers><Condition>Neuroblastoma</Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; propranolol; vinblastin</Interventions><Reference>2011-004593-29; DRKS00010901; METRO-NB2012; NCT02641314; UNI-KOELN-1495</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Barbara Ann Karmanos Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="27256"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Cyclooxygenase-2; PGE2; VEGF</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib; docetaxel; docetaxel + celecoxib</Interventions><Reference>AVENTIS-WSU-C-2304; CDR0000069164; NCI-V01-1688; NCT00030420; P30CA022453; WSU-06-08-01-M01-FB; WSU-C-2304</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43262"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191066; NCT00633386</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Study on the Efficacy of Celecoxib in Patients With Postoperative Pain (A Multicenter, Randomized, Open-Label, Parallel-Group, Controlled Study of Celecoxib versus Loxoprofen)</ProtocolTitle><Sponsor>Nippon Medical School Foundation</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="154576"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>230</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>loxoprofen</Controls><EnrollmentCount>230</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>JPRN-UMIN000011302</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small-Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43983"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers>COX-2</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>CPT-11; celecoxib; cisplatin</Interventions><Reference>2003-0352; NCT00346801</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, 12-week, multicentre, double-blind, parallel group study to compare the efficacy and incidence of gastroduodenal ulcer associated with celecoxib with that of diclofenac for the treatment of patients with osteoarthritis or rheumatoid arthritis in Hong Kong</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79836"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>89</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>89</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191280; I49-98-02-107</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, 12-week, multicentre, double-blind, parallel group study to compare the efficacy and incidence of gastroduodenal ulcer associated with celecoxib with that of diclofenac for the treatment of patients with osteoarthritis or rheumatoid arthritis in Hong Kong</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79836"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>89</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>89</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191280; I49-98-02-107</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Selective COX-2 Inhibition on Ulcer Healing</ProtocolTitle><Sponsor>Chinese University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22621"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Arthritis</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib; dologesics; famotidine</Interventions><Reference>5NA study; NCT00153673</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Selective COX-2 Inhibition on Ulcer Healing</ProtocolTitle><Sponsor>Chinese University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22621"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Stomach ulcer</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib; dologesics; famotidine</Interventions><Reference>5NA study; NCT00153673</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Celecoxib on Electrophysiological Property in Brain of Healthy Volunteer</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="256202"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Motor evoked potential</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; electroencephalography (EEG); transmagnetic stimulation (TMS)</Interventions><Reference>H-1509-130-708; NCT02711579</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>COX-2I trial</ProtocolAcronym><ProtocolTitle>Significance of COX-2 Inhibition in First Line Treatment of Extensive Disease Small-Cell Lung Cancer (ED-SCLC)</ProtocolTitle><Sponsor>The University Clinic of Pulmonary and Allergic Diseases Golnik</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="138270"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>C reactive protein (CRP); Urinary prostaglandin E metabolite (PGE-M)</Biomarkers><Condition>Small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2012-001877-94; COX-2I; COX-2I trial</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23014"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>D1120C00007; NCT00729495</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA)</ProtocolTitle><Sponsor>Novartis Pharmaceuticals Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21791"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1464</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>1464</EnrollmentCount><Interventions>lumiracoxib</Interventions><Reference>CCOX189A2360; NCT00366938</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>MMPITR</ProtocolAcronym><ProtocolTitle>Pre-induction Analgesia: Multimodel Regimen versus Aceteminophen for Post-Ureteroscopy Pain</ProtocolTitle><Sponsor>University of Iowa</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="342540"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Tylenol</Controls><EnrollmentCount></EnrollmentCount><Interventions>Laser lithotripsy; Tylenol; Ureteroscopy; celecoxib; gabapentin; oxycodone</Interventions><Reference>201805826; MMPITR; MMPITR2018; NCT03549611</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex (Celecoxib) Treatment of Laryngeal Papilloma</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23271"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Verruca vulgaris</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00592319; R01DC006617; RDC-006617A</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex (Celecoxib) Treatment of Laryngeal Papilloma</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23271"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Benign tumor</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00592319; R01DC006617; RDC-006617A</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex (Celecoxib) Treatment of Laryngeal Papilloma</ProtocolTitle><Sponsor>Boston University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23271"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Respiratory tract tumor</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00592319; R01DC006617; RDC-006617A</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43711"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Cancer</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; thalidomide</Interventions><Reference>01-046; NCT00165451</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, double-blind, placebo-controlled, randomized, 6-week, comparative clinical trial to evaluate the efficacy of celecoxib and rofecoxib in relieving the signs and symptoms of osteoarthritis of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80087"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>182</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib; rofecoxib</Interventions><Reference>N49-99-02-152</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Efficacy And Safety Versus Diclofenac In Acute Pain Due To Cervical Sprain Related To A Traffic Accident</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="54482"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>8</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>diclofenac</Controls><EnrollmentCount>8</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191352; NCT00894790</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Who Are Receiving Anticonvulsant Drugs and Undergoing Radiation Therapy</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="24080"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers></Biomarkers><Condition>Glioblastoma</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>celecoxib; phenytoin</Interventions><Reference>JHOC-NABTT-2100; NABTT-2100; NABTT-2100 CDR0000328117; NCT00068770; U01CA062475</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of etanercept and celecoxib to treat temporo-mandibular disorders (painful joint conditions)</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13036"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Tumor necrosis factor alpha</Biomarkers><Condition>Pain</Condition><Controls>naproxen</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; etanercept</Interventions><Reference>00-D-0037; 000037; NCT00001955</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of etanercept and celecoxib to treat temporo-mandibular disorders (painful joint conditions)</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13036"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Tumor necrosis factor alpha</Biomarkers><Condition>Arthralgia</Condition><Controls>naproxen</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; etanercept</Interventions><Reference>00-D-0037; 000037; NCT00001955</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of etanercept and celecoxib to treat temporo-mandibular disorders (painful joint conditions)</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13036"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Tumor necrosis factor alpha</Biomarkers><Condition>Temporomandibular joint syndrome</Condition><Controls>naproxen</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; etanercept</Interventions><Reference>00-D-0037; 000037; NCT00001955</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open study, two periods, two treatments, two sequences, cross, randomized, unique dose to evaluate the bioequivalence of celecoxib 200 mg capsules: celecoxib versus Celebrex in fasting conditions</ProtocolTitle><Sponsor>Alpharma S A de C V Lab</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="342621"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>BE14047</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28105"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Dinoprostone; Prostaglandin G/H synthase 2</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000068727; NCI-G01-1966; NCT00020878; P30CA016042; UCLA-0012067</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exclusive usage of Octreotide or combined with celecoxib to prevent and treat with severe acute pancreatitis: a clinical randomized, controlled trial</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="99860"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>372</Patients><Biomarkers>Interleukin 10; Interleukin 6; Somatostatin; Tumor necrosis factor-alpha</Biomarkers><Condition>Pancreatitis</Condition><Controls></Controls><EnrollmentCount>488</EnrollmentCount><Interventions>celecoxib; octreotide; octreotide</Interventions><Reference>ChiCTR-TRC-10000844</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb clinical trial to assess the efficacy of celecoxib on the symptoms of ankylosing spondylitis in comparison to naproxen and placebo</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80170"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>611</Patients><Biomarkers>C-reactive protein</Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>611</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>A3191125; N49-01-02-193</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multimodal analgesia for total knee arthroplasty operation during perioperative period</ProtocolTitle><Sponsor>Karamay City Peoples Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="308396"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>Lo Pacan; celecoxib; femoral nerve block; iv analgesia pump block; ondansetron (Toland); oxycodone; ropivacaine; tramadol</Interventions><Reference>ChiCTR-IOQ-15005898</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Determining the Function of Live-Attenuated Vaccine Induced Pro-Inflammatory Responses in Eliciting Vaccine-Associated Adverse Events and Immunogenicity</ProtocolTitle><Sponsor>Singapore General Hospital Pte Ltd</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="381908"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Infectious disease</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>YF-NSAIDs-01</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thyme gel in reducing knee pain due to Arthritis</ProtocolTitle><Sponsor>Shahrekord University of Medical Sciences and Health Services</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="299728"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Thymus daenensis extract gel; celecoxib; celecoxib; diclofenac</Interventions><Reference>IR.SKUMS.REC.1395.54; IRCT2016112231025N1</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dexmedetomidine Wound Infiltration in Cesarean Section</ProtocolTitle><Sponsor>Attikon Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="323841"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; dexmedetomidine; dexmedetomidine; morphine; paracetamol; ropivacaine; ropivacaine</Interventions><Reference>NCT03382938; WIWDICS</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of adding celecoxib on brain-derived neurotrophic factor and on the severity of symptoms in patients with bipolar disorder who receive electroconvulsive therapy</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="187620"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Brain-derived neurotrophic factor</Biomarkers><Condition>Mania</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>10809-15866; IRCT201401177202N7</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="194683"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Cytokines; Dendritic cells; Granulocyte-macrophage colony-stimulating factor; Hematopoietic progenitor cell antigen CD34; Interferon gamma; Interleukin-2; Interleukin-6; T-Lymphocytes</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>calcitriol; calcitriol; celecoxib; celecoxib</Interventions><Reference>CLIN-003-09S; NCT00953849</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="194683"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Cytokines; Dendritic cells; Granulocyte-macrophage colony-stimulating factor; Hematopoietic progenitor cell antigen CD34; Interferon gamma; Interleukin-2; Interleukin-6; T-Lymphocytes</Biomarkers><Condition>Mouth tumor</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>calcitriol; calcitriol; celecoxib; celecoxib</Interventions><Reference>CLIN-003-09S; NCT00953849</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of 200 mg Celecoxib Capsules in Healthy Volunteers</ProtocolTitle><Sponsor>Berlin Pharmaceutical Industry Co Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="301569"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>42</EnrollmentCount><Interventions>celecoxib test</Interventions><Reference>TCTR20170612004</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, multicenter, double-blind, placebo-controlled, randomized comparative clinical trial to evaluate the efficacy and safety of celecoxib and naproxen for the treatment of patients with osteoarthritis of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80018"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>1214</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>1214</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>N49-96-02-021</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of CG-100649 Versus Celecoxib in Osteoarthritis Patients</ProtocolTitle><Sponsor>CrystalGenomics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="76768"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>125</EnrollmentCount><Interventions>CG-100649</Interventions><Reference>CG100649-2-02; NCT01341405</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Does Optimal Control of Pre-Operative Chronic and Acute Pain Predict Improved Function After Orthopedic Surgery?</ProtocolTitle><Sponsor>Sunnybrook Health Sciences Centre</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22257"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>31</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>31</EnrollmentCount><Interventions>celecoxib; pregabalin</Interventions><Reference>216-2007; NCT00581685; PSI-07-52</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>CRESCENT</ProtocolAcronym><ProtocolTitle>A phase IV, double-blind, randomized, parallel-group, comparative clinical trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-h blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79893"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>404</Patients><Biomarkers></Biomarkers><Condition>Hypertension</Condition><Controls></Controls><EnrollmentCount>404</EnrollmentCount><Interventions>celecoxib; naproxen; rofecoxib</Interventions><Reference>635-IFL-0508-002; A3191077; CRESCENT</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>CRESCENT</ProtocolAcronym><ProtocolTitle>A phase IV, double-blind, randomized, parallel-group, comparative clinical trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-h blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79893"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>404</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>404</EnrollmentCount><Interventions>celecoxib; naproxen; rofecoxib</Interventions><Reference>635-IFL-0508-002; A3191077; CRESCENT</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>CRESCENT</ProtocolAcronym><ProtocolTitle>A phase IV, double-blind, randomized, parallel-group, comparative clinical trial to evaluate the effects of celecoxib, rofecoxib, and naproxen on 24-h blood pressure (BP) in patients with type 2 diabetes, hypertension, and osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79893"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>404</Patients><Biomarkers></Biomarkers><Condition>Non-insulin dependent diabetes</Condition><Controls></Controls><EnrollmentCount>404</EnrollmentCount><Interventions>celecoxib; naproxen; rofecoxib</Interventions><Reference>635-IFL-0508-002; A3191077; CRESCENT</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Timed Aspirin Chronobiome Study</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="346860"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Blood pressure; Mean arterial pressure</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>aspirin; celecoxib</Interventions><Reference>829532; NCT03590821</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the selective cyclooxygenase-2 inhibitor and non-selective cyclooxygenase inhibitor in benign prostatic hyperplasia</ProtocolTitle><Sponsor>Islamic Azad University of Pharmaceutical Science</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="318077"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Post-void residual urine; Prostate; Prostate-specific antigen</Biomarkers><Condition>Prostate hyperplasia</Condition><Controls>omeprazole; tamsulosin</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; naproxen; omeprazole; tamsulosin</Interventions><Reference>IR.IUA.PS.REC.1395.35; IRCT2017091836241N2</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Testing the feasibility of a clinical trial comparing a pre-surgery medication cocktail and nerve-numbing injections for pain management after minimally invasive shoulder surgery</ProtocolTitle><Sponsor>Canadian Institutes of Health Research</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="365411"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>bupivacaine; bupivacaine; celecoxib; interscalene block; naproxen; pregabalin; ropivacaine; ropivacaine</Controls><EnrollmentCount>36</EnrollmentCount><Interventions>celecoxib; naproxen; pregabalin</Interventions><Reference>ISRCTN14069845; PJT-156259</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Lung Cancer in Former Heavy Smokers</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29173"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>112</Patients><Biomarkers>Antigen KI-67; COX-2</Biomarkers><Condition>Lung tumor</Condition><Controls></Controls><EnrollmentCount>112</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000271912; NCT00055978; P30CA016042; U01CA096134; UCLA-0108074</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Treatment for Lung Cancer</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="41805"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>COX-2</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00108186; ONCA-043-04S</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Treatment for Lung Cancer</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="41805"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>COX-2</Biomarkers><Condition>Carcinoma</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00108186; ONCA-043-04S</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-Pancreas Cancer</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="65933"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>220</Patients><Biomarkers></Biomarkers><Condition>Cholangiocarcinoma</Condition><Controls></Controls><EnrollmentCount>220</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>B-0712-052-006 (local IRB); NCT01111591; SNUBH-GS-HBP2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-Pancreas Cancer</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="65933"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>220</Patients><Biomarkers></Biomarkers><Condition>Pancreas tumor</Condition><Controls></Controls><EnrollmentCount>220</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>B-0712-052-006 (local IRB); NCT01111591; SNUBH-GS-HBP2</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The influence of fast-track surgery on the bone condition around prothesis after total hip arthroplasty</ProtocolTitle><Sponsor>First Hospital of Jilin University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="285351"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Bone mineral density</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; fast-track treatment with drainage tube; fast-track treatment without drainage tube; fast-track treatment without oral Analgesic drugs; fast-track treatment  with oral Analgesic drugs</Interventions><Reference>ChiCTR-INR-17010451</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib on the Reduction of Pain After Periodontal Surgery</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="133013"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; prednisolone</Interventions><Reference>IRCT138709051081N2</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Sirolimus in Solid Tumors</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="76190"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>p70S6 kinase</Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; sirolimus</Interventions><Reference>Aflac ST0901; Aflac ST0901 CHOANOME; IRB00047016; NCT01331135</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Impact of Dexamethasone on the Duration of Sensory and Motor Block Following Spinal Anesthesia</ProtocolTitle><Sponsor>Centre hospitalier de l'Université de Montréal (CHUM)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="290618"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Heart rate; Systolic blood pressure</Biomarkers><Condition>Anesthesia</Condition><Controls>bupivacaine</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>acetaminophen; bupivacaine; celecoxib; dexamethasone; dimenhydrinate; haloperidol; hydromorphone; ondansetron</Interventions><Reference>16.374; NCT03078062</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>KTcesar</ProtocolAcronym><ProtocolTitle>Additional Effect of Wound Infiltration After Cesariean Section With Optimal Standard Analgesia</ProtocolTitle><Sponsor>Poissy-Saint Germain Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="101963"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>68</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>68</EnrollmentCount><Interventions>Continuous wound infiltration; celecoxib; levobupivacaine; morphine; nefopam; paracetamol</Interventions><Reference>KTcesar; NCT01751256; PoissyStGermainH</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels</ProtocolTitle><Sponsor>Buddhist Tzu Chi General Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="90852"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers>CRP; PSA; Post-void residual urine; Prostate</Biomarkers><Condition>Prostate hyperplasia</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>celecoxib; doxazosin; doxazosin</Interventions><Reference>NCT01678313; TCGHUROL004</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vaccine Therapy and Celecoxib in Treating Patients With Metastatic Nasopharyngeal Cancer</ProtocolTitle><Sponsor>National Cancer Centre of Singapore</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="44013"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>16</Patients><Biomarkers>EBV DNA; Epstein-Barr virus DNA; LMP1-specific T cell; LMP2-specific T cell; T-Lymphocytes</Biomarkers><Condition>Nasopharyngeal carcinoma</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>Ad5f35-LMPd1-2-transduced autologous dendritic cells (EBV-associated cancer), NCI; celecoxib</Interventions><Reference>CDR0000579355; NCT00589186; SINGAPORE-NCC-07-11-NPC</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized Study Comparing Epidural Anesthesia And Pregabalin For Perioperative Pain Control After Thoracotomy</ProtocolTitle><Sponsor>Teikyo University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="175276"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>96</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>celecoxib; fentanyl; pregabalin; ropivacaine</Interventions><Reference>UMIN000013189</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gefitinib and Capecitabine in Treating Patients With Advanced Solid Tumors</ProtocolTitle><Sponsor>Colorado State University, University of Colorado at Denver and Health Sciences Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="40512"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>41</Patients><Biomarkers></Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>41</EnrollmentCount><Interventions>capecitabine; celecoxib; gefitinib</Interventions><Reference>CDR0000069379; NCI-2012-02467; NCT00039390; U01CA099176; UCHSC-01479</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="123597"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>366</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>366</EnrollmentCount><Interventions>celecoxib; celecoxib; pregabalin</Interventions><Reference>A0081296; NCT01838044</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Controlled, Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer</ProtocolTitle><Sponsor>Maastricht University Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="92772"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers>CASP3 gene; CD34; Hematopoietic progenitor cell; Ki-67</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>MUMC MEC 04-038; NCT01695226</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women</ProtocolTitle><Sponsor>Rockefeller University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="146430"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>10</Patients><Biomarkers>PGE-M</Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT01901679; PHO-0807</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22955"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1045</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>aspirin; celecoxib</Controls><EnrollmentCount>1045</EnrollmentCount><Interventions>aspirin; lansoprazole; naproxen</Interventions><Reference>LAN-0003-0041; NCT00175032; U1111-1114-2275</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22955"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1045</Patients><Biomarkers></Biomarkers><Condition>Peptic ulcer</Condition><Controls>aspirin; celecoxib</Controls><EnrollmentCount>1045</EnrollmentCount><Interventions>aspirin; lansoprazole; naproxen</Interventions><Reference>LAN-0003-0041; NCT00175032; U1111-1114-2275</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Multicenter, Non-Randomized, Controlled, Open-Label, Post-Marketing Study To Investigate The Clinical Effectiveness Of Non-cytotoxic Drug- Gastric Carcinoma D2 Radical Correction- Capecitabine Combined Therapy In Gastric Carcinoma</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="98273"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Stomach tumor</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>capecitabine; capecitabine; celecoxib; lanreotide</Interventions><Reference>ChiCTR-TNRC-08000052</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind, randomized, placebo-controlled, multicenter, parallel-group, comparative clinical trial to evaluate the safety and efficacy of celecoxib in inhibiting the progression of Alzheimer’s disease</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="78984"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>425</Patients><Biomarkers></Biomarkers><Condition>Alzheimers disease</Condition><Controls></Controls><EnrollmentCount>425</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191292; IQ5-97-02-001</Reference></Row><Row><ArmCount>14</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Comparing Three Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="155969"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>259</Patients><Biomarkers></Biomarkers><Condition>Spinal stenosis</Condition><Controls></Controls><EnrollmentCount>259</EnrollmentCount><Interventions>Group or hands-on exercises; Lumbar epdural injection; acetaminophen; celecoxib; diclofenac; duloxetine; gabapentin; hydroxynortriptyline; ibuprofen; mirtazapine; misoprostol; sertraline; tramadol; trazodone</Interventions><Reference>587; NCT01943435; PRO12120422</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study Between Celecoxib 200 Mg Capsules Of Mavi Pharmaceutical, SA De CV And Celebrex 200 Mg Capsules (Pfizer, SA De CV)</ProtocolTitle><Sponsor>Mavi Pharmaceutical, SA de CV</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="163451"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>BE-CXB-028/0513</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy</ProtocolTitle><Sponsor>UNC Lineberger Comprehensive Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29231"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>PSA; testosterone</Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000341468; LCCC 0109; NCT00073970; UNC-01-SURG-655-ORC</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative pharmacokinetic and bioequivalence study of the drug celecoxib, 200 mg capsule, producer - Scan Biotec Ltd., India) and Celebrex (celecoxib 200 mg capsules Pfizer Manufacturing GmbH, Germany) in healthy volunteers</ProtocolTitle><Sponsor>LLC "MERIDIAN"</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="196389"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>36</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>36</EnrollmentCount><Interventions>celecoxib, Scan Biotech</Interventions><Reference>CEL-654</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, 6-week, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group clinical trial to evaluate the efficacy and tolerability of celecoxib, naproxen versus placebo for the treatment of patients with osteoarthritis (OA) of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79848"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>362</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>367</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>A3191052; I49-01-02-210</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>DISSCO</ProtocolAcronym><ProtocolTitle>Effect of Diacerein Versus Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis</ProtocolTitle><Sponsor>TRB Chemedica SA</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="254079"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>380</Patients><Biomarkers>Body temperature; Heart rate; Joint swelling; Systolic blood pressure/Diastolic blood pressure ratio; Total body mass</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>380</EnrollmentCount><Interventions>diacerein</Interventions><Reference>2015-002933-23; DAR-INT-14-01; DISSCO; NCT02688400</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Nonopioid Analgesia After Anterior Cruciate Ligament Reconstruction</ProtocolTitle><Sponsor>Henry Ford Health System</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="367957"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>hydrocodone-acetaminophen</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>acetaminophen; celecoxib; diazepam; gabapentin; ketorolac</Interventions><Reference>123192; NCT03818932</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Dysmenorrhea</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Keratosis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Gout</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Alzheimers disease</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Renal cell carcinoma</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Tenosynovitis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Pancreas tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Prostate tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Non-Hodgkin lymphoma</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Back pain</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Bladder tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Cachexia</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Uterine cervix tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single oral dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover, bioequivalence study of celecoxib 200 mg capsules manufactured by Laboratories Senosiain, SA de CV versus Celebrex (celecoxib) 200 mg capsules manufactured by Pfizer, SA de CV, in healthy adult subjects under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Senosiain</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="164353"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Breast tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Senosiain)</Interventions><Reference>AS/AA/DIC-12/0007</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37579"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers>5-lipoxygenase; CYFRA; cyclo-oxygenase-2; vascular endothelial growth factor</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>carboplatin; celecoxib; gemcitabine; zileuton</Interventions><Reference>CALGB-30203; CDR0000334573; NCT00070486; U10CA031946</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37579"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers>5-lipoxygenase; CYFRA; cyclo-oxygenase-2; vascular endothelial growth factor</Biomarkers><Condition>Adenocarcinoma</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>carboplatin; celecoxib; gemcitabine; zileuton</Interventions><Reference>CALGB-30203; CDR0000334573; NCT00070486; U10CA031946</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37579"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers>5-lipoxygenase; CYFRA; cyclo-oxygenase-2; vascular endothelial growth factor</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>carboplatin; celecoxib; gemcitabine; zileuton</Interventions><Reference>CALGB-30203; CDR0000334573; NCT00070486; U10CA031946</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37579"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers>5-lipoxygenase; CYFRA; cyclo-oxygenase-2; vascular endothelial growth factor</Biomarkers><Condition>Large cell lung carcinoma</Condition><Controls></Controls><EnrollmentCount>140</EnrollmentCount><Interventions>carboplatin; celecoxib; gemcitabine; zileuton</Interventions><Reference>CALGB-30203; CDR0000334573; NCT00070486; U10CA031946</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="258086"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>210</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>210</EnrollmentCount><Interventions>celecoxib; tramadol hydrochloride</Interventions><Reference>HYST 7; NCT02736019</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer</ProtocolTitle><Sponsor>Stanford University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="74105"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>1</Patients><Biomarkers>Receptors, antigen, T-cell; Serum cytokines; T-cell receptor (TCR) repertoire</Biomarkers><Condition>Colon tumor</Condition><Controls></Controls><EnrollmentCount>1</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>19588; COL0001; IRB-19588; NCT01284504; SU-10182010-7110</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Cancer/testis antigen 1; Cyclin-dependent kinase inhibitor 1; p16</Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>FR-901228; celecoxib; decitabine</Interventions><Reference>CDR0000069448; NCI-02-C-0205; NCI-5270; NCT00037817; NCT00041158</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Cancer/testis antigen 1; Cyclin-dependent kinase inhibitor 1; p16</Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>FR-901228; celecoxib; decitabine</Interventions><Reference>CDR0000069448; NCI-02-C-0205; NCI-5270; NCT00037817; NCT00041158</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Cancer/testis antigen 1; Cyclin-dependent kinase inhibitor 1; p16</Biomarkers><Condition>Mesothelioma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>FR-901228; celecoxib; decitabine</Interventions><Reference>CDR0000069448; NCI-02-C-0205; NCI-5270; NCT00037817; NCT00041158</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Cancer/testis antigen 1; Cyclin-dependent kinase inhibitor 1; p16</Biomarkers><Condition>Metastatic lung cancer</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>FR-901228; celecoxib; decitabine</Interventions><Reference>CDR0000069448; NCI-02-C-0205; NCI-5270; NCT00037817; NCT00041158</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Cancer/testis antigen 1; Cyclin-dependent kinase inhibitor 1; p16</Biomarkers><Condition>Lung tumor</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>FR-901228; celecoxib; decitabine</Interventions><Reference>CDR0000069448; NCI-02-C-0205; NCI-5270; NCT00037817; NCT00041158</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty</ProtocolTitle><Sponsor>University of Southern California</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="282021"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>23</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>acetaminophen; celecoxib; gabapentin; hydromorphone; ketorolac; oxycodone; pantoprazole</Controls><EnrollmentCount>23</EnrollmentCount><Interventions>Diprivan; acetaminophen; celecoxib; dexamethasone; dextromethorphan; gabapentin; hydromorphone; ketorolac; ondansetron; oxycodone; pantoprazole</Interventions><Reference>HS-16-00739; NCT02987920</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Trial of Early Administration of Pregabalin for Post Operative Thoracotomy Pain</ProtocolTitle><Sponsor>Nagasaki University School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162160"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>pregabalin</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; ropivacaine</Interventions><Reference>JPRN-UMIN000012386</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of a Non-hormonal Cox-2 Inhibitor (Celebrex) on Ovulation</ProtocolTitle><Sponsor>Oregon Health Sciences University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="67031"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Estradiol; Luteinizing Hormone; Progesterone</Biomarkers><Condition>Female contraception</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>NCT01129245; OHSU FAMPLAN SFP3-7</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="27054"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>7</Patients><Biomarkers></Biomarkers><Condition>Lung tumor</Condition><Controls>carboplatin; paclitaxel</Controls><EnrollmentCount>7</EnrollmentCount><Interventions>carboplatin; celecoxib; paclitaxel</Interventions><Reference>CDR0000304540; NCT00062179; NYH-CMC-0902-464; P30CA016042; PHARMACIA-COXAON-0509-106; UCLA-0208074</Reference></Row><Row><ArmCount>8+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Erector Spinae Plane Block Versus Intercostal for VATS</ProtocolTitle><Sponsor>McGill University Health Center</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="376456"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>acetaminophen; bupivacaine; celecoxib; desflurane; dexamethasone; epinephrine; fentanyl; hydromorphone; intercostal nerve block; morphine sulfate; nalbuphine; ondansetron; patient controlled analgesia; polyethylene glycol; propofol; rocuronium; sevoflurane; video-assisted thoracic surgery</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>acetaminophen; bupivacaine; celecoxib; desflurane; dexamethasone; epinephrine; fentanyl; hydromorphone; intercostal nerve block; lidocaine; morphine sulfate; nalbuphine; ondansetron; patient controlled analgesia; polyethylene glycol; propofol; rocuronium; sevoflurane; ultrasound guided erector spinae plane block; video-assisted thoracic surgery</Interventions><Reference>2020-5553; ESP versus Intercostal; NCT03902782</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Erlotinib in Treating Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28342"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>22</Patients><Biomarkers>COX-2; Epidermal growth factor; PGE-M</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>celecoxib; celecoxib + erlotinib; erlotinib</Interventions><Reference>CDR0000335434; NCT00072072; UCLA-0306083</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>REMAGUS02</ProtocolAcronym><ProtocolTitle>A Randomized, Phase II Study of Cytotoxic Chemotherapy or Cytotoxic Chemotherapy Combined With Celecoxib or Trastuzumab as Primary Chemotherapy for Patients With High Risk Localized Breast Cancer Not Amenable to Breast Conserving Therapy</ProtocolTitle><Sponsor>Institut Curie</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="151352"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>340</Patients><Biomarkers>HER2; Progesterone receptor</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>340</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; docetaxel; epirubicin; trastuzumab</Interventions><Reference>ISRCTN10059974; REMAGUS02; REMAGUS02; Remagus 0002</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastasis</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="49337"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>14</Patients><Biomarkers>Prostate-Specific Antigen (PSA)</Biomarkers><Condition>Bone metastases</Condition><Controls>doxorubicin; strontium-89</Controls><EnrollmentCount>14</EnrollmentCount><Interventions>celecoxib; doxorubicin; strontium-89</Interventions><Reference>CDR0000355360; ID02-035; MDA-ID-02035; NCT00080782; P30CA016672; P50CA090270</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastasis</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="49337"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>14</Patients><Biomarkers>Prostate-Specific Antigen (PSA)</Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls>doxorubicin; strontium-89</Controls><EnrollmentCount>14</EnrollmentCount><Interventions>celecoxib; doxorubicin; strontium-89</Interventions><Reference>CDR0000355360; ID02-035; MDA-ID-02035; NCT00080782; P30CA016672; P50CA090270</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The central mechanism of celebrex for knee osteoarthritis：a fMRI study</ProtocolTitle><Sponsor>Chengdu University of Traditional Chinese Medicine</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="309749"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>108</Patients><Biomarkers>Blood flow</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ChiCTR-IOR-17012365</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CUSP9v3</ProtocolAcronym><ProtocolTitle>A Proof-of-concept Clinical Trial Assessing the Safety of the Co-ordinated Undermining of Survival Paths by Nine Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma</ProtocolTitle><Sponsor>Universitat Ulm, University Hospital Ulm</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="260751"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Glioblastoma</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>aprepitant; auranofin; captopril; celecoxib; disulfiram; itraconazole; minocycline; ritonavir; sertraline; temozolomide</Interventions><Reference>2014-004197-42; CUSP9V3; CUSP9v3; NCT02770378</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="41803"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>Ak+; BAX; BCL2; COX-2; Ki-67; Platelet endothelial cell adhesion molecule; RAC-alpha serine/threonine-protein kinase; Vascular endothelial growth factors; prostaglandin E2</Biomarkers><Condition>Leukoplakia</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>02-024; CDR0000258562; DFCI-02024; DFCI-2002-P-00150/2; NCT00052611; P30CA006516</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="41803"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>Ak+; BAX; BCL2; COX-2; Ki-67; Platelet endothelial cell adhesion molecule; RAC-alpha serine/threonine-protein kinase; Vascular endothelial growth factors; prostaglandin E2</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>02-024; CDR0000258562; DFCI-02024; DFCI-2002-P-00150/2; NCT00052611; P30CA006516</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Keratosis</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Alzheimers disease</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Non-Hodgkin lymphoma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Carcinoma</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celecoxib Bioavailability in Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Cancer</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191202; NCT00296127</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Feasibility Study of the Metronomic Chemotherapy Using for Recurrent Gynecological Cancers</ProtocolTitle><Sponsor>Saitama Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221667"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Fallopian tube cancer</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>UFT; celecoxib; cyclophosphamide</Interventions><Reference>UMIN000016438</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Feasibility Study of the Metronomic Chemotherapy Using for Recurrent Gynecological Cancers</ProtocolTitle><Sponsor>Saitama Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221667"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Peritoneal tumor</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>UFT; celecoxib; cyclophosphamide</Interventions><Reference>UMIN000016438</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Feasibility Study of the Metronomic Chemotherapy Using for Recurrent Gynecological Cancers</ProtocolTitle><Sponsor>Saitama Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221667"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Uterus tumor</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>UFT; celecoxib; cyclophosphamide</Interventions><Reference>UMIN000016438</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Feasibility Study of the Metronomic Chemotherapy Using for Recurrent Gynecological Cancers</ProtocolTitle><Sponsor>Saitama Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221667"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>UFT; celecoxib; cyclophosphamide</Interventions><Reference>UMIN000016438</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Celecoxib (IFA) (Celecoxib Capsules, 200 mg) versus Celebrex (Celecoxib Capsules, 200 mg)</ProtocolTitle><Sponsor>Pharmaceutical Research, SA de CV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="211954"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Dysmenorrhea</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Investigación Farmacéutica)</Interventions><Reference>IICO-CEL-04</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Celecoxib (IFA) (Celecoxib Capsules, 200 mg) versus Celebrex (Celecoxib Capsules, 200 mg)</ProtocolTitle><Sponsor>Pharmaceutical Research, SA de CV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="211954"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Gout</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Investigación Farmacéutica)</Interventions><Reference>IICO-CEL-04</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Celecoxib (IFA) (Celecoxib Capsules, 200 mg) versus Celebrex (Celecoxib Capsules, 200 mg)</ProtocolTitle><Sponsor>Pharmaceutical Research, SA de CV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="211954"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Investigación Farmacéutica)</Interventions><Reference>IICO-CEL-04</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Celecoxib (IFA) (Celecoxib Capsules, 200 mg) versus Celebrex (Celecoxib Capsules, 200 mg)</ProtocolTitle><Sponsor>Pharmaceutical Research, SA de CV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="211954"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Investigación Farmacéutica)</Interventions><Reference>IICO-CEL-04</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Celecoxib (IFA) (Celecoxib Capsules, 200 mg) versus Celebrex (Celecoxib Capsules, 200 mg)</ProtocolTitle><Sponsor>Pharmaceutical Research, SA de CV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="211954"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Investigación Farmacéutica)</Interventions><Reference>IICO-CEL-04</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Celecoxib (IFA) (Celecoxib Capsules, 200 mg) versus Celebrex (Celecoxib Capsules, 200 mg)</ProtocolTitle><Sponsor>Pharmaceutical Research, SA de CV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="211954"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition>Breast tumor</Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Investigación Farmacéutica)</Interventions><Reference>IICO-CEL-04</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>How effective are the drugs pregabalin and celecoxib in relieving pain after laproscopic gall bladder surgery?</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="157109"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; celecoxib; pregabalin; pregabalin</Interventions><Reference>ACTRN12612000447853; ANZCTR362391; U1111-1130-0146</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty</ProtocolTitle><Sponsor>National Taiwan University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13928"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>950704; NCT00598234</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Perioperative Pain Control With Celecoxib (Celebrex) in Total Knee Arthroplasty</ProtocolTitle><Sponsor>National Taiwan University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13928"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>950704; NCT00598234</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>SPORE</ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Early-Stage Rectal Cancer</ProtocolTitle><Sponsor>Vanderbilt-Ingram Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="44027"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>10</Patients><Biomarkers>COX-2; PGE-M; VEGF</Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00608595; SPORE; VICC GI 0174; VU-VICC-GI-0174</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, 12-week, multicenter, double-blind, double-dummy, parallel-group study to compare the efficacy and incidence of gastroduodenal ulcer associated with celecoxib with that of diclofenac for the treatment of  patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in the People’s Republic of China</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79875"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>666</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>diclofenac</Controls><EnrollmentCount>666</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191282; I49-98-02-105</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, 12-week, multicenter, double-blind, double-dummy, parallel-group study to compare the efficacy and incidence of gastroduodenal ulcer associated with celecoxib with that of diclofenac for the treatment of  patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in the People’s Republic of China</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79875"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>666</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>diclofenac</Controls><EnrollmentCount>666</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191282; I49-98-02-105</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of celecoxib, capsules 200 mg, manufactured by Micro Labs Limited versus Celebrex (celecoxib, capsules, 200 mg)</ProtocolTitle><Sponsor>Micro Labs Ltd</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="164548"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Micro Labs Ltd)</Interventions><Reference>IICO-CEL-02/DIX-EB-13-013</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PRECISION</ProtocolAcronym><ProtocolTitle>Prospective, Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen Or Naproxen</ProtocolTitle><Sponsor>AstraZeneca plc, Eli Lilly &amp; Co, Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10010"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>24081</Patients><Biomarkers>Blood pressure; Creatinine; Systolic blood pressure</Biomarkers><Condition>Cardiac hypertrophy</Condition><Controls>ibuprofen; naproxen</Controls><EnrollmentCount>24081</EnrollmentCount><Interventions>aspirin; celecoxib; esomeprazole</Interventions><Reference>2004-002441-13; A3191172; NCT00346216; PRECISION; PRECISION-ABPM</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PRECISION</ProtocolAcronym><ProtocolTitle>Prospective, Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen Or Naproxen</ProtocolTitle><Sponsor>AstraZeneca plc, Eli Lilly &amp; Co, Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10010"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>24081</Patients><Biomarkers>Blood pressure; Creatinine; Systolic blood pressure</Biomarkers><Condition>Osteoarthritis</Condition><Controls>ibuprofen; naproxen</Controls><EnrollmentCount>24081</EnrollmentCount><Interventions>aspirin; celecoxib; esomeprazole</Interventions><Reference>2004-002441-13; A3191172; NCT00346216; PRECISION; PRECISION-ABPM</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>PRECISION</ProtocolAcronym><ProtocolTitle>Prospective, Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen Or Naproxen</ProtocolTitle><Sponsor>AstraZeneca plc, Eli Lilly &amp; Co, Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10010"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>24081</Patients><Biomarkers>Blood pressure; Creatinine; Systolic blood pressure</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>ibuprofen; naproxen</Controls><EnrollmentCount>24081</EnrollmentCount><Interventions>aspirin; celecoxib; esomeprazole</Interventions><Reference>2004-002441-13; A3191172; NCT00346216; PRECISION; PRECISION-ABPM</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide and Celecoxib in Treating Patients With Advanced Cancer</ProtocolTitle><Sponsor>City of Hope Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44040"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>57</Patients><Biomarkers></Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>57</EnrollmentCount><Interventions>celecoxib; cyclophosphamide</Interventions><Reference>00191; CDR0000570416; CHNMC-00191; NCT00551889; P30CA033572</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, 4-week, multicenter, parallel-group, randomized, comparative, open clinical trial to compare anti-arthritic effect and safety of celecoxib and aceclofenac for the patients with osteoarthritis on the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79837"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>211</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>211</EnrollmentCount><Interventions>aceclofenac; celecoxib</Interventions><Reference>635-IFL-0508-007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Cancer in Patients at High Risk for Ovarian Epithelial Cancer Who Are Undergoing Prophylactic Oophorectomy</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29257"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers>Breast cancer type 1 susceptibility protein; Breast cancer type 2 susceptibility protein</Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000352114; NCT00084370; UAB-0134</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265419"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>210</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>210</EnrollmentCount><Interventions>celecoxib; tramadol</Interventions><Reference>CELECOXIB IUD; NCT02827487</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CBET</ProtocolAcronym><ProtocolTitle>Celecoxib to Prevent Cancer in Patients With Barrett's Esophagus</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="26985"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients>100</Patients><Biomarkers>6-keto-PGF1; APC; E-cadherin; PGD2; PGE2; PGF2; cyclooxygenase-1/2; p16; thromboxane B2</Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CBET; JHOC-99061108; JHOC-J9932; JHOC-J9932, CDR0000067917; NCI-P00-0145; NCT00005878; P30CA006973</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of the Prophylactic Analgesic Effects of Acetaminophen and Celecoxib in Patients Undergoing Rhinoplasty Operation</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="139319"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>acetaminophen</Controls><EnrollmentCount>70</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>90-11-16; IRCT2012102111191N1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ABSOLUTE-OS</ProtocolAcronym><ProtocolTitle>The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Chong Kun Dang Pharmaceutical Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="100817"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>234</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>234</EnrollmentCount><Interventions>Imotun capsule; celecoxib</Interventions><Reference>238KOA12F; ABSOLUTE-OS; NCT01743287</Reference></Row><Row><ArmCount>9+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis</ProtocolTitle><Sponsor>Chung Shan Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="230664"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>Arcoxia; Arcoxia; Tonec; Tonec; adalimumab; adalimumab; celecoxib; celecoxib; etanercept; etanercept; golimumab; golimumab; meloxicam; meloxicam; sulfasalazine; sulfasalazine</Interventions><Reference>CS09128; NCT02456363</Reference></Row><Row><ArmCount>11+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Orthostatic Hypotension in Autonomic Failure</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95783"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>65</Patients><Biomarkers>Aldosterone; Angiotensin-2; Bradykinin; C-reactive protein; Cardiac Output; Catecholamines; Creatinine; Cytokines; F2-isoprostanes; Glucose; Muscle strength; Norepinephrine; Plasminogen activator inhibitor-1; Renin; Systolic blood pressure; blood pressure; heart rate</Biomarkers><Condition>Orthostatic hypotension</Condition><Controls></Controls><EnrollmentCount>389</EnrollmentCount><Interventions>Afrin; Bovril; Cafergot; Celebrex; Celebrex; Diamox; Diamox; Exelon; Indocin; Lodosyn; Mestinon; Mestinon; Parnate; Precose; ProAmatine; ProAmatine; Provigil; Ritalin; Sandostatin; Sinemet; Sinemet; Sudafed; Yocon; Yocon; Zantac; Zantac; abdominal binder; atomoxetine; atomoxetine; diphenhydramine hydrochloride; diphenhydramine hydrochloride; ergotamine; ibuprofen</Interventions><Reference>000814; HL46681; NCT00223691</Reference></Row><Row><ArmCount>11+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Orthostatic Hypotension in Autonomic Failure</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95783"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>65</Patients><Biomarkers>Aldosterone; Angiotensin-2; Bradykinin; C-reactive protein; Cardiac Output; Catecholamines; Creatinine; Cytokines; F2-isoprostanes; Glucose; Muscle strength; Norepinephrine; Plasminogen activator inhibitor-1; Renin; Systolic blood pressure; blood pressure; heart rate</Biomarkers><Condition>Autonomic nervous system disease</Condition><Controls></Controls><EnrollmentCount>389</EnrollmentCount><Interventions>Afrin; Bovril; Cafergot; Celebrex; Celebrex; Diamox; Diamox; Exelon; Indocin; Lodosyn; Mestinon; Mestinon; Parnate; Precose; ProAmatine; ProAmatine; Provigil; Ritalin; Sandostatin; Sinemet; Sinemet; Sudafed; Yocon; Yocon; Zantac; Zantac; abdominal binder; atomoxetine; atomoxetine; diphenhydramine hydrochloride; diphenhydramine hydrochloride; ergotamine; ibuprofen</Interventions><Reference>000814; HL46681; NCT00223691</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>PINK study</ProtocolAcronym><ProtocolTitle>PPI-NSAID Kyushu University study</ProtocolTitle><Sponsor>Fukuoka University, Kyushu University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="304312"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Gastric injury</Condition><Controls>celecoxib</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; rabeprazole</Interventions><Reference>FS30; PINK study; UMIN000008883</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II trial to evaluate the efficacy of celecoxib in combination with paclitaxel, carboplatin and chest radiation therapy in patients with stage III non-small-cell lung cancer (NSCLC)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="49245"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>5</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>5</EnrollmentCount><Interventions>carboplatin; celecoxib; paclitaxel</Interventions><Reference>THO-0059</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chicory gel effect on the treatment of osteoarthritis</ProtocolTitle><Sponsor>Shahrekord University of Medical Sciences and Health Services</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="320067"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; diclofenac gel</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Cichorium intybus L hydroalcoholic extract gel; celecoxib</Interventions><Reference>IR.SKUMS.REC.1396.154; IRCT2017103037093N1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Diclofenac Capsules to Treat Pain Following Bunionectomy</ProtocolTitle><Sponsor>Iroko Pharmaceuticals LLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82116"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>428</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>428</EnrollmentCount><Interventions>diclofenac (SoluMatrix/capsule, dental pain), Iroko/iCeutica</Interventions><Reference>DIC3-08-04; NCT01462435</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25269"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>75</Patients><Biomarkers></Biomarkers><Condition>Glioblastoma</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>6-thioguanine; CCNU; capecitabine; celecoxib; temozolomide</Interventions><Reference>2003-0600; NCT00504660</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="67623"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2440</Patients><Biomarkers></Biomarkers><Condition>Colon tumor</Condition><Controls></Controls><EnrollmentCount>2500</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; celecoxib; leucovorin calcium; oxaliplatin</Interventions><Reference>Alliance/SWOG 80702; C80702; CALGB-80702; CDR0000675693; NCT01150045; U10CA031946</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-label, randomized, crossover study of the comparative pharmacokinetics and bioequivalence of drugs celecoxib capsules 200 mg (Joint-Stock Company "Vertex", Russia) and Celebrex capsules of 200 mg ("Pfizer Manufacturing Deutschland GmbH", Germany)</ProtocolTitle><Sponsor>JSC Vertex</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="260320"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib, Vertex</Interventions><Reference>06072015-CelVert-001</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Metronomic dose finding study in patients with oral cavity cancers</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="259216"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>96</Patients><Biomarkers>Angiopoietin; Angiopoietin-1 receptor; Angiostatins; Circulating endothelial cells; Collagen alpha-1(XVIII) chain; Delta-like protein 1; Forkhead box protein P3; Hypoxia-inducible factor alpha; Interleukin-2; Regulatory T-Lymphocytes; SPARC; Thrombospondin-1; Thymidine phosphorylase; Vascular endothelial growth factor receptor-1; Vascular endothelial growth factors</Biomarkers><Condition>Cancer</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>celecoxib; erlotinib; methotrexate</Interventions><Reference>190; CTRI/2016/04/006834</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer</ProtocolTitle><Sponsor>University of Medicine and Dentistry of New Jersey</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29492"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>72</Patients><Biomarkers>cyclooxygenase</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>celecoxib; letrozole</Interventions><Reference>040402-4671; CDR0000407502; CINJ-040402; CINJ-5076v3; CINJ-NJ1103; NCT00101062; P30CA072720; UMDNJ-4761</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Biosynthesis of PGD2 in Vivo</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="200827"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>22</Patients><Biomarkers>Blood flow; Prostaglandin D2; Prostaglandin G/H synthase 2</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>Celebrex; Niaspan; aspirin; aspirin; niacin</Interventions><Reference>806115 - FITZGERALD, MD; AMERICAN HEART ASSOCIATION; NCT01275300</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>XBD</ProtocolAcronym><ProtocolTitle>Celebrex and Metformin for Postoperative Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Guangxi Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="301531"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls>Celebrex; metformin</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Celebrex; metformin</Interventions><Reference>CELEBREX FOR HCC; NCT03184493; XBD</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Recombinant Interferon Alfa-2b and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver</ProtocolTitle><Sponsor>Roswell Park Comprehensive Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="326053"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>12</Patients><Biomarkers>C-C chemokine receptor type 4; C-C chemokine receptor type 5; C-C chemokine receptor type 6; C-C motif chemokine 22; C-X-C chemokine receptor type 3; C-X-C chemokine receptor type 4; C-X-C motif chemokine 10; C-X-C motif chemokine 11; C-X-C motif chemokine 9; CD4/CD8 ratio; Cytotoxic T-Lymphocytes; Forkhead box protein P3; Ras GTPases; Regulatory T-Lymphocytes; Stromal cell-derived factor 1; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Liver tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Alfatronol; Ampligen; Celebrex</Interventions><Reference>I 52917; NCI-2017-02471; NCT03403634; P30CA016056</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Recombinant Interferon Alfa-2b and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver</ProtocolTitle><Sponsor>Roswell Park Comprehensive Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="326053"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Patients>12</Patients><Biomarkers>C-C chemokine receptor type 4; C-C chemokine receptor type 5; C-C chemokine receptor type 6; C-C motif chemokine 22; C-X-C chemokine receptor type 3; C-X-C chemokine receptor type 4; C-X-C motif chemokine 10; C-X-C motif chemokine 11; C-X-C motif chemokine 9; CD4/CD8 ratio; Cytotoxic T-Lymphocytes; Forkhead box protein P3; Ras GTPases; Regulatory T-Lymphocytes; Stromal cell-derived factor 1; T-Helper Lymphocytes; T-Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Alfatronol; Ampligen; Celebrex</Interventions><Reference>I 52917; NCI-2017-02471; NCT03403634; P30CA016056</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, double-blind, randomized, three arm, two-period, cross-over study to compare the efficacy and safety of celecoxib, acetaminophen, and placebo in patients for the treatment of patients with osteoarthritis of the hip or knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80195"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>556</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>556</EnrollmentCount><Interventions>acetaminophen; celecoxib</Interventions><Reference>COXA-0508-249</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="26772"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>11</Patients><Biomarkers>Human Epidermal Growth Factor Receptor 2</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>celecoxib; trastuzumab; trastuzumab + celecoxib</Interventions><Reference>CDR0000068255; MSKCC-00078; NCI-G00-1869; NCT00006381</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Oral versus Intravenous Acetaminophen</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="249991"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>110</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>110</EnrollmentCount><Interventions>acetaminophen (Tylenol); celecoxib</Interventions><Reference>052015-068; NCT02643394</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MACE-CTRT</ProtocolAcronym><ProtocolTitle>The study of oral chemotherapy in locally advanced head and neck cancer post-radical chemoradiation</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="273577"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1038</Patients><Biomarkers></Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls>observation</Controls><EnrollmentCount>1038</EnrollmentCount><Interventions>celecoxib; methotrexate</Interventions><Reference>CTRI/2016/09/007315; MACE-CTRT</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MACE-CTRT</ProtocolAcronym><ProtocolTitle>The study of oral chemotherapy in locally advanced head and neck cancer post-radical chemoradiation</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="273577"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1038</Patients><Biomarkers></Biomarkers><Condition>Head and neck tumor</Condition><Controls>observation</Controls><EnrollmentCount>1038</EnrollmentCount><Interventions>celecoxib; methotrexate</Interventions><Reference>CTRI/2016/09/007315; MACE-CTRT</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Clinical Efficacy of Non-Steroidal Anti-Inflammation Drugs in Patients With Benign Prostatic Hyperplasia</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="35238"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers>Prostate specific antigen (PSA)</Biomarkers><Condition>Prostate hyperplasia</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>alfuzosin; celecoxib; doxazosin; tamsulosin; terazosin</Interventions><Reference>2006-07-084; NCT00687388</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>UAB 0040</ProtocolAcronym><ProtocolTitle>Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23665"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>F001228004; NCT00582660; NQ8-00-02-008; UAB 0040</Reference></Row><Row><ArmCount>11</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Optimal Multimodal Analgesia in Abdominal Hysterectomy</ProtocolTitle><Sponsor>HS Hvidovre Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="36474"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Surgical procedure</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Nimbex; S-ketamine; celecoxib; dexamethasone; droperidol; gabapentin; lidocaine; ondansetron; propofol; remifentanil; sufentanil</Interventions><Reference>NCT00209872; OMA-AH01; eudraCT # 2005-003595-38</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Of Nasopharyngeal Carcinoma (NPC) Treated With Celecoxib And ZD-1839</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="30991"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers></Biomarkers><Condition>Nasopharyngeal carcinoma</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>celecoxib; gefitinib</Interventions><Reference>NCT00212108; NP01/07/03</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled, single-blind, five-way crossover study to evaluate the predictive validity of laser-evoked potentials in normal, ultraviolet B-inflamed and capsaicin-irritated skin with four analgesic compounds in healthy volunteers</ProtocolTitle><Sponsor>Boehringer Ingelheim Pharma KG</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="320164"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>25</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>celecoxib; duloxetine; lacosamide; pregabalin</Interventions><Reference>2012-003202-26</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized study comparing epidural anesthesia and pregabalin for perioperative pain control after thoracotomy</ProtocolTitle><Sponsor>Teikyo University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="289661"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>96</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>celecoxib; fentanyl; pregabalin; ropivacaine</Interventions><Reference>UMIN000026336</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="174966"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>210</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>210</EnrollmentCount><Interventions>Hysteroscopy; celecoxib; tramadol (Trama SR, Global Napi)</Interventions><Reference>GANY-124; NCT02071303</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on the Effect of Berberine Hydrochloride in the Treatment of Familial Patients with Familial Adenomatous Polyposis</ProtocolTitle><Sponsor>Beijing Command General Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="243503"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>40</Patients><Biomarkers>Adenomatous polyposis coli protein</Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls>celecoxib</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>berberine hydrochloride; berberine hydrochloride; celecoxib</Interventions><Reference>2015-027; ChiCTR-IOR-15007227</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty</ProtocolTitle><Sponsor>Albany Medical College</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="321385"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>114</Patients><Biomarkers>Body Mass Index; Body height; Creatinine; Hematocrit; Hemoglobin; Total body mass</Biomarkers><Condition>Bleeding</Condition><Controls></Controls><EnrollmentCount>114</EnrollmentCount><Interventions>Percocet; aspirin; bupivacaine; celecoxib; epinephrine; ketorolac; methylprednisolone acetate; morphine; pregabalin; ropivacaine; tranexamic Acid</Interventions><Reference>4744; NCT03359525</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of NSAIDs on Sleep Quality in Chronic Low Back Pain Patients with Sleep Disorder (A Randomized, Open-label, Parallel-group, Comparison Study)</ProtocolTitle><Sponsor>Showa University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="129669"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Insomnia</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; loxoprofen</Interventions><Reference>JPRN-UMIN000009333</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect Of COX-2 Selective Inhibitor To Synovial Fluids And Synovial Tissues Of Osteoarthritis Of The Knee</ProtocolTitle><Sponsor>Hokkaido University Graduate School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="229379"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers>Cytokines; Hyaluronic acid </Biomarkers><Condition>Osteoarthritis</Condition><Controls>diclofenac sodium</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UMIN000017481</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Efficacy of Tibial nerve block and Obturator nerve block combined with Continuous Femoral Triangle block after Total knee arthroplasty : A Randomized, controlled trial</ProtocolTitle><Sponsor>Bumrungrad Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="298489"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Knee motion</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>celecoxib; levobupivacaine; morphine; paracetamol; parecoxib; pregabalin; shot obturator nerve block with continuous Femoral triangle block; single shot Obturator and tibial nerve block with continuous Femoral triangle block; single shot Tibial nerve block with continuous Femoral triangle block</Interventions><Reference>TCTR20170515002</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of celecoxib versus ibuprofen on craving in opioid abusers during withdrawal period</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="300004"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib; ibuprofen</Interventions><Reference>IR.TUMS.REC.1395.2584; IRCT201609207202N11</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym>REACT</ProtocolAcronym><ProtocolTitle>European Celecoxib Trial in Primary Breast Cancer</ProtocolTitle><Sponsor>Imperial College London</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="228055"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2639</Patients><Biomarkers>Estrogen receptor; Progesterone receptor</Biomarkers><Condition>Breast tumor</Condition><Controls>Radiotherapy; endocrine therapy</Controls><EnrollmentCount>2639</EnrollmentCount><Interventions>Radiotherapy; celecoxib; endocrine therapy; exemestane; tamoxifen</Interventions><Reference>BIG 1- 03; C/20/01; GBG 27; ICCG C/20/01; ISRCTN48254013; NCT02429427; REACT</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex for Pain Relief After Oral Surgery</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12558"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Ibuprofen</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>00-D-0027; 000027; NCT00006299</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate Bioequivalence between Celecoxib (Test Drug) Elaborated by Productos Farmaceuticos Collins, SA de CV and Celebrex(Reference Medicine) elaborated by Pfizer, SA de CV, both formulations contain 200 mg of Celecoxib</ProtocolTitle><Sponsor>GRUPO COLLINS</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="381512"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Musculoskeletal disease</Condition><Controls>Celebrex</Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>BE-CEL-017/0618</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate Bioequivalence between Celecoxib (Test Drug) Elaborated by Productos Farmaceuticos Collins, SA de CV and Celebrex(Reference Medicine) elaborated by Pfizer, SA de CV, both formulations contain 200 mg of Celecoxib</ProtocolTitle><Sponsor>GRUPO COLLINS</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="381512"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Injury</Condition><Controls>Celebrex</Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>BE-CEL-017/0618</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib versus placebo as an adjunct in the treatment of adolescents with bipolar mood disorder</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="299582"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Bipolar disorder</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; lithium; risperidone</Interventions><Reference>IR.TUMS.REC.1394.517; IRCT2015080423478N1</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25076"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition>Glioma</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide phosphate; thalidomide</Interventions><Reference>01-278; CDR0000257584; CELGENE-2001-P-001757/3; DFCI-01278; NCI-G02-2117; NCT00047281; P30CA006516</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>SCOTLSSS</ProtocolAcronym><ProtocolTitle>The Standard Care Versus Celecoxib Outcome Trial</ProtocolTitle><Sponsor>University of Dundee</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="20660"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>7297</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>diclofenac; ibuprofen; meloxicam; naproxen; nsNSAID</Controls><EnrollmentCount>7297</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2007-000012-90; 9.3; 9.6; NCT00447759; SCOT Trial; SCOTLSSS</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>SCOTLSSS</ProtocolAcronym><ProtocolTitle>The Standard Care Versus Celecoxib Outcome Trial</ProtocolTitle><Sponsor>University of Dundee</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="20660"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>7297</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>diclofenac; ibuprofen; meloxicam; naproxen; nsNSAID</Controls><EnrollmentCount>7297</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2007-000012-90; 9.3; 9.6; NCT00447759; SCOT Trial; SCOTLSSS</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, double-blind, placebo-controlled, randomized comparative clinical trial to study of the efficacy and upper gastrointestinal safety of celecoxib and naproxen for the treatment of patients with rheumatoid arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80016"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1148</Patients><Biomarkers>C-Reactive Protein</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>1148</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>N49-96-02-022</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CELAROM</ProtocolAcronym><ProtocolTitle>Exemestane + Celecoxib versus Exemestane + Placebo in Metastatic Breast Cancer</ProtocolTitle><Sponsor>ARCAGY/ GINECO GROUP</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44045"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>157</Patients><Biomarkers></Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>157</EnrollmentCount><Interventions>celecoxib; exemestane</Interventions><Reference>CELAROM; CELAROM; NCT00525096</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, two-stage, single-center, randomized, crossover, comparative study evaluating bioequivalence of drugs Simcoxib, capsules of 200 mg of "Simpex Pharma Pvt. Ltd." India and Celebrex, capsules of 200 mg, the company "Pfizer Manufacturing Deutschland GmbH", Germany in healthy volunteers following a single dose on an empty stomach</ProtocolTitle><Sponsor>JSC "Coral-Med"</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="275414"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>68</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>68</EnrollmentCount><Interventions>celecoxib (Simcoxib), Simpex Pharma</Interventions><Reference>SIM-05_16</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>COLA</ProtocolAcronym><ProtocolTitle>A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC</ProtocolTitle><Sponsor>Brigham &amp; Women's Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233507"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Forced expiratory volume; Prostaglandins; Tuberin; Vascular endothelial growth factor D</Biomarkers><Condition>Lymphangioleiomyomatosis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2015P000954; COLA; NCT02484664</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>COLA</ProtocolAcronym><ProtocolTitle>A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC</ProtocolTitle><Sponsor>Brigham &amp; Women's Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233507"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Forced expiratory volume; Prostaglandins; Tuberin; Vascular endothelial growth factor D</Biomarkers><Condition>Tuberous sclerosis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2015P000954; COLA; NCT02484664</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery</ProtocolTitle><Sponsor>St. Louis Joint Replacement Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47956"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>107</Patients><Biomarkers>Knee motion</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>107</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>GA3190YM; NCT00474773</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy</ProtocolTitle><Sponsor>HaEmek Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="68908"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>celecoxib; cytophosphan; methotrexate</Interventions><Reference>0082-09-EMC; NCT01175772</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Minocycline and Celecoxib as Adjunctive Treatments of Bi-polar Depression</ProtocolTitle><Sponsor>Pakistan Institute of Learning and Living</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="255392"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers></Biomarkers><Condition>Bipolar I disorder</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>celecoxib; celecoxib; minocycline; minocycline</Interventions><Reference>MIN-BPD; NCT02703363</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Minocycline and Celecoxib as Adjunctive Treatments of Bi-polar Depression</ProtocolTitle><Sponsor>Pakistan Institute of Learning and Living</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="255392"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers></Biomarkers><Condition>Bipolar II disorder</Condition><Controls></Controls><EnrollmentCount>240</EnrollmentCount><Interventions>celecoxib; celecoxib; minocycline; minocycline</Interventions><Reference>MIN-BPD; NCT02703363</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>ACCeRT</ProtocolAcronym><ProtocolTitle>Anti-inflammatory and nutritional support, with simple exercises in lung cancer patients with weight loss</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="85020"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>21</Patients><Biomarkers>Interleukin 1; Interleukin 1 (IL-1); Interleukin 6 (IL-6); Lean body mass; Muscle strength; Tumor necrosis factor-alpha (TNF-alpha)</Biomarkers><Condition>Cachexia</Condition><Controls>celecoxib; eicosapentaenoic acid</Controls><EnrollmentCount>21</EnrollmentCount><Interventions>celecoxib; eicosapentaenoic acid; essential amino acids</Interventions><Reference>1111 – 1123 - 4962; ACCeRT; ACTRN12611000870954; ANZCTR343304</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>COMPLETED</ProtocolAcronym><ProtocolTitle>A Study of Two Approved Drugs in Patients With Osteoarthritis</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="193325"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>395</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>413</EnrollmentCount><Interventions>rofecoxib</Interventions><Reference>0966-220; 2004_071; COMPLETED; NCT00092365</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Short-term Efficacy of Antidepressant in Patients Underwent TKA</ProtocolTitle><Sponsor>Dalian Municipal Central Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="294630"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>32</EnrollmentCount><Interventions>duloxetine</Interventions><Reference>I84412001; NCT03110172</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Short-term Efficacy of Antidepressant in Patients Underwent TKA</ProtocolTitle><Sponsor>Dalian Municipal Central Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="294630"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>32</EnrollmentCount><Interventions>duloxetine</Interventions><Reference>I84412001; NCT03110172</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Hemangiopericytoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Angiosarcoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Chondrosarcoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Fibrosarcoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Leiomyosarcoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Liposarcoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Stage II or Stage III Soft Tissue Sarcoma of the Arm, Hand, Leg, or Foot That Has Been Removed by Surgery</ProtocolTitle><Sponsor>University of Miami</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>3</Patients><Biomarkers></Biomarkers><Condition>Histiocytoma</Condition><Controls></Controls><EnrollmentCount>3</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>20030283; EPROST-20030283; NCT00450736; SCCC-2003053; WIRB-20051240</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47196"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>2</Patients><Biomarkers>Breast cancer type 2 susceptibility protein; Cadherin-1; Cyclin-dependent kinases regulatory subunit 2; Insulin-like growth factor binding protein 6; NT-3 growth factor receptor; Neurogenic locus notch homolog protein 1; Protein C-ets-1; Serine-protein kinase ATM; Transforming growth factor beta 1; Tumor necrosis factor ligand superfamily member 10; Tyrosine-protein kinase HCK</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; erlotinib</Interventions><Reference>0405-2006; 5R01CA112643; IRB00021851; NCT00400374</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="47196"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>2</Patients><Biomarkers>Breast cancer type 2 susceptibility protein; Cadherin-1; Cyclin-dependent kinases regulatory subunit 2; Insulin-like growth factor binding protein 6; NT-3 growth factor receptor; Neurogenic locus notch homolog protein 1; Protein C-ets-1; Serine-protein kinase ATM; Transforming growth factor beta 1; Tumor necrosis factor ligand superfamily member 10; Tyrosine-protein kinase HCK</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; erlotinib</Interventions><Reference>0405-2006; 5R01CA112643; IRB00021851; NCT00400374</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Shanghai Chest Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="125684"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>81</Patients><Biomarkers>Vascular endothelial growth factors</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; cisplatin; vinorelbine</Interventions><Reference>ChiCTR-TNRC-11001601; ChiCTR-TRC-11001601</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb/IV, single-center, double-blind, randomized, two-period, crossover clinical trial to study the safety, tolerability and renal effects of celecoxib versus ibuprofen for the treatment of patients with mild to moderate congestive heart failure</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="80141"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>7</Patients><Biomarkers>2,3 dinor-6-keto-PGF1alfa; 6-keto-PGF1alfa; Hematocrit; PGE2; Plasma renin; Serum C-reactive protein; Serum creatinine; blood urea nitrogen (BUN); interleukin-6; tumor necrosis factor-alfa</Biomarkers><Condition>Congestive heart failure</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>celecoxib; ibuprofen</Interventions><Reference>A3191129; N49-01-02-199</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus</ProtocolTitle><Sponsor>Weill Medical College of Cornell University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="27438"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>39</Patients><Biomarkers>COX-2</Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>carboplatin; celecoxib; paclitaxel</Interventions><Reference>CDR0000316464; NCT00066716; NYWCCC-0902-463</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of preemptive analgesia on the fast-track surgery of colon carcinoma</ProtocolTitle><Sponsor>Fourth Military Medical University PLA, Xijing Hospital of Digestive Diseases</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="311084"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>69</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>69</EnrollmentCount><Interventions>celecoxib; dexamethasone; dezocine; flurbiprofen axetil; levobupivacaine; sufentanil; tropisetron</Interventions><Reference>ChiCTR-IPR-15005931</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Dysmenorrhea</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Keratosis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Gout</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Alzheimers disease</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Renal cell carcinoma</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Periarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Tenosynovitis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Pancreas tumor</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Prostate tumor</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Non-Hodgkin lymphoma</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Back pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Bladder tumor</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Cachexia</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Uterine cervix tumor</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study, single-dose, randomized, balanced, open, two-treatment, two-sequences, two-period, crossover Celecoxib 200 mg capsules in healthy adult subjects under fasted conditions</ProtocolTitle><Sponsor>Aspen Labs</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="207504"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Breast tumor</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Aspen Labs, Mexico)</Interventions><Reference>AS/AB/OCT-13/0025</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>TOPIQS study</ProtocolAcronym><ProtocolTitle>Effect of Pegylated Interferon and Ribavirin Therapy on the QOL in the Treatment of Chronic Hepatitis C</ProtocolTitle><Sponsor>Tokai University School of Medicine, Japan</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="140269"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Hepatitis C virus infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Pegasys; celecoxib; peginterferon alfa-2b; ribavirin; ribavirin (oral tablet, HCV), Roche</Interventions><Reference>JPRN-UMIN000003988; TOPIQS study</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>GCRP</ProtocolAcronym><ProtocolTitle>Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer</ProtocolTitle><Sponsor>Second Affiliated Hospital ZheJiang University College of Medicine</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="336260"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>480</Patients><Biomarkers>CA19-9 antigen</Biomarkers><Condition>Pancreas tumor</Condition><Controls>gemcitabine</Controls><EnrollmentCount>480</EnrollmentCount><Interventions>celecoxib; gemcitabine</Interventions><Reference>GCRP; NCT03498326; SAHZhejiangU-GCRP</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of Celecoxib on Bone Ingrowth</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="12778"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>9</Patients><Biomarkers>Bones</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>9</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>IIR#2005-0300; NCT00585156</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Anti-Inflammatory Treatment for Age-Associated Memory Impairment: A Double-Blind, Placebo-Controlled Trial</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94242"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>135</Patients><Biomarkers>APOE-4; Apolipoprotein E</Biomarkers><Condition>Amnesia</Condition><Controls></Controls><EnrollmentCount>135</EnrollmentCount><Interventions>FDG PET scan; celecoxib; magnetic resonance imaging (MRI)</Interventions><Reference>IA0015; NCT00000185; NCT00009230; R01MH058156</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MpeTK01</ProtocolAcronym><ProtocolTitle>Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion</ProtocolTitle><Sponsor>Advantagene Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="162412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Mesothelioma</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>aglatimagene besadenovec; celecoxib; valaciclovir</Interventions><Reference>MPETK01; MpeTK01; NCT01997190</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MpeTK01</ProtocolAcronym><ProtocolTitle>Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion</ProtocolTitle><Sponsor>Advantagene Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="162412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>aglatimagene besadenovec; celecoxib; valaciclovir</Interventions><Reference>MPETK01; MpeTK01; NCT01997190</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MpeTK01</ProtocolAcronym><ProtocolTitle>Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion</ProtocolTitle><Sponsor>Advantagene Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="162412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>aglatimagene besadenovec; celecoxib; valaciclovir</Interventions><Reference>MPETK01; MpeTK01; NCT01997190</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MpeTK01</ProtocolAcronym><ProtocolTitle>Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion</ProtocolTitle><Sponsor>Advantagene Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="162412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>aglatimagene besadenovec; celecoxib; valaciclovir</Interventions><Reference>MPETK01; MpeTK01; NCT01997190</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MpeTK01</ProtocolAcronym><ProtocolTitle>Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion</ProtocolTitle><Sponsor>Advantagene Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="162412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Pleural disease</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>aglatimagene besadenovec; celecoxib; valaciclovir</Interventions><Reference>MPETK01; MpeTK01; NCT01997190</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MpeTK01</ProtocolAcronym><ProtocolTitle>Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion</ProtocolTitle><Sponsor>Advantagene Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="162412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>aglatimagene besadenovec; celecoxib; valaciclovir</Interventions><Reference>MPETK01; MpeTK01; NCT01997190</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MpeTK01</ProtocolAcronym><ProtocolTitle>Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion</ProtocolTitle><Sponsor>Advantagene Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="162412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>19</Patients><Biomarkers></Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>aglatimagene besadenovec; celecoxib; valaciclovir</Interventions><Reference>MPETK01; MpeTK01; NCT01997190</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive And/or Refractory Pediatric Malignancies: A Double-Blind, Placebo-Controlled, Randomized Study</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="150821"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers>VEGF</Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide; thalidomide, Celgene</Interventions><Reference>CTRI/2013/06/003734</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer</ProtocolTitle><Sponsor>Roswell Park Comprehensive Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="196683"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>Cytotoxic T-Lymphocytes; T-cell surface glycoprotein CD8 alpha chain; Tumor-Infiltrating Lymphocytes</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls>surgical resection</Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib; interferon alfa-2b; rintatolimod</Interventions><Reference>10-131; NCT01545141</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="27486"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers>Cyclooxygenase-2; Epidermal growth factor receptor</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib; erlotinib</Interventions><Reference>CDR0000304495; LUNG 2002-01; NCI-2012-02720; NCI-5416; NCT00062101</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Patients With Osteoarthritis</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85662"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>239</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>239</EnrollmentCount><Interventions>etoricoxib</Interventions><Reference>0663-112; MK 0663-112; NCT01554163</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Home-Based Quadriceps Muscle Strengthening and Range of Motion Exercises for Knee Osteoarthritis, A Randomized, Controlled Trial; Motor Function In Lower extremities ADL And Mental State</ProtocolTitle><Sponsor>Juntendo Tokyo Koto Geriatric Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="126101"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers>Blood cells; Erythrocyte; Erythrocyte sedimentation rate; IL-10; IL-1beta; IL-1ra; IL-6; hs-CRP</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Exercise; celecoxib; celecoxib; hyaluronic acid; hyaluronic acid</Interventions><Reference>JPRN-UMIN000006178</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Lumiracoxib</ProtocolTitle><Sponsor>Novartis Pharma GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21632"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>330</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>330</EnrollmentCount><Interventions>lumiracoxib</Interventions><Reference>CCOX189A2301; NCT00267215</Reference></Row><Row><ArmCount>6+</ArmCount><ProtocolAcronym>STAMPEDE</ProtocolAcronym><ProtocolTitle>Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy</ProtocolTitle><Sponsor>Medical Research Council</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="44024"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>3984</Patients><Biomarkers>Alanine transaminase; Aspartate aminotransferase; PSA</Biomarkers><Condition>Metastatic prostate cancer</Condition><Controls></Controls><EnrollmentCount>12200</EnrollmentCount><Interventions>Celebrex; Progynova TS; Taxotere; Xtandi; Zometa; Zytiga; androgen deprivation therapy; hormone therapy alone (Control arm); metformin; prednisolone; radiotherapy (36 Gy in 6 fractions of 6 Gy or 55 Gy in 20 fractions of 2.75 Gy); standard of care</Interventions><Reference>2004-000193-31; 4/MRE07/35; CDR0000455008; CRUK/06/019; EU-205102; ISRCTN78818544; MRC-PR08; MRC-STAMPEDE; MREC 04/MRE07/35; NCT00268476; PR08; STAMPEDE; UKCRN 1409</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Changes in Biomarkers Using Prostaglandin Inhibitors</ProtocolTitle><Sponsor>Hartford Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="104833"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>31</Patients><Biomarkers>1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial; 15-PGDH; COX-2; PGE2; Transforming growth factor beta 1; Transforming growth factor beta-2; Vitamin D-binding protein</Biomarkers><Condition>Breast tumor</Condition><Controls>cholecalciferol</Controls><EnrollmentCount>31</EnrollmentCount><Interventions>celecoxib; cholecalciferol</Interventions><Reference>200807-001; NCT01769625</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CONCEPT</ProtocolAcronym><ProtocolTitle>Condrosulf Versus Celebrex Versus Placebo in the Treatment of Knee OA</ProtocolTitle><Sponsor>Institut Biochimique SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="176680"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>603</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>604</EnrollmentCount><Interventions>Condrosulf</Interventions><Reference>12EU/Ct06; 2013-001619-62; CONCEPT; NCT02079727</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>19</Patients><Biomarkers>Regulatory T-Lymphocytes; T regs cells</Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0111; 110111; NCT01313429</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>19</Patients><Biomarkers>Regulatory T-Lymphocytes; T regs cells</Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0111; 110111; NCT01313429</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>19</Patients><Biomarkers>Regulatory T-Lymphocytes; T regs cells</Biomarkers><Condition>Stage IV melanoma</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0111; 110111; NCT01313429</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>19</Patients><Biomarkers>Regulatory T-Lymphocytes; T regs cells</Biomarkers><Condition>Pleural disease</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0111; 110111; NCT01313429</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>19</Patients><Biomarkers>Regulatory T-Lymphocytes; T regs cells</Biomarkers><Condition>Lung tumor</Condition><Controls></Controls><EnrollmentCount>19</EnrollmentCount><Interventions>K562/GM-CSF; celecoxib; cyclophosphamide</Interventions><Reference>11-C-0111; 110111; NCT01313429</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, multiple-dose clinical trial to assess the interaction of celecoxib on prothrombin time with acenocoumarol or phenprocoumon</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79885"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Arthritis</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>acenocoumarol; acenocoumarol + celecoxib; celecoxib; phenprocoumon; phenprocoumon + celecoxib</Interventions><Reference>A3191106; E49-00-02-146</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Disease Modifying Activity of Celecoxib on Articular Cartilage in Osteoarthritis</ProtocolTitle><Sponsor>Sint Franciscus Gasthuis</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="122123"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>172</Patients><Biomarkers>COX-1; COX-2; prostaglandin E2; proteoglycan</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>172</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>2007/36 METC Rotterdam; NTR1579</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The study of small dose chemotherapy after surgery not fit for radiotherapy in recurrent head and neck cancers patients</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="259819"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>400</Patients><Biomarkers>Circulating endothelial cells; Microvessel density; Progenitor cells; Vascular endothelial growth factor receptors</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>celecoxib; methotrexate</Interventions><Reference>CTRI/2016/04/006872</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CONSUL</ProtocolAcronym><ProtocolTitle>NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="259715"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>156</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls>golimumab</Controls><EnrollmentCount>156</EnrollmentCount><Interventions>celecoxib; golimumab</Interventions><Reference>2016-000615-33; CONSUL; CONSUL2016; NCT02758782</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in preventing cancer in patients with rectal polyps or colorectal neoplasia</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="27618"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000069498; NCI-02-C-0194; NCT00043043; NCT00056615</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery</ProtocolTitle><Sponsor>Vanderbilt-Ingram Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="45399"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Cyclo-oxygenase-2</Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>Radiotherapy; celecoxib; fluorouracil</Interventions><Reference>NCT00336960; P30CA068485; P50CA095103; VICC GI 0173; VICC-020031; VICC-GI-0173</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of AKB-6548 on the Pharmacokinetics of Celecoxib</ProtocolTitle><Sponsor>Akebia Therapeutics Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="235210"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Cytochrome P450 2C9</Biomarkers><Condition>Anemia</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>AKB-6548; celecoxib; celecoxib</Interventions><Reference>AKB-6548-CI-0019; NCT02502500</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers></Biomarkers><Condition>Pancreas tumor</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>celecoxib; gemcitabine</Interventions><Reference>2003-0288; CDR0000322827; MDA-2003-0288; NCI-6167; NCT00068432; P30CA016672</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Combined Use of Naloxone and Tramacet on Postop Analgesia in Elderly Patients Having Joint Replacement Surgery</ProtocolTitle><Sponsor>Lawson Health Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="170807"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>Tylenol; celebrex; morphine; naloxone; tramacet</Interventions><Reference>13659; NCT00679614; R-07-427</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, crossover, randomized, single-dose, two-treatments, two-periods and two-sequences, bioequivalence study of two pharmaceutical preparations of celecoxib 200 mg capsules in mexican population under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Best, S A</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="200124"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>42</EnrollmentCount><Interventions>celecoxib (Laboratorios Best)</Interventions><Reference>/A232-12</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Platelet-Rich Plasma Injection Plus Oral Celecoxib versus Saline Injection Plus Oral Celecoxib to Treat Knee Osteoarthritis: a Randomized, Single-Blind Clinical Trial</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="141628"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; platelet-rich plasma injection</Interventions><Reference>IRCT201301167274</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparsion of 2% Tanacetum Parthenium Gel with 1% Diclofenac Gel on the pain of patients with primary knee osteoarthritis</ProtocolTitle><Sponsor>Shahrekord University of Medical Sciences and Health Services</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="315684"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Tanacetum parthenium gel; celecoxib; diclofenac</Interventions><Reference>IR.SKUMS.REC.1394.309; IRCT2017092710222N14</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparsion of 2% Tanacetum Parthenium Gel with 1% Diclofenac Gel on the pain of patients with primary knee osteoarthritis</ProtocolTitle><Sponsor>Shahrekord University of Medical Sciences and Health Services</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="315684"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Tanacetum parthenium gel; celecoxib; diclofenac</Interventions><Reference>IR.SKUMS.REC.1394.309; IRCT2017092710222N14</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>KHUH-K01</ProtocolAcronym><ProtocolTitle>An open-label, crossover clinical study to investigate the effects of Ojeoksan on the pharmacokinetics of Celecoxib capsules in healthy male volunteers</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="314067"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>26</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>Ojeoksan; celecoxib</Interventions><Reference>2016-10-025; KCT0002447; KHUH-K01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="179893"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Dinoprostone; Prostaglandin G/H synthase 1; Prostaglandin G/H synthase 2</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>N01-CN-85183-STEP1; N01CN85183; NCI-2014-00525; NCI-2014-00525; NCT02099136; NQ4-99-02-008</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dexmedetomidine as Adjuvant for FNB in TKA</ProtocolTitle><Sponsor>First Affiliated Hospital of Sun Yat-Sen University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="352360"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Muscle strength</Biomarkers><Condition>Anesthesia</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>celecoxib; continuous femoral nerve block; dexmedetomidine; intravenous patient-controlled analgesia pump; morphine; ropivacaine; ultrasound-guided femoral nerve block</Interventions><Reference>NCT03658421; [2018]099; [2018]45</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dexmedetomidine as Adjuvant for FNB in TKA</ProtocolTitle><Sponsor>First Affiliated Hospital of Sun Yat-Sen University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="352360"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Muscle strength</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>celecoxib; continuous femoral nerve block; dexmedetomidine; intravenous patient-controlled analgesia pump; morphine; ropivacaine; ultrasound-guided femoral nerve block</Interventions><Reference>NCT03658421; [2018]099; [2018]45</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratosis</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23633"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Keratosis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000069099; NCI-P00-0161; NCI-P01-0197; NCT00027976; UAB-9833; UAB-NQ401A4009; UAB-NQ49902009</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratosis</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23633"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Skin cancer</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000069099; NCI-P00-0161; NCI-P01-0197; NCT00027976; UAB-9833; UAB-NQ401A4009; UAB-NQ49902009</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ARACONDRO</ProtocolAcronym><ProtocolTitle>A Randomized, Multicenter, Double-Blind, Double-Dummy and Parallel Study to Evaluate the Efficacy of the Combination of Chondroitin Sulfate and Glucosamine Hydrochloride in a Single Dose Chewable Tablet Versus Placebo, Using Celecoxib as an Active Control in Patients With Knee Osteoarthritis With Moderate to Severe Pain</ProtocolTitle><Sponsor>Arafarma Group Sa</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="130834"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>501</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>501</EnrollmentCount><Interventions>glucosamine hydrochloride + chondroitin sulfate</Interventions><Reference>ARACONDRO; ARACONDRO-001; EudraCT 2011-005398-22</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel in Normal Volunteers</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="52550"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Prostacyclin</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>aspirin; aspirin; celecoxib; celecoxib; clopidogrel</Interventions><Reference>COREA-volunteer; NCT00882388</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III, Randomized Trial Comparing Two Regimens for Treatment of Cancer Anorexia/Cachexia syndrome (CACS)</ProtocolTitle><Sponsor>Azienda Ospedaliero Universitaria di Cagliari</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="118426"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>148</Patients><Biomarkers></Biomarkers><Condition>Appetite loss</Condition><Controls>megestrol acetate</Controls><EnrollmentCount>148</EnrollmentCount><Interventions>carbocisteine; celecoxib; levocarnitine</Interventions><Reference>CACS-2010; EudraCT 2010-019831-36</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III, Randomized Trial Comparing Two Regimens for Treatment of Cancer Anorexia/Cachexia syndrome (CACS)</ProtocolTitle><Sponsor>Azienda Ospedaliero Universitaria di Cagliari</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="118426"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>148</Patients><Biomarkers></Biomarkers><Condition>Cachexia</Condition><Controls>megestrol acetate</Controls><EnrollmentCount>148</EnrollmentCount><Interventions>carbocisteine; celecoxib; levocarnitine</Interventions><Reference>CACS-2010; EudraCT 2010-019831-36</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, 12-week, multicenter, double-blind, parallel-group clinical trial to compare the efficacy and incidence of gastroduodenal ulcer associated with celecoxib with that of diclofenac  for the treatment of patients with osteoarthritis or rheumatoid arthritis in Taiwan</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79838"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>125</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191327; I49-98-02-106</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, 12-week, multicenter, double-blind, parallel-group clinical trial to compare the efficacy and incidence of gastroduodenal ulcer associated with celecoxib with that of diclofenac  for the treatment of patients with osteoarthritis or rheumatoid arthritis in Taiwan</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79838"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>125</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>125</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191327; I49-98-02-106</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies</ProtocolTitle><Sponsor>All India Institute of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="133657"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>108</Patients><Biomarkers>Vascular endothelial growth factors</Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>108</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; etoposide phosphate; thalidomide</Interventions><Reference>IEC/NP-63/2013; NCT01858571</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Open-Label Study Of Celecoxib In Patients With Post-traumatic Pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60320"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>80</Patients><Biomarkers>Alanine aminotransferase; Aspartate aminotransferase; Beta-2-microglobulin urine; Beta-N-acetyl-D-glucosaminidase; Blood bilirubin; Blood creatinine phosphokinase; Blood lactate dehydrogenase; Urobilin urine</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191357; JapicCTI-090863; NCT00976716</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Barbara Ann Karmanos Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="27255"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib; docetaxel; docetaxel + celecoxib</Interventions><Reference>CDR0000069163; NCI-V01-1687; NCT00030407; P30CA022453; WSU-C-2305</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetic non-interaction study between Celecoxib 200 mg and Paracetamol 500 mg, administered individually or in combination, single dose in healthy subjects, both sexes in fasting conditions</ProtocolTitle><Sponsor>Laboratorios Silanes SA De CV</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="378494"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celecoxib (Celebrex ®, Pfizer, SA de CV); paracetamol (Tylenol caplets ®, Janssen Cilag, SA de CV)</Controls><EnrollmentCount>42</EnrollmentCount><Interventions>Celecoxib/paracetamol (prepared by Laboratorios Silanes, SA de CV)</Interventions><Reference>BD CP-Sil No. 104-18</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of Celecoxib 400 mg in Healthy Thai volunteers under fed condition</ProtocolTitle><Sponsor>All Research Co., Ltd.</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="307787"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>46</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>Generic Celecoxib</Interventions><Reference>TCTR20170807001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A prospective, open, randomized, comparative, crossover study of pharmacokinetics and bioequivalence of celecoxib drug capsules, 200 mg ("Atlantic Pharmaceuticals - Prodyukos Farmasyutikas SA", Portugal) in comparison with the drug Celebrex, capsules, 200 mg ("Pfizer Pharmaceuticals LLC", the United States) in healthy volunteers after single oral administration on an empty stomach</ProtocolTitle><Sponsor>Valeant Russia, LLC</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="269031"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>46</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>celecoxib, Atlantic Pharmaceuticals</Interventions><Reference>CEL-200-2015</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="116083"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Autologous tumor cell vaccine; Iscomatrix; celecoxib; radiation therapy (100 Gy)</Interventions><Reference>11-C-0041; 110041; NCT01258868</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="116083"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Mesothelioma</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Autologous tumor cell vaccine; Iscomatrix; celecoxib; radiation therapy (100 Gy)</Interventions><Reference>11-C-0041; 110041; NCT01258868</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="116083"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Sarcoma</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Autologous tumor cell vaccine; Iscomatrix; celecoxib; radiation therapy (100 Gy)</Interventions><Reference>11-C-0041; 110041; NCT01258868</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="116083"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Thymus neoplasm</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Autologous tumor cell vaccine; Iscomatrix; celecoxib; radiation therapy (100 Gy)</Interventions><Reference>11-C-0041; 110041; NCT01258868</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="116083"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Thymoma</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Autologous tumor cell vaccine; Iscomatrix; celecoxib; radiation therapy (100 Gy)</Interventions><Reference>11-C-0041; 110041; NCT01258868</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="116083"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Pleural disease</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Autologous tumor cell vaccine; Iscomatrix; celecoxib; radiation therapy (100 Gy)</Interventions><Reference>11-C-0041; 110041; NCT01258868</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="116083"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Lung tumor</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Autologous tumor cell vaccine; Iscomatrix; celecoxib; radiation therapy (100 Gy)</Interventions><Reference>11-C-0041; 110041; NCT01258868</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>POPAID</ProtocolAcronym><ProtocolTitle>Influence of Lactobacillus salivarius WB21 on small bowel injuries in subjects who take NSAID and PPI; a randomized, double-blind, placebo-controlled trial</ProtocolTitle><Sponsor>Fukuoka Sanno Hospital, Iwate Medical University, Kyushu University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="289659"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Intestine disease</Condition><Controls>celecoxib; rabeprazole</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Lactobacillus salivarius WB21; celecoxib; rabeprazole</Interventions><Reference>FS-181; POPAID; UMIN000026358</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Precancerous Lesions of the Mouth</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="27940"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>00-111; MSKCC-00111; NCI-G01-1930; NCT00014404</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Pharmacokinetic Interaction Between Celecoxib and Rebamipide</ProtocolTitle><Sponsor>Hanlim Pharmaceutical Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85526"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib; celecoxib; rebamipide; rebamipide</Interventions><Reference>AN11273-002; HL-CER-101; KCT0000381; NCT01549743</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Does Saline Injection Around Phrenic Nerve Reduce Incidence of Diaphragmatic Paresis Following Interscalene Block?</ProtocolTitle><Sponsor>Adelaide and Meath Hospital, Tallaght Regional Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="270790"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>36</Patients><Biomarkers>Forced Vital Capacity; Forced expiratory volume; Peak expiratory flow rate</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>Diprivan; antibiotics therapy; celecoxib; chlorhexidine; cyclizine lactate; dexamethasone; fentanyl; levobupivacaine; lidocaine; midazolam hydrochloride; morphine; ondansetron; oxynorm; paracetamol; parecoxib; rocuronium; sevoflurane; sugammadex</Interventions><Reference>AMNCH-A-SIPPIB; NCT02893228</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Antidepressant Effects of Celecoxib in the Treatment of Patients With Colon Cancer</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="238263"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Major depressive disorder</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>IR.TUMS.REC.1394.568; IRCT201508201556N79</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in preventing breast cancer in pre-menopausal women</ProtocolTitle><Sponsor>Southwest Oncology Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29477"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>8</Patients><Biomarkers>Antigen KI-67; Breast cancer type 1 susceptibility protein; Breast cancer type 2 susceptibility protein; Cyclo-oxygenase-2 (COX-2); IGF binding protein-3; Insulin-like growth factor (IGF)-1; Insulin-like growth factor 1; Ki-67 protein; Prostaglandin E2; Prostaglandin G/H synthase 2</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>8</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000377698; NCT00088972; S0300; SWOG-S0300; U10CA012027; U10CA037429</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preemptive Analgesia in Cruciate Reconstruction</ProtocolTitle><Sponsor>Prince of Songkla University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="62119"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>102</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>102</EnrollmentCount><Interventions>celecoxib; etoricoxib</Interventions><Reference>EC50/369-007; NCT01017380</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study evaluating survival benefit of use of low-dose continuous chemotherapy drugs along with surgery and radiation in treatment of advanced stage cancers of the oral cavity</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="225561"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Mouth tumor</Condition><Controls></Controls><EnrollmentCount>400</EnrollmentCount><Interventions>adjuvant radiation therapy; celecoxib; chemoradiation; methotrexate; standard surgery</Interventions><Reference>CTRI/2015/01/005405</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Stage IIIB or IV Non-small-cell Lung Cancer</ProtocolTitle><Sponsor>Jonsson Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29866"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>7</Patients><Biomarkers>CD25+ T-lymphocyte regulatory cells; CD4+ T lymphocyte regulatory cells; FOXP3; Interleukin-2 receptor alpha chain ; T-cell surface glycoprotein CD4; Treg cells; cyclooxygenase-2</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000415733; NCT00104767; NCT00744783; UCLA-0407028-01</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MOSAIC</ProtocolAcronym><ProtocolTitle>Study of the Effect of Chondroitin Sulfate on Structural Changes in Knee Osteoarthritis Patients Assessed by MRI</ProtocolTitle><Sponsor>Bioiberica SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="105698"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>119</Patients><Biomarkers>C-reactive protein; C-terminal telopeptide of collagen type I; Cartilage; Complement factor D; Hyaluronic acid; Interstitial collagenase; Joint swelling; Knee stiffness; Leptin; Meniscus; Procollagen Type I N-terminal peptide; Stromelysin-1; Synovial fluid; Synovial membrane</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>194</EnrollmentCount><Interventions>chondroitin sulfate (Condrosan)</Interventions><Reference>CS/III-DMOAD-02; MOSAIC; NCT01354145</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Quadratus Lumborum Block Versus Fascia Iliaca Nerve Block for Patients Undergoing Total Hip Replacement</ProtocolTitle><Sponsor>Adelaide and Meath Hospital, Tallaght Regional Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="343254"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Hip motion; Knee motion</Biomarkers><Condition>Pain</Condition><Controls>Fascia Iliaca Block</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Spinal anaesthesia; Transmuscular Quadratus Lumborum; bupivacaine; celecoxib; chlorhexidine; cyclizine; morphine; ondansetron; paracetamol; parecoxib; tranexamic acid</Interventions><Reference>2017/1/01-2018-01; NCT03551860</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ATRA, Celecoxib, and Itraconazole as Maintenance</ProtocolTitle><Sponsor>University of Iowa</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="225422"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>1</Patients><Biomarkers>Creatinine; Retinoic acid receptor alpha</Biomarkers><Condition>Multiple myeloma</Condition><Controls></Controls><EnrollmentCount>1</EnrollmentCount><Interventions>celecoxib; itraconazole; tretinoin</Interventions><Reference>201311791; NCT02401295</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, double-blind, placebo-controlled, randomized comparative clinical trial to study the efficacy and safety of celecoxib and naproxen for treating the signs and symptoms of osteoarthritis of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80093"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>1004</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>1004</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>N49-96-02-020</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="31774"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>26</Patients><Biomarkers>COX-2; Carbonic anhydrase-I; Carbonic anhydrase-II; Cyclooxygenase-2 dependent PGE2; PGD-M; PGE-M; PGE2; PGI-M; TxB-M; TxB2</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>26</EnrollmentCount><Interventions>CG-100649</Interventions><Reference>807821; NCT00780325</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib for Reducing Morphine Requirement After Thyroid Surgery: A Randomized Controlled Trial</ProtocolTitle><Sponsor>Mahidol University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13004"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00520338; Si 117/2007</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib</ProtocolTitle><Sponsor>Chinese University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21772"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>273</Patients><Biomarkers></Biomarkers><Condition>Arthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>273</EnrollmentCount><Interventions>esomeprazole</Interventions><Reference>7NB study; NCT00365313</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preventing Recurrent Ulcer Bleeding in Arthritis Patients Using Esomeprazole Plus Celecoxib</ProtocolTitle><Sponsor>Chinese University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21772"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>273</Patients><Biomarkers></Biomarkers><Condition>Ulcer</Condition><Controls>celecoxib</Controls><EnrollmentCount>273</EnrollmentCount><Interventions>esomeprazole</Interventions><Reference>7NB study; NCT00365313</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>ADAPT</ProtocolAcronym><ProtocolTitle>Alzheimer's Disease Anti-Inflammatory Prevention Trial</ProtocolTitle><Sponsor>Seattle Institute for Biomedical and Clinical Research</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="1219"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2528</Patients><Biomarkers>APOE; beta-amyloid protein 42</Biomarkers><Condition>Alzheimers disease</Condition><Controls></Controls><EnrollmentCount>2625</EnrollmentCount><Interventions>Aleve; celecoxib</Interventions><Reference>ADAPT; IA0026; NCT00007189; U01AG15477</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The efficacy and mechanism of imrecoxib in axial spondyloarthritis</ProtocolTitle><Sponsor>Jiangsu Hengrui Medicine Co Ltd, The First Affiliated Hospital of Zhengzhou University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="207631"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers>15-hydroxyprostaglandin dehydrogenase (NAD+); C-reactive protein; Erythrocyte sedimentation rate; Prostaglandin E2 receptor EP4 subtype; Prostaglandin G/H synthase 2</Biomarkers><Condition>Spondylarthritis</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Celebrex; imrecoxib</Interventions><Reference>ChiCTR-TRC-14004718</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical study to evaluate the bioequivalence of Celecoxib 200 mg capsules in healthy volunteers, celecoxib (Landsteiner Scientific, SA de CV) versus Celebrex (Pfizer, SA de CV)</ProtocolTitle><Sponsor>Landsteiner Scientific Sa De Cv</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="228853"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>34</Patients><Biomarkers>Body height; Total body mass</Biomarkers><Condition></Condition><Controls>celebrex</Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib (Landsteiner)</Interventions><Reference>15-005CEL</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Testing the effectiveness of celecoxib in patients with painful sore throat</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13062"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>269</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>269</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191334; NCT00402987</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Testing the effectiveness of celecoxib in patients with painful sore throat</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="13062"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>269</Patients><Biomarkers></Biomarkers><Condition>Pharyngitis</Condition><Controls></Controls><EnrollmentCount>269</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191334; NCT00402987</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy And Safety Of Chuna Treatment As An Adjunctive Therapy After Knee Replacement</ProtocolTitle><Sponsor>Gachon University Gil Oriental Medical Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="349577"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Knee motion</Biomarkers><Condition>Pain</Condition><Controls>celecoxib; esomeprazole</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Chuna therapy; Physical therapy; celecoxib; esomeprazole</Interventions><Reference>ISEE_2018_TKA_CN; NCT03625050</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label, Randomized, Two-way Crossover, Two-sequence, Two-period, Two-treatment Bioequivalence Study of Celecoxib Capsules 200 mg Preparations in Healthy Thai Volunteers</ProtocolTitle><Sponsor>Micro Labs Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="284033"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>48</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>48</EnrollmentCount><Interventions>Celecoxib, Micro Labs Limited</Interventions><Reference>TCTR20170104001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, double-blind, placebo-controlled, parallel-group, randomized comparative clinical trial to study the efficacy and safety of celecoxib and naproxen for the treatment of patients with signs and symptoms of osteoarthritis of the hip</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80014"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>1061</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>1061</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>N49-96-02-054</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer</ProtocolTitle><Sponsor>New Mexico Cancer Care Alliance</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="43969"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers></Biomarkers><Condition>Rectal tumor</Condition><Controls></Controls><EnrollmentCount>38</EnrollmentCount><Interventions>capecitabine; capecitabine + oxaliplatin + celecoxib + radiation; celecoxib; oxaliplatin; radiation</Interventions><Reference>3304C; NCI-2011-02685; NCT00250835</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical control non-randomized, controlled, open-label, post-marketing study for treatment of gastric precancerous change by celecoxib</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="98459"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>COX-2; NAG-1; NF-KB; SST (Somatostatin)</Biomarkers><Condition>Gastritis</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>amoxicillin; celecoxib; celecoxib; clarithromycin; esomeprazole</Interventions><Reference>ChiCTR-TNRC-08000150</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol</ProtocolTitle><Sponsor>Turku University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75222"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib; etoricoxib; tramadol</Interventions><Reference>119/180/2010; 2010-023373-19; NCT01304069</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celecoxib and Etoricoxib on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol</ProtocolTitle><Sponsor>Turku University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="75222"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Cancer pain</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib; etoricoxib; tramadol</Interventions><Reference>119/180/2010; 2010-023373-19; NCT01304069</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pain Management in Head and Neck Surgery Patients</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="295657"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Norco</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Celebrex; Neurontin; OxyContin; Tylenol</Interventions><Reference>IRB-170310004; NCT03121963; X170310004</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Upper Gastrointestinal Endoscopic Findings in Japanese With Rheumatoid Arthritis (RA) Receiving Long-Term NSAIDs Therapy, and the Usefulness of Switching to Selective COX-2 Inhibitor Celecoxib</ProtocolTitle><Sponsor>Kyushu Kosei Nenkin Hosipital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="140430"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; famotidine</Interventions><Reference>JPRN-UMIN000004271</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>INSTEP</ProtocolAcronym><ProtocolTitle>INSTEP Trial</ProtocolTitle><Sponsor>St Vincents Hospital (Melbourne) Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="258162"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>VATS pleurodesis; celecoxib</Interventions><Reference>ACTRN12605000082606; ANZCTR87; INSTEP</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>INSTEP</ProtocolAcronym><ProtocolTitle>INSTEP Trial</ProtocolTitle><Sponsor>St Vincents Hospital (Melbourne) Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="258162"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Lung disease</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>VATS pleurodesis; celecoxib</Interventions><Reference>ACTRN12605000082606; ANZCTR87; INSTEP</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effects of a Prostaglandin Inhibitor on Ovulation and the Menstrual Cycle</ProtocolTitle><Sponsor>Oregon Health Sciences University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="56151"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>11</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>NCT00614406; OHSU FAMPLAN 3854</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-diagnosed Metastatic Ewing's Sarcoma Family of Tumors</ProtocolTitle><Sponsor>Children's Oncology Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25982"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>35</Patients><Biomarkers>Neutrophils</Biomarkers><Condition>Ewing sarcoma</Condition><Controls></Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; doxorubicin hydrochloride; etoposide; ifosfamide; mesna; vinblastine; vincristine</Interventions><Reference>AEWS02P1; CDR0000302409; NCT00061893</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on the Neoadjuvant Use of Chemotherapy and Celecoxib Therapy in Patients With Invasive Breast Cancer</ProtocolTitle><Sponsor>Organisation for Oncology and Translational Research Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44018"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>34</Patients><Biomarkers>Lactate dehydrogenase; N-terminal Pro Brain Natriuretic Peptide; Troponin I, cardiac muscle</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>57</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; cyclophosphamide; epirubicin</Interventions><Reference>FEC-DOC-CXB-A3; NCT00135018</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>GI-REASONS</ProtocolAcronym><ProtocolTitle>A Trial Of GI Safety Of Celecoxib Compared With Non-Selective Nonsteroidal Antiinflammatory Drugs (NSAIDS)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21861"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>8067</Patients><Biomarkers>hematocrit; hemoglobin</Biomarkers><Condition>Osteoarthritis</Condition><Controls>non-selective nonsteroidal anti-inflammatory drug therapy</Controls><EnrollmentCount>8067</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191331; GI-REASONS; NCT00373685</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC</ProtocolTitle><Sponsor>Maastricht Radiation Oncology</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="41635"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>41</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>102</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CKTO 2003-07; IKL 2003-02; MEC MAASTRO 0205; NCT00181532; P02.1376L</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Lidocaine Patch 5% Versus Celecoxib 200 mg in Chronic Axial Low Back Pain</ProtocolTitle><Sponsor>Endo Health Solutions Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="55513"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>98</Patients><Biomarkers></Biomarkers><Condition>Back pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>98</EnrollmentCount><Interventions>lidocaine</Interventions><Reference>EN3220-013; NCT00904397</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>‍‍‍Comparing the effect of acupuncture and medical treatment on clinical symptoms and Electromyography/Nerve Conduction Velocity (EMG/NCV) changes in patients with CTS</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="239624"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Compound muscle action potential; Distal motor latency; Motor nerve conduction velocity</Biomarkers><Condition>Carpal tunnel syndrome</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Acupuncture; Celebrex</Interventions><Reference>910775 (IR.MUMS.REC.1391.701); IRCT2012122811912N1</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-opioid Analgesia After Arthroscopic Meniscus Surgery</ProtocolTitle><Sponsor>Henry Ford Health System</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="368169"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>hydrocodon + acetaminophen (Norco)</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>acetaminophen; celecoxib; diazepam; gabapentin; ketorolac</Interventions><Reference>123193; NCT03820193</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison Survey On Adding Celecoxib To Gabapentin In Decreasing Postoperative Pain</ProtocolTitle><Sponsor>Kermanshah University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="123017"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Blood pressure; Heart rate</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>celecoxib; gabapentin; gabapentin</Interventions><Reference>30047; IRCT138903301617N4</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of efficacy of sodium valproate in cervical and lumbar radicular pain management</ProtocolTitle><Sponsor>Shahid Sadoughi University of Medical Sciences and Health Services</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="185555"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>acetaminophen; celecoxib; valproic acid</Interventions><Reference>17/1/248644/پ; IRCT201403101836N8</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Comparison of Analgesic Effect Between Loxoprofen and Celecoxib  and the Frequency of the Hemorrhage Following Tonsillectomy</ProtocolTitle><Sponsor>Tosei General Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="281150"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib; loxoprofen</Interventions><Reference>UMIN000024363</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>EPOCA</ProtocolAcronym><ProtocolTitle>EPOCA</ProtocolTitle><Sponsor>National Hospital Organization Mito Medical Center, University of Tsukuba</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="206255"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Knee motion</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; fentanyl</Interventions><Reference>EPOCA; UMIN000014624</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers</ProtocolTitle><Sponsor>Montefiore Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29639"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>COX-2; apoptosis; p21</Biomarkers><Condition>Uterus disease</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>MMC-03-04-084; NCT00231829</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers</ProtocolTitle><Sponsor>Montefiore Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29639"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>COX-2; apoptosis; p21</Biomarkers><Condition>Cancer</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>MMC-03-04-084; NCT00231829</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma</ProtocolTitle><Sponsor>The Second People's Hospital of Nanning</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="239669"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Body Mass Index</Biomarkers><Condition>Nasopharyngeal carcinoma</Condition><Controls>nedaplatin</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Concurrent radiotherapy (68 to 74 Gy for primary tumor and 50 to 54 Gy for lymphatic positive area); celecoxib; nedaplatin</Interventions><Reference>NCT02537925</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preemptive Celecoxib for the Management of Post-Embolization Syndrome After Partial Splenic Embolization: a Randomized Controlled Trial</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="130387"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>160</Patients><Biomarkers></Biomarkers><Condition>Thrombocytopenia</Condition><Controls></Controls><EnrollmentCount>160</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ChiCTR-TRC-08000062</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination Gene Transfer and Chemotherapy</ProtocolTitle><Sponsor>Abramson Cancer Center of the University of Pennsylvania</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="67482"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Cytokines; Interferon-alpha; Natural killer cells; Regulatory T-Lymphocytes; T-Lymphocytes</Biomarkers><Condition>Mesothelioma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>SCH-721015; celecoxib; gemcitabine; pemetrexed</Interventions><Reference>811318; NCT01119664; UPCC 02510</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination Gene Transfer and Chemotherapy</ProtocolTitle><Sponsor>Abramson Cancer Center of the University of Pennsylvania</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="67482"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Cytokines; Interferon-alpha; Natural killer cells; Regulatory T-Lymphocytes; T-Lymphocytes</Biomarkers><Condition>Pleural disease</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>SCH-721015; celecoxib; gemcitabine; pemetrexed</Interventions><Reference>811318; NCT01119664; UPCC 02510</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee</ProtocolTitle><Sponsor>InVentiv Health Philippines Inc, Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="237983"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3021</Patients><Biomarkers>Blood pressure; Heart rate; Joint space; Knee stiffness</Biomarkers><Condition>Pain</Condition><Controls>celecoxib; diclofenac; naproxen</Controls><EnrollmentCount>3021</EnrollmentCount><Interventions>tanezumab</Interventions><Reference>2012-003721-22; 2015-CT0303; A4091058; JapicCTI-153113; NCT02528188; OA SAFETY STUDY; PHRR160322-001197</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee</ProtocolTitle><Sponsor>InVentiv Health Philippines Inc, Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="237983"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3021</Patients><Biomarkers>Blood pressure; Heart rate; Joint space; Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; diclofenac; naproxen</Controls><EnrollmentCount>3021</EnrollmentCount><Interventions>tanezumab</Interventions><Reference>2012-003721-22; 2015-CT0303; A4091058; JapicCTI-153113; NCT02528188; OA SAFETY STUDY; PHRR160322-001197</Reference></Row><Row><ArmCount>7</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The drug therapy for adults patients with Kashin-Beck disease</ProtocolTitle><Sponsor>Ministry of Science and Technology of the People´s Republic of China, Sichuan University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="98629"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>420</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>420</EnrollmentCount><Interventions>acetaminophen; celecoxib; diacerein; glucosamine; ibuprofen; meloxicam; naproxen</Interventions><Reference>ChiCTR-TRC-09000395</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Sel/Cel</ProtocolAcronym><ProtocolTitle>Selenium for Prevention of Adenomatous Colorectal Polyps</ProtocolTitle><Sponsor>University of Arizona</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="106239"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1374</Patients><Biomarkers>15 kDa selenoprotein; 20-Hydroxy-5,8,11,14-eicosatetraenoic acid; 5-Hydroxy-6,8,11,14-eicosatetraenoic acid; 8-Hydroxyeicosatetraenoic acid; Cytochrome P450 2C9; GPx-1 polymorphism; GPx-2 polymorphism; Glutathione peroxidase 2; Glutathione peroxidase-1; SEP15 polymorphism; Systolic blood pressure; UDP-glucuronosyltransferase 1-6; cytochrome p450 2C9 loci; cytochrome p450 UGT1A6 loci</Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>883</EnrollmentCount><Interventions>celecoxib; selenium (SelenoExcell); selenium (SelenoExcell)</Interventions><Reference>CDR0000353185; NCT00078897; P01CA041108; P30CA023074; Sel/Cel; UARIZ-00-0430-01; UARIZ-HSC-00142</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer</ProtocolTitle><Sponsor>Mount Sinai School of Medicine</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60074"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>14</Patients><Biomarkers></Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib; celecoxib + erlotinib; erlotinib</Interventions><Reference>GCO # 06-0509; MSSM 06-0509; NCT00970502</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Double-Blind and Randomized Trial of Celecoxib Added to Risperidone in Treatment-Naive First-Episode Schizophrenia</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="36041"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>200</Patients><Biomarkers>Interleukin-10; Interleukin-2; Interleukin-6; Interleukin-8; cytokines</Biomarkers><Condition>Schizophrenia</Condition><Controls>risperidone</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib; risperidone</Interventions><Reference>03T-459; SCH-A01; NCT00686140; SMRI 03T-459</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Radiation Therapy in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Radiation Therapy Oncology Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="37762"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>21</Patients><Biomarkers>Basic fibroblast growth factor; Interleukin-8; Vascular endothelial growth factor; Vascular endothelial growth factors; interleukin-1; interleukin-6; tranforming growth factor-beta</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>21</EnrollmentCount><Interventions>Thoracic radiotherapy; celecoxib</Interventions><Reference>CDR0000069476; NCT00046839; RTOG-0213</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Roswell Park Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="18885"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>2</Patients><Biomarkers></Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>2</EnrollmentCount><Interventions>celecoxib; irinotecan</Interventions><Reference>NCT00084721; RP 02-24; RPCI-RP-0224</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="38871"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2720</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib; naproxen</Controls><EnrollmentCount>2720</EnrollmentCount><Interventions>celecoxib; naproxen; tanezumab; tanezumab + celecoxib; tanezumab + naproxen</Interventions><Reference>A4091025; NCT00809354</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="38871"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2720</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; naproxen</Controls><EnrollmentCount>2720</EnrollmentCount><Interventions>celecoxib; naproxen; tanezumab; tanezumab + celecoxib; tanezumab + naproxen</Interventions><Reference>A4091025; NCT00809354</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia</ProtocolTitle><Sponsor>Gynecologic Oncology Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>130</Patients><Biomarkers>Antigen KI-67; COX-2; Vascular endothelial growth factors; bFGF</Biomarkers><Condition>Cervical dysplasia</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>CDR0000360805; GOG-0207; NCT00081263; U10CA101165</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Pantoprazole in a Patients with Head and Neck Cancers</ProtocolTitle><Sponsor>Tata Memorial Centre</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="329213"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>140</Patients><Biomarkers></Biomarkers><Condition>Metastatic head and neck cancer</Condition><Controls>celecoxib; cisplatin; methotrexate</Controls><EnrollmentCount>140</EnrollmentCount><Interventions>celecoxib; cisplatin; methotrexate; pantoprazole</Interventions><Reference>249; CTRI/2018/02/011824</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Laser and Medical Treatment of Diabetic Macular Edema</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="93771"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>86</Patients><Biomarkers>Blood pressure; Cholesterol; Hemoglobin A1C; serum lipids</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>ETDRS style focal photocoagulation; celecoxib; diode (micropulse) laser photocoagulation</Interventions><Reference>03-EI-0065; 030065; NCT00050479</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celebrex in Prevention of Preterm Labor</ProtocolTitle><Sponsor>Kashan University of Medical Sciences and Health Services</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="117699"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Inflammatory disease</Condition><Controls>magnesium sulfate</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>IRCT201204232967N3</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Celebrex in Prevention of Preterm Labor</ProtocolTitle><Sponsor>Kashan University of Medical Sciences and Health Services</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="117699"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Premature labor</Condition><Controls>magnesium sulfate</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>IRCT201204232967N3</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>BLAST</ProtocolAcronym><ProtocolTitle>Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="270723"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>15</Patients><Biomarkers>Cytochrome c oxidase subunit 2; Keratin, type I cytoskeletal 14; Phospho-Histone H3</Biomarkers><Condition>Bladder cancer</Condition><Controls></Controls><EnrollmentCount>15</EnrollmentCount><Interventions>celecoxib; cisplatin; gemcitabine</Interventions><Reference>BLAST; H-36486; NCT02885974</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase I, open-label, pharmacokinetics study of GTx-024 in combination with celecoxib in healthy volunteers</ProtocolTitle><Sponsor>Ohio State University</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="290084"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>celecoxib; enobosarm; enobosarm</Interventions><Reference>Study 4</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized trial for prevention of post ERCP pancreatitis with celecox tablets</ProtocolTitle><Sponsor>Osaka City University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="252008"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>170</Patients><Biomarkers></Biomarkers><Condition>Pancreatitis</Condition><Controls></Controls><EnrollmentCount>170</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UMIN000012964</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Celecoxib Capsule (400 mg) relative to CELEBREXTM (Original Celecoxib Capsule (400 mg)) in healthy Thai volunteers under fasting condition</ProtocolTitle><Sponsor>Bio-innova and Synchron.Co.,Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="374787"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>46</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>46</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CEL-007-18; TCTR20190318001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Chemoprevention of Oral Premalignant Lesions</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43235"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Cancer</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00036283; NQ4-00-02-011</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43284"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>408</Patients><Biomarkers>calprotectin; hematocrit; hemoglobin</Biomarkers><Condition></Condition><Controls>ibuprofen; ibuprofen + omeprazole; omeprazole</Controls><EnrollmentCount>408</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191071; NCT00640809</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="44009"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>212</Patients><Biomarkers>Beta-glucuronidase; Carcinoembryonic antigen; Cytokines</Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>212</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; irinotecan; leucovorin</Interventions><Reference>IQ8-01-02-016; NCT00037180</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="44009"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>212</Patients><Biomarkers>Beta-glucuronidase; Carcinoembryonic antigen; Cytokines</Biomarkers><Condition>Neoplasm</Condition><Controls></Controls><EnrollmentCount>212</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; irinotecan; leucovorin</Interventions><Reference>IQ8-01-02-016; NCT00037180</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="44009"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>212</Patients><Biomarkers>Beta-glucuronidase; Carcinoembryonic antigen; Cytokines</Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>212</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; irinotecan; leucovorin</Interventions><Reference>IQ8-01-02-016; NCT00037180</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>PD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="350776"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>54</Patients><Biomarkers>Microsatellite instability; Tumor mutational burden</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>54</EnrollmentCount><Interventions>BAT-1306; Celebrex; aspirin</Interventions><Reference>GIHSYSU13; NCT03638297</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pharmacokinetics Of Celecoxib Test Formulations</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="200874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191355; NCT00925106</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MOVES</ProtocolAcronym><ProtocolTitle>Study on the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Hydrochloride Versus Celecoxib in Knee Osteoarthritis Treatment</ProtocolTitle><Sponsor>Bioiberica SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="162796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>607</Patients><Biomarkers>COMP; Coll2-1; Coll2-1 NO2; Fib3-2</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>607</EnrollmentCount><Interventions>chondroitin sulfate + glucosamine hydrochloride</Interventions><Reference>2010-024010-61; DRO/IV-ART-01; MOVES; NCT01425853</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing the effect of topical 1% Avy extract gel with 1% Diclofenac gel in the treatment of patients with primary knee osteoarthritis referred to orthopedic clinic</ProtocolTitle><Sponsor>Shahrekord University of Medical Sciences and Health Services</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="318853"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Pain</Condition><Controls>celecoxib; diclofenac</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Hedera helix extract; celecoxib</Interventions><Reference>IR.SKUMS.REC.1395.40; IRCT2017050133740N1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing the effect of topical 1% Avy extract gel with 1% Diclofenac gel in the treatment of patients with primary knee osteoarthritis referred to orthopedic clinic</ProtocolTitle><Sponsor>Shahrekord University of Medical Sciences and Health Services</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="318853"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; diclofenac</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Hedera helix extract; celecoxib</Interventions><Reference>IR.SKUMS.REC.1395.40; IRCT2017050133740N1</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>CALF</ProtocolAcronym><ProtocolTitle>Correlation Between Acute Analgesia and Long-Term Function Following Ankle Injuries</ProtocolTitle><Sponsor>Canadian Department of National Defence</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="252075"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>160</Patients><Biomarkers>Ankle motion</Biomarkers><Condition>Pain</Condition><Controls>physiotherapy</Controls><EnrollmentCount>160</EnrollmentCount><Interventions>acetaminophen; celecoxib; naproxen; physiotherapy</Interventions><Reference>2013-12-126-004-0001; CALF; NCT02667730</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>CALF</ProtocolAcronym><ProtocolTitle>Correlation Between Acute Analgesia and Long-Term Function Following Ankle Injuries</ProtocolTitle><Sponsor>Canadian Department of National Defence</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="252075"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>160</Patients><Biomarkers>Ankle motion</Biomarkers><Condition>Joint injury</Condition><Controls>physiotherapy</Controls><EnrollmentCount>160</EnrollmentCount><Interventions>acetaminophen; celecoxib; naproxen; physiotherapy</Interventions><Reference>2013-12-126-004-0001; CALF; NCT02667730</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>APC</ProtocolAcronym><ProtocolTitle>Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Completed</TrialStatus><Trial id="26967"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2035</Patients><Biomarkers>15-hydroxyprostaglandin dehydrogenase (NAD+); Adenomatous polyposis coli protein  ; Prostaglandin G/H synthase 2</Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>1170</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>98-008; APC; BWH-NO1-CN-95015; CDR0000067750; NCI-2012-02327; NCI-P00-0141; NCT00005094; NYH-CMC-0298-108; SC-IQ4-99-02-005; STRANG-98-008</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Oral Celecoxib Combined With BCG Instillation Therapy in Treatment of Carcinoma in Situ (CIS), TaG3 and T1 Disease of Urinary Bladder</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="143152"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers></Biomarkers><Condition>Bladder tumor</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>BCG vaccine; celecoxib</Interventions><Reference>Cox052006; EudraCT 2006-004465-33</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="43976"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>4</Patients><Biomarkers>Prostaglandin G/H synthase 2</Biomarkers><Condition>Metastatic stomach cancer</Condition><Controls></Controls><EnrollmentCount>4</EnrollmentCount><Interventions>capecitabine; celecoxib; oxaliplatin</Interventions><Reference>2003-3414; NCT00256321; UCI 03-34</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="43976"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>4</Patients><Biomarkers>Prostaglandin G/H synthase 2</Biomarkers><Condition>Metastatic esophageal cancer</Condition><Controls></Controls><EnrollmentCount>4</EnrollmentCount><Interventions>capecitabine; celecoxib; oxaliplatin</Interventions><Reference>2003-3414; NCT00256321; UCI 03-34</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Versus Hyoscine Butyl-bromide in Reducing Pain Associated With IUD</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="336463"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>celecoxib; copper T380A; hyoscine butylbromide; hyoscine butylbromide; intrauterine device insertion</Interventions><Reference>IUD INSERTION PAIN; NCT03499743</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>RAD0201</ProtocolAcronym><ProtocolTitle>Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44038"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Cox-2</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>F020703003; Link No: 000276825; NCT00581971; RAD0201; RAD0201</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib prevents postoperative fever in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization: a prospective, randomized trial</ProtocolTitle><Sponsor>Lishui Central Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="284389"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; transcatheter arterial chemoembolization</Interventions><Reference>ChiCTR-IPR-17010323</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib prevents postoperative fever in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization: a prospective, randomized trial</ProtocolTitle><Sponsor>Lishui Central Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="284389"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Fever</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; transcatheter arterial chemoembolization</Interventions><Reference>ChiCTR-IPR-17010323</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Molecular Phenotype Changes and Personalized Treatment for CRPC</ProtocolTitle><Sponsor>Tianjin Medical University Cancer Institute and Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="207544"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>150</Patients><Biomarkers>Alpha-type platelet-derived growth factor receptor; Androgen receptor; Antigen KI-67; B-Raf proto-oncogene serine/threonine-protein kinase; Cadherin-1; Cellular tumor antigen p53; Epidermal growth factor receptor; HER2; N-myc proto-oncogene protein; Neural cell adhesion molecule 1; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; RAC-alpha serine/threonine-protein kinase; Serine/threonine-protein kinase 6; Synaptophysin; Vimentin</Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; cisplatin; docetaxel; etoposide; everolimus; gefitinib; lapatinib; prednisone; sunitinib; vemurafenib</Interventions><Reference>E2014064; NCT02208583</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A bioequivalence study of a randomized, open-label, single-dose, two-way crossover design with two-period, two-treatment and two-sequence of celecoxib 400 mg capsules relative to Celebrex 400 mg capsules in healthy Thai volunteers under fasting condition</ProtocolTitle><Sponsor>Bio-innova and Synchron.Co.,Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="365051"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CEL-017-18; TCTR20181214003</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Megestrol Acetate plus Celecoxib versus Megestrol Acetate alone in Cachexia</ProtocolTitle><Sponsor>Mazandaran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="302564"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>80</Patients><Biomarkers>Albumin; C-reactive protein; Interleukin 1; Interleukin-6; Total body mass; Tumor necrosis factor</Biomarkers><Condition>Cachexia</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib; megestrol acetate; megestrol acetate</Interventions><Reference>IR.MAZUMS.REC.94-1087; IRCT201407222027N4</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Analgesic Efficacy of Celecoxib 400 mg in Patients After Oral Surgery</ProtocolTitle><Sponsor>Tokai University School of Medicine, Japan</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="179642"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>JPRN-UMIN000013503</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Direct Effects of NSAIDS on Osteoarthritic Knee Cartilage</ProtocolTitle><Sponsor>Universiteit Utrecht</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="123457"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>42</Patients><Biomarkers>Prostaglandin E2; Proteoglycan</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>celecoxib; indomethacin; naproxen</Interventions><Reference>ISRCTN90366351; NTR159</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, double-blind, placebo-controlled, randomized, parallel-group clinical trial to compare the safety and efficacy of celecoxib with naproxen for the treatment of patients with rheumatoid arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79839"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>1102</Patients><Biomarkers>C-reactive protein (CRP)</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>1102</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>N49-96-02-023</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Withdrawal treatment in medication overuse headache</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="155901"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Headache</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; prednisolone</Interventions><Reference>91/d/130/1428; IRCT2013061211560N6</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Indomethacin Capsules to Treat Pain Following Bunionectomy</ProtocolTitle><Sponsor>Iroko Pharmaceuticals LLC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85394"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>462</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>462</EnrollmentCount><Interventions>indomethacin</Interventions><Reference>IND3-08-04b; NCT01543685</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The evaluation of effectiveness of topical basil oil on clinical symptoms in patients with knee osteoarthritis</ProtocolTitle><Sponsor>Fasa University of Medical Sciences</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312489"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Joint stiffness; Knee motion</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>basil oil; celecoxib; diclofenac</Interventions><Reference>IR.FUMS.REC.1394.39; IRCT2017081711341N7</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The evaluation of effectiveness of topical basil oil on clinical symptoms in patients with knee osteoarthritis</ProtocolTitle><Sponsor>Fasa University of Medical Sciences</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312489"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Joint stiffness; Knee motion</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>basil oil; celecoxib; diclofenac</Interventions><Reference>IR.FUMS.REC.1394.39; IRCT2017081711341N7</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of Pelubiprofen Tablet and Celebrex Capsule in Rheumatoid Arthritis Patients</ProtocolTitle><Sponsor>Daewon Pharm Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="107518"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; pelubiprofen</Interventions><Reference>DW Plb RA301; NCT01781702</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Dexamethasone and Celecoxib for Prophylaxis for Transcatheter Arterial Chemoembolization</ProtocolTitle><Sponsor>Chonnam National University Hwasun Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="379352"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>216</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls>celecoxib; dexamethasone; ramosetron</Controls><EnrollmentCount>216</EnrollmentCount><Interventions>dexamethasone; ramosetron; transarterial chemo-embolization chemotherapy</Interventions><Reference>CNUHH-2019-063; KCT0003860</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer</ProtocolTitle><Sponsor>Tel Aviv Sourasky Medical Center</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="45876"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Colon tumor</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; curcumin; gemcitabine</Interventions><Reference>NCT00295035; tasmc-05-na-05160-ctil</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bipolar Depression and Inflammation</ProtocolTitle><Sponsor>Loyola University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82714"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>88</Patients><Biomarkers></Biomarkers><Condition>Bipolar I disorder</Condition><Controls>escitalopram</Controls><EnrollmentCount>88</EnrollmentCount><Interventions>celecoxib; escitalopram</Interventions><Reference>203368; NCT01479829</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bipolar Depression and Inflammation</ProtocolTitle><Sponsor>Loyola University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82714"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>88</Patients><Biomarkers></Biomarkers><Condition>Bipolar II disorder</Condition><Controls>escitalopram</Controls><EnrollmentCount>88</EnrollmentCount><Interventions>celecoxib; escitalopram</Interventions><Reference>203368; NCT01479829</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bipolar Depression and Inflammation</ProtocolTitle><Sponsor>Loyola University of Chicago</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="82714"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>88</Patients><Biomarkers></Biomarkers><Condition>Depression</Condition><Controls>escitalopram</Controls><EnrollmentCount>88</EnrollmentCount><Interventions>celecoxib; escitalopram</Interventions><Reference>203368; NCT01479829</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Role of COX-2 Inhibition in Salt Sensitivity of Blood Pressure</ProtocolTitle><Sponsor>University of Delaware</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44034"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>134024-1; NCT00624559</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Minimal Opioid Use After Total Hip Replacement (THR)</ProtocolTitle><Sponsor>Hospital for Special Surgery NY</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="291754"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>180</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>180</EnrollmentCount><Interventions>Acetaminophen; Periarticular injection (Deep injection); Periarticular injection (Superficial injection); acetylsalicylic acid; bupivacaine; cefazolin; celecoxib; clonidine; duloxetine; ketorolac; mepivacaine; methyprednislone; morphine hydrochloride</Interventions><Reference>2016-0721; NCT03090152</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head and Neck Carcinoma</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="44035"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>122</Patients><Biomarkers></Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>122</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>3058; NCT00603759</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="95242"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>120</Patients><Biomarkers>Peripheral Blood Lymphocyte</Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>Celebrex; Celebrex; human mesenchymal stem cells</Interventions><Reference>NCT01709656; [2012]2-31</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety of Celecoxib in Patients With Crohn's Disease</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="17886"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>28</Patients><Biomarkers></Biomarkers><Condition>Crohns disease</Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>0312013; NCT00177866</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The clinical effect of Cox-2 inhibitor on symptoms in patients who undergo prostate brachytherapy</ProtocolTitle><Sponsor>Nara Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="338722"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>310</Patients><Biomarkers></Biomarkers><Condition>Urinary retention</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; prostate brachytherapy; tamsulosin; tamsulosin</Interventions><Reference>UMIN000003649</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The clinical effect of Cox-2 inhibitor on symptoms in patients who undergo prostate brachytherapy</ProtocolTitle><Sponsor>Nara Medical University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="338722"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>310</Patients><Biomarkers></Biomarkers><Condition>Abdominal pain</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; prostate brachytherapy; tamsulosin; tamsulosin</Interventions><Reference>UMIN000003649</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Atorvastatin Calcium and Celecoxib in Treating Patients with Rising PSA Levels After Local Therapy for Prostate Cancer</ProtocolTitle><Sponsor>Rutgers University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="71339"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>27</Patients><Biomarkers>IL6; NFkB; PSA; extracellular signal-regulated kinase; prostaglandin E2</Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>atorvastatin; celecoxib</Interventions><Reference>0220090006; 0220090006, 080811; 080811; CDR0000636488; CINJ-080811; NCI-2012-00540; NCT01220973</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, multicenter, triple-dummy, double-blind, placebo- and active-controlled, randomized, 2-week study, comparing small bowel lesions associated with celecoxib versus naproxen plus omeprazole in healthy adult subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80055"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>356</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>356</EnrollmentCount><Interventions>celecoxib; naproxen; naproxen + omeprazole; omeprazole</Interventions><Reference>COXA-0508-253</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Pre-eclampsia</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="22865"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Pre-eclampsia</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00442676; VCU IRB HM10590</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA</ProtocolTitle><Sponsor>Seoul St Mary's Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="326181"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib; diacerein</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>celecoxib; diacerein</Interventions><Reference>DIA IIT_01; NCT03404479</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center, National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28251"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>75</Patients><Biomarkers>AKT; COX-2; ERK1/2 MAP kinase; Estrogen receptor; HER-2/neu; Ki67; PGE-2; PI3-K; RNA expression</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000329919; MSKCC-03027; N01-CN-35112; N01CN35112; NCI-2012-0144; NCT00070057; P30CA008748</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, 12-week randomized, double-blind, placebo-controlled, multicenter parallel-group clinical trial to evaluate the analgesic efficacy of celecoxib for the treatment of patients with chronic low back pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="78991"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>790</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>790</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>COXA-0508-269</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MEMMAT</ProtocolAcronym><ProtocolTitle>Metronomic and Targeted Anti-Angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma</ProtocolTitle><Sponsor>Medical University of Vienna</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="77477"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Medulloblastoma</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>bevacizumab; celecoxib; cyclophosphamide; etoposide; fenofibric acid; liposomal cytarabine; thalidomide</Interventions><Reference>2010-023691-33; MEMMAT; MEMMAT; MUV-MEMMAT-01; NCT01356290</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym>CILON-T</ProtocolAcronym><ProtocolTitle>The Efficacy of Cilostazol on Ischemic Complications After DES Implantation</ProtocolTitle><Sponsor>Ministry of Health, Welfare and Family Affairs, Republic of Korea Government, Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="31741"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>474</Patients><Biomarkers>CYP2C19 LOF; Cytochrome P450 2C19; Cytochrome P450 3A4; Cytochrome P450 3A5; Heart rate; High-density lipoprotein cholesterol; Lipids; Low-density lipoprotein cholesterol; P2Y12; Total cholesterol; Triglycerides; albumin; creatinine</Biomarkers><Condition>Coronary artery disease</Condition><Controls></Controls><EnrollmentCount>960</EnrollmentCount><Interventions>aspirin; aspirin + clopidogrel; aspirin + clopidogrel + cilostazol; atorvastatin; celecoxib; cilostazol; clopidogrel; rosuvastatin</Interventions><Reference>CILON-T; NCT00776828</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>GLORIA</ProtocolAcronym><ProtocolTitle>Healing Effect of Gastric Mucosal Lesion of Patient With Osteoarthritis or Rheumatism by Cox2-Inhibitor and Anti Ulcer agent(Rebamipide) Combination Therapy</ProtocolTitle><Sponsor>Mie University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="158850"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Gastrointestinal disease</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib; celecoxib; rebamipide</Interventions><Reference>GLORIA; JPRN-UMIN000002112</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>GLORIA</ProtocolAcronym><ProtocolTitle>Healing Effect of Gastric Mucosal Lesion of Patient With Osteoarthritis or Rheumatism by Cox2-Inhibitor and Anti Ulcer agent(Rebamipide) Combination Therapy</ProtocolTitle><Sponsor>Mie University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="158850"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib; celecoxib; rebamipide</Interventions><Reference>GLORIA; JPRN-UMIN000002112</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparision of two types of chemotherapy regimen in head and neck cancer</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="365696"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>455</Patients><Biomarkers></Biomarkers><Condition>Head and neck tumor</Condition><Controls>best supportive care</Controls><EnrollmentCount>455</EnrollmentCount><Interventions>celecoxib; docetaxel; erlotinib; methotrexate</Interventions><Reference>CTRI/2019/01/016837</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23250"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>51</Patients><Biomarkers>COX-2; Human papillomavirus DNA</Biomarkers><Condition>Papillomavirus infection</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>1 U01 DC007946-01A2; NCT00297999; NCT00571701; NIH grant U01DC007946-01A2; U01DC007946</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="23250"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>51</Patients><Biomarkers>COX-2; Human papillomavirus DNA</Biomarkers><Condition>Respiratory tract infection</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>1 U01 DC007946-01A2; NCT00297999; NCT00571701; NIH grant U01DC007946-01A2; U01DC007946</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A multicenter, phase II, randomized, open-label trial to evaluate the efficacy and safety of irinotecan and docetaxel and irinotecan and gemcitabine, with or without cetuximab, in second-line treatment of non–small-cell lung cancer (NSCLC)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="68937"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>133</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>133</EnrollmentCount><Interventions>celecoxib; docetaxel; gemcitabine; irinotecan; irinotecan + docetaxel; irinotecan + docetaxel + celecoxib; irinotecan + gemcitabine; irinotecan + gemcitabine + celecoxib</Interventions><Reference>CPTAIV-0020-362</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>ANGIOCOMB</ProtocolAcronym><ProtocolTitle>ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors</ProtocolTitle><Sponsor>University of Helsinki</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="103037"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>49</Patients><Biomarkers></Biomarkers><Condition>Glioma</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Irradiation (54 Gy); celecoxib; etoposide phosphate; thalidomide, Celgene; topotecan</Interventions><Reference>2005-004850-28; 300864; ANGIOCOMB; Angiocomb; NCT01756989</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative efficacy evaluation of ultrasound-guided pulsed radiofrequency or acupotomy treatment in managing the Knee Osteoarthritis: A randomized and controlled trial</ProtocolTitle><Sponsor>Huadong Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="207668"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>295</Patients><Biomarkers>C-reactive protein; Osteocalcin; Six-minute walk distance</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>295</EnrollmentCount><Interventions>Acupotomy; Pulsed radiofrequency treatment; celecoxib</Interventions><Reference>ChiCTR-TRC-14004825</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44036"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>12</Patients><Biomarkers>COX-2 mRNA; Eicosanoid; Eicosanoids; IGF-1; IGFBP-3; Ki67; PGE-M; Prostaglandin G/H synthase 2; Prostaglandins; p-EGFR</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>03-147; NCT00596219</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma</ProtocolTitle><Sponsor>Memorial Sloan-Kettering Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44036"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>12</Patients><Biomarkers>COX-2 mRNA; Eicosanoid; Eicosanoids; IGF-1; IGFBP-3; Ki67; PGE-M; Prostaglandin G/H synthase 2; Prostaglandins; p-EGFR</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>03-147; NCT00596219</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Perioperative Celecoxib for Hip Arthroscopy</ProtocolTitle><Sponsor>Northwestern University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="261579"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>96</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>96</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT02779166; STU00067550</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>COX study</ProtocolAcronym><ProtocolTitle>Efficacy of Celecoxib for Prevention of Oxaliplatin Related Injection Pain in Patients With Stage II/III Colon Cancer: A Randomized, Phase II Trial</ProtocolTitle><Sponsor>Yokohama City University</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="126311"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>81</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>capecitabine; celecoxib; celecoxib; oxaliplatin</Interventions><Reference>COX study; JPRN-UMIN000008814</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SMMART</ProtocolAcronym><ProtocolTitle>A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia</ProtocolTitle><Sponsor>OHSU Knight Cancer Institute</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Acute myelogenous leukemia</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>Farydak; Zolinza; abiraterone; afatinib; bevacizumab; bortezomib; cabazitaxel; cabozantinib; carboplatin; celecoxib; dasatinib; enzalutamide; erlotinib; everolimus; fluorouracil; folinic acid; idelalisib; imatinib; ipilimumab; lenvatinib; nivolumab; olaparib; oxaliplatin; palbociclib; pembrolizumab; pertuzumab; ponatinib; ruxolitinib; sirolimus; sorafenib; sunitinib; trametinib; tretinoin; vemurafenib; venetoclax</Interventions><Reference>NCT03878524; SMMART; STUDY00015588</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SMMART</ProtocolAcronym><ProtocolTitle>A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia</ProtocolTitle><Sponsor>OHSU Knight Cancer Institute</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>Farydak; Zolinza; abiraterone; afatinib; bevacizumab; bortezomib; cabazitaxel; cabozantinib; carboplatin; celecoxib; dasatinib; enzalutamide; erlotinib; everolimus; fluorouracil; folinic acid; idelalisib; imatinib; ipilimumab; lenvatinib; nivolumab; olaparib; oxaliplatin; palbociclib; pembrolizumab; pertuzumab; ponatinib; ruxolitinib; sirolimus; sorafenib; sunitinib; trametinib; tretinoin; vemurafenib; venetoclax</Interventions><Reference>NCT03878524; SMMART; STUDY00015588</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SMMART</ProtocolAcronym><ProtocolTitle>A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia</ProtocolTitle><Sponsor>OHSU Knight Cancer Institute</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Metastatic prostate cancer</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>Farydak; Zolinza; abiraterone; afatinib; bevacizumab; bortezomib; cabazitaxel; cabozantinib; carboplatin; celecoxib; dasatinib; enzalutamide; erlotinib; everolimus; fluorouracil; folinic acid; idelalisib; imatinib; ipilimumab; lenvatinib; nivolumab; olaparib; oxaliplatin; palbociclib; pembrolizumab; pertuzumab; ponatinib; ruxolitinib; sirolimus; sorafenib; sunitinib; trametinib; tretinoin; vemurafenib; venetoclax</Interventions><Reference>NCT03878524; SMMART; STUDY00015588</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>SMMART</ProtocolAcronym><ProtocolTitle>A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia</ProtocolTitle><Sponsor>OHSU Knight Cancer Institute</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition>Metastatic pancreas cancer</Condition><Controls></Controls><EnrollmentCount>52</EnrollmentCount><Interventions>Farydak; Zolinza; abiraterone; afatinib; bevacizumab; bortezomib; cabazitaxel; cabozantinib; carboplatin; celecoxib; dasatinib; enzalutamide; erlotinib; everolimus; fluorouracil; folinic acid; idelalisib; imatinib; ipilimumab; lenvatinib; nivolumab; olaparib; oxaliplatin; palbociclib; pembrolizumab; pertuzumab; ponatinib; ruxolitinib; sirolimus; sorafenib; sunitinib; trametinib; tretinoin; vemurafenib; venetoclax</Interventions><Reference>NCT03878524; SMMART; STUDY00015588</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis</ProtocolTitle><Sponsor>Janssen Pharmaceutica Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="98524"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>473</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>473</EnrollmentCount><Interventions>celecoxib; celecoxib; tramadol + paracetamol (oral), Johnson &amp; Johnson</Interventions><Reference>CR013696; NCT01728246; TRAMAPNAP4002</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>CYCLUS</ProtocolAcronym><ProtocolTitle>Effect of Celecoxib on Survival in Patients With Advanced Non-Small-Cell Lung Cancer Receiving Chemotherapy</ProtocolTitle><Sponsor>Linköping University Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="43275"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>316</Patients><Biomarkers>Prostaglandin G/H synthase 2; Vascular endothelial growth factors</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls>carboplatin; gemcitabine; vinorelbine</Controls><EnrollmentCount>319</EnrollmentCount><Interventions>carboplatin; celecoxib; gemcitabine; vinorelbine</Interventions><Reference>2005-000717-35; CYCLUS; NCT00300729; SLCSG0501</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers</ProtocolTitle><Sponsor>National University Hospital (Singapore) Pte Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="245694"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>18</Patients><Biomarkers></Biomarkers><Condition>Mycobacterium tuberculosis infection</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>celecoxib; celecoxib; pyrazinamide; pyrazinamide; rifampicin; rifampicin</Interventions><Reference>CELECOXIB_WBA; NCT02602509</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>celecoxib in the treatment of depressed patients with brucellosis</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="192730"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Major depressive disorder</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib; doxycycline hyclate; rifampin</Interventions><Reference>24320; IRCT201405271556N59</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial</ProtocolTitle><Sponsor>Cleveland Clinic Florida</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="297628"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>84</Patients><Biomarkers>Post-void residual urine</Biomarkers><Condition>Urinary retention</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>acetaminophen; autofill Void Trial; backfill Void Trial; celecoxib; colace; dexamethasone; foley catheter; heparin; ibuprofen; ondansetron; oxycodone; povidone-iodine; tylenol</Interventions><Reference>FLA 17-020; NCT03141372</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer</ProtocolTitle><Sponsor>University of Michigan</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="38364"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>5</Patients><Biomarkers>Prostaglandins</Biomarkers><Condition>Pancreas tumor</Condition><Controls></Controls><EnrollmentCount>5</EnrollmentCount><Interventions>celecoxib; cisplatin; gemcitabine</Interventions><Reference>C2442; NCT00176813; UMCC 2001-071</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Add on Therapy in Drug Naive Depressed Women</ProtocolTitle><Sponsor>Islamic Azad University of Tehran-Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="125181"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Depression</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; sertraline</Interventions><Reference>4114; IRCT201009043106N3</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of different Analgesic Methods after Total Hip Arthroplasty or Total Knee Arthroplasty</ProtocolTitle><Sponsor>The Affiliated Hospital of Xuzhou Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="382102"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>600</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>600</EnrollmentCount><Interventions>celecoxib; celecoxib; femoral nerve block; paracetamol; paracetamol; periarticular injection of cocktail</Interventions><Reference>ChiCTR1900023312</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>mini-COREA</ProtocolAcronym><ProtocolTitle>Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="20921"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>909</Patients><Biomarkers></Biomarkers><Condition>Restenosis</Condition><Controls></Controls><EnrollmentCount>900</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>H-0611-011-188; NCT00500279; mini-COREA</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="179551"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>celecoxib; oxycodone</Interventions><Reference>A9011030; NCT00484718</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study to Evaluate Effect on QT/QTc Interval After Multiple Dose of Celecoxib</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="368485"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>28</Patients><Biomarkers>PR interval; QRS complex; QT interval; R-R interval</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>28</EnrollmentCount><Interventions>Avelox; Celebrex; water</Interventions><Reference>2016-11-053; NCT03822520</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prosperity of celecoxib for pain relief after elective cesarean section delivery, a double-blind, randomized controlled trial</ProtocolTitle><Sponsor>Navamindhradhiraj University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="366096"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>TCTR20190109003</Reference></Row><Row><ArmCount>13</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Randomized, Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer</ProtocolTitle><Sponsor>Hoosier Cancer Research Network</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="180289"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>196</Patients><Biomarkers>Breast cancer type 1 susceptibility protein; DNA topoisomerase 2-alpha; Epidermal growth factor receptor; Equilibrative nucleoside transporter 1; Estrogen receptor; HER2; Hepatocyte growth factor receptor; Methylated-DNA-protein-cysteine methyltransferase; Myc proto-oncogene protein; Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Poly [ADP-ribose] polymerase 1; Progesterone receptor; Prostaglandin G/H synthase 2; Somatostatin receptor type 2; Thymidine phosphorylase; Vascular endothelial growth factor A</Biomarkers><Condition>Breast tumor</Condition><Controls>capecitabine</Controls><EnrollmentCount>196</EnrollmentCount><Interventions>bevacizumab; capecitabine; celecoxib; cetuximab; cisplatin; crizotinib; doxorubicin; everolimus; gemcitabine; octreotide acetate; olaparib; paclitaxel; temozolomide</Interventions><Reference>BRE12-158; NCT02101385</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis</ProtocolTitle><Sponsor>The Armed Forces Capital Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301934"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Osteitis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>Hong Ki Min; NCT03190603</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis</ProtocolTitle><Sponsor>The Armed Forces Capital Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301934"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Spondylarthritis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>Hong Ki Min; NCT03190603</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis</ProtocolTitle><Sponsor>The Armed Forces Capital Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="301934"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>12</Patients><Biomarkers></Biomarkers><Condition>Bone marrow disease</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>Hong Ki Min; NCT03190603</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A post-marketing, randomized, prospective, parallel, controlled study to assess the safety and efficacy of celecoxib in combination with FP regimen chemotherapy in patients with adjuvant stage operable gastric carcinoma</ProtocolTitle><Sponsor>LanZhou University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="97247"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Stomach tumor</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; cisplatin</Interventions><Reference>ChiCTR-TRC-11001309</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer</ProtocolTitle><Sponsor>Sidney Kimmel Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28111"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers>COX-1; COX-2; Ki-67; PSA; Prostaglandin levels; factor VIII; kip1; p21</Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>73</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>00-03-08-01; CDR0000068812; CDR0000068812; J0007; JHOC-00030801; JHOC-J0007; NCI-N01-95129; NCI-N01-95129; NCI-P01-0186; NCI-P01-0186; NCT00022399; P30CA006973; P50CA058236</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dendritic Cell Based Therapy of Malignant Melanoma</ProtocolTitle><Sponsor>Herlev Hospital Region Hovedstaden</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="133063"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>25</Patients><Biomarkers>HLA A2</Biomarkers><Condition>Melanoma</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>Proleukin; Tumor antigen loaded autologous dendritic cells; celecoxib; cyclophosphamide</Interventions><Reference>MM0413; NCT00197912</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>NSAIDs Versus Coxibs in the Presence of Aspirin</ProtocolTitle><Sponsor>Inova Health Care Services</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="355818"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Arterial tone; C-reactive protein; Cell adhesion molecules; Oxidized low density lipoprotein; Platelet aggregation; Thromboxane; Thromboxane B2</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Aleve; Bayer aspirin; Celebrex</Interventions><Reference>17-2915; NCT03699293</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>NSAIDs Versus Coxibs in the Presence of Aspirin</ProtocolTitle><Sponsor>Inova Health Care Services</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="355818"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Arterial tone; C-reactive protein; Cell adhesion molecules; Oxidized low density lipoprotein; Platelet aggregation; Thromboxane; Thromboxane B2</Biomarkers><Condition>Cardiovascular disease</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>Aleve; Bayer aspirin; Celebrex</Interventions><Reference>17-2915; NCT03699293</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>COXOA</ProtocolAcronym><ProtocolTitle>Efficacy of the Treatment With a COX-2 Specific Inhibitor Celecoxib in Osteoarthritic Patients</ProtocolTitle><Sponsor>Hospital de Tortosa Verge de la Cinta, Spain</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="141494"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>30</Patients><Biomarkers>Dinoprostone; Interleukin 1 beta; Nitric oxide synthase; Prostaglandin E synthase; Prostaglandin G/H synthase 2; Tumor necrosis factor</Biomarkers><Condition>Osteoarthritis</Condition><Controls>aceclofenac</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>COXOA; ISRCTN55717501</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC, Janssen-Cilag International NV (BE)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="216695"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>111</Patients><Biomarkers>Joint stiffness; Knee stiffness</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>111</EnrollmentCount><Interventions>celecoxib; fulranumab</Interventions><Reference>2014-003224-40; 42160443PAI3007; CR106249; NCT02301234; PAI3007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravitreal Celecoxib for Chronic Uveitis</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="185445"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>4</Patients><Biomarkers></Biomarkers><Condition>Uveitis</Condition><Controls></Controls><EnrollmentCount>4</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>IND for Celecoxib; NCT02131012</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, multicenter, randomized, active- and placebo-controlled comparative clinical trial to compare the incidence of gastroduodenal ulcers associated with celecoxib + low dose ASA versus naproxen + low dose ASA in healthy subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80066"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>463</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>464</EnrollmentCount><Interventions>ASA; celecoxib; celecoxib + ASA; naproxen; naproxen + ASA; placebo + ASA</Interventions><Reference>A3191073; COXA-0508-258</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Perioperative Use of a Selective COX2 Inhibitor in Patients Undergoing Elective Colorectal Surgery: The Effect on Post-operative Bowel Motility and Post-operative Pain</ProtocolTitle><Sponsor>Sheba Medical Center</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="262734"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2913-16-SMC; NCT02790203</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of celecoxib for pain relief and antipyresis in pregnant women receiving misoprostol for termination of pregnancy</ProtocolTitle><Sponsor>Prince of Songkhla University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="250592"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Fever</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>TCTR20160109001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of celecoxib for pain relief and antipyresis in pregnant women receiving misoprostol for termination of pregnancy</ProtocolTitle><Sponsor>Prince of Songkhla University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="250592"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>TCTR20160109001</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single-Center, Randomized, Controlled, Clinical Trail</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="279114"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>130</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls>sorafenib</Controls><EnrollmentCount>130</EnrollmentCount><Interventions>Celebrex; sorafenib</Interventions><Reference>2016-FXY-006; NCT02961998</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single-Center, Randomized, Controlled, Clinical Trail</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="279114"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>130</Patients><Biomarkers></Biomarkers><Condition>Acral erythema</Condition><Controls>sorafenib</Controls><EnrollmentCount>130</EnrollmentCount><Interventions>Celebrex; sorafenib</Interventions><Reference>2016-FXY-006; NCT02961998</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="25458"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>8</Patients><Biomarkers>15-Keto-13,14-dihydroprostaglandin E2; Dinoprostone</Biomarkers><Condition>Pancreatic intraductal papillary-mucinous tumor</Condition><Controls></Controls><EnrollmentCount>8</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>0305-20; NCT00198081</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, 6-week, multicenter, randomized, double-blind, placebo-controlled, active-comparator, parallel-group study to evaluate the safety and efficacy of celecoxib and naproxen versus placebo for the treatment of African American subjects with osteoarthritis (OA) of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80133"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>316</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>322</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>A3191051; N49-01-02-209</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>OPTIMOX2</ProtocolAcronym><ProtocolTitle>Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Groupe Cooperateur Multidisciplinaire en Oncologie</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="43179"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>42</Patients><Biomarkers></Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>celecoxib; celecoxib + FOLFOX7; fluorouracil; leucovorin calcium; oxaliplatin</Interventions><Reference>CDR0000340181; EU-20325; GERCOR-OPTIMOX2-CELECOXIB-2002; NCT00072553; OPTIMOX2</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination Chemotherapy and Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Northwestern University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44369"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>17</Patients><Biomarkers>COX-2; CYP3A4; UGT1A1; Vascular endothelial growth factor</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>celecoxib; docetaxel; irinotecan; irinotecan + celecoxib + docetaxel</Interventions><Reference>NCT00073866; NU 01L2; NU-01L2; PHARMACIA-NU-01L2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Comparing the Effectiveness and Safety of Extended Release Tramadol HCl at 100, 200 and 300 mg Doses to Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis (OA)</ProtocolTitle><Sponsor>Biovail Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12719"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1001</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>tramadol (Smartcoat extended release, pain), Biovail</Interventions><Reference>B02.CT3.021.TRA P03; NCT00348452</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11308"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>458</Patients><Biomarkers>C-reactive protein</Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls>diclofenac</Controls><EnrollmentCount>458</EnrollmentCount><Interventions>celecoxib; celecoxib (bid); celecoxib (qd)</Interventions><Reference>A3191098; COXA-0508-243; NCT00648141</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial to assess the bone resorption activity of celecoxib, estradiol , estradiol and celecoxib, and placebo for the treatment of women with osteopenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80161"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>58</Patients><Biomarkers>Bone specific alkaline phosphatase (BSAP); Deoxypyridinoline cross-links (Dpyr)/creatinine ratio; N-terminal procollagen peptides (PINP); Osteocalcin; urinary NTx/creatinine; urinary c-Telopeptides (CTx)/creatinine ratio</Biomarkers><Condition>Osteopenia</Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>celecoxib; celecoxib; celecoxib + estradiol; estradiol; estradiol</Interventions><Reference>A3191130; N49-01-02-200</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients</ProtocolTitle><Sponsor>Peking Union Medical College Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="206401"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>246</Patients><Biomarkers>Blood cell count; Body temperature; C-reactive protein; Dinoprostone; Erythrocyte sedimentation rate; Interleukin-10; Interleukin-6; Interleukin-8; Knee circumference</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>246</EnrollmentCount><Interventions>celecoxib; parecoxib; tramcontin</Interventions><Reference>NCT02198924; WI1180091</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>TCOG</ProtocolAcronym><ProtocolTitle>Trial of Celecoxib With Preoperative Chemo- Radiation for Locally Advanced Rectal Cancer</ProtocolTitle><Sponsor>National Health Research Institutes</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="58454"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>55</Patients><Biomarkers>Cyclooxygenase 2</Biomarkers><Condition>Rectal tumor</Condition><Controls></Controls><EnrollmentCount>55</EnrollmentCount><Interventions>UFT; UFT + folinate + celecoxib + radiotherapy; celecoxib; folinate; radiotherapy (44 Gy)</Interventions><Reference>NCT00931203; T2207; TCOG</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Nonopioid Analgesia After Labral Surgery</ProtocolTitle><Sponsor>Henry Ford Health System</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="368542"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>Norco</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>Celebrex; Neurontin; Toradol; Tylenol; Valium</Interventions><Reference>1231914; NCT03825809</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Severe Influenza A Infection</ProtocolTitle><Sponsor>The University of Hong Kong</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="181239"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>120</Patients><Biomarkers>Cytokines; Interleukin-10; Interleukin-6</Biomarkers><Condition>Influenza virus A infection</Condition><Controls>oseltamivir</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; oseltamivir</Interventions><Reference>NCT02108366; UW 13-009</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CLOAK</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Celecoxib Versus Naproxen in the 6-Month Treatment of Knee Osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22166"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>586</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>naproxen</Controls><EnrollmentCount>586</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191152; CLOAK; NCT00643799</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>NPC COX-2</ProtocolAcronym><ProtocolTitle>A Pilot Study for Radiosensitization with COX-2 Inhibitor for Nasopharyngeal Carcinoma</ProtocolTitle><Sponsor></Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="128005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Nasopharyngeal carcinoma</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>HKCTR-1182; NPC COX-2; UW 04-283 T/605</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With High-Grade Squamous Intraepithelial Lesions of the Cervix</ProtocolTitle><Sponsor>Southwest Oncology Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29235"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Patients></Patients><Biomarkers>cyclooxygenase-2</Biomarkers><Condition>Uterine cervix tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000340176; NCT00072540; S0212; SWOG-S0212; U10CA037429</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="111736"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>6</Patients><Biomarkers>Cycloxygenase-2 (COX-2); Prostaglandin E2 (PGE-2)</Biomarkers><Condition>Nicotine dependence</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>Aspirin; Aspirin; celecoxib; celecoxib</Interventions><Reference>NCT01796951; VR5137</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer</ProtocolTitle><Sponsor>International Breast Cancer Study Group, NCIC Clinical Trials Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="51649"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>7576</Patients><Biomarkers>Body Mass Index; Breast; Estrogen receptor; Progesterone receptor</Biomarkers><Condition>Breast tumor</Condition><Controls>anastrozole</Controls><EnrollmentCount>7576</EnrollmentCount><Interventions>anastrozole; celecoxib; exemestane; exemestane</Interventions><Reference>2005-001893-28; ACTRN12605000389606; ANZCTR483; CALGB-CAN-NCIC-MA27; CAN-NCIC-MA27; CAN-NCIC-MA27 (NON-COMPANION); CDR0000316325; CDR0000530110; ECOG-CAN-NCIC-MA27; IBCSG 30-04/NCIC CTG MA.27; IBCSG-30-04; MA27; NCCTG-MA27; NCIC CTG MA.27; NCT00066573; NCT00438529; SWOG-CAN-NCIC-MA27</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multimodal Analgesia in Shoulder Arthroplasty</ProtocolTitle><Sponsor>Rush University Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="346430"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>74</Patients><Biomarkers>Muscle strength; Shoulder motion</Biomarkers><Condition>Anesthesia</Condition><Controls>Norco; OxyContin; morphine; ropivacaine</Controls><EnrollmentCount>74</EnrollmentCount><Interventions>OxyContin; acetaminophen; celecoxib; epinephrine; ketorolac; meloxicam; oxycodone; ropivacaine; tramadol</Interventions><Reference>NCT03586934; ORA 17071004</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Multimodal Analgesia in Shoulder Arthroplasty</ProtocolTitle><Sponsor>Rush University Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="346430"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>74</Patients><Biomarkers>Muscle strength; Shoulder motion</Biomarkers><Condition>Pain</Condition><Controls>Norco; OxyContin; morphine; ropivacaine</Controls><EnrollmentCount>74</EnrollmentCount><Interventions>OxyContin; acetaminophen; celecoxib; epinephrine; ketorolac; meloxicam; oxycodone; ropivacaine; tramadol</Interventions><Reference>NCT03586934; ORA 17071004</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Perioperative analgesia with a buprenorphine transdermal patch for foot and ankle surgery: A randomized, controlled trial</ProtocolTitle><Sponsor>Mundipharma International Corp Ltd, Xiangya Hospital Of Central South University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="333781"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>buprenorphine; celecoxib; flurbiprofen axetil</Interventions><Reference>ChiCTR1800015249</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The evaluation of Effectiveness of Topical Sesame Oil on Clinical Symptoms in Patients with Knee Osteoarthritis</ProtocolTitle><Sponsor>Fasa University of Medical Sciences</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="315812"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Joint stiffness; Knee motion</Biomarkers><Condition>Osteoarthritis</Condition><Controls>diclofenac gel</Controls><EnrollmentCount>90</EnrollmentCount><Interventions>sesame oil</Interventions><Reference>IR.FUMS.REC.1394.39; IRCT2017081711341N8</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>PROMET 2</ProtocolAcronym><ProtocolTitle>Docetaxel and Prednison in Association With Metronomic Therapy With Ciclophosphamide and Celecoxin in Hormone-refractory Prostatic Cancer Patients : Phase II Clinical Trial With Pharmacodynamic and Pharmacogenetic Evaluations</ProtocolTitle><Sponsor>Gruppo Oncologico del Nord-Ovest</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="178997"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>celecoxib; cyclophosphamide; docetaxel; prednisone</Interventions><Reference>2006-004478-29; 2006-004478-29-IT; ASL606LIOM02; PROMET 2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses</ProtocolTitle><Sponsor>University of Wisconsin-Madison</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="301592"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers>Antigen KI-67; Collagen; Cytokines; Estrogen receptor; Leukocyte elastase; Macrosialin; Progesterone receptor; Prostaglandin G/H synthase 2; Scavenger receptor cysteine-rich type 1 protein M130; Smooth muscle actin; Syndecan-1; Vimentin</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>Celebrex</Interventions><Reference>2017-0219; NCT03185871; P30CA014520; UW16141</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The preventional effect of celecoxib on acute pancreatitis after endoscopic retrograde cholangiopancreatography</ProtocolTitle><Sponsor>Nagasaki University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="332261"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Alpha-amylase 1</Biomarkers><Condition>Pancreatitis</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UMIN000007467</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of Parecoxib Sodium Intravenous Patient-controlled Analgesia in Laparotomic Liver Resection</ProtocolTitle><Sponsor>The First Affiliated Hospital of Harbin Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="226061"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>fentanyl citrate; ondansetron; saline</Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib; parecoxib</Interventions><Reference>LIANXIN-001; NCT02408146</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43532"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>22</Patients><Biomarkers>CYP19; Estrogen receptor; HER-2; Ki-67; Progesterone receptor</Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>22</EnrollmentCount><Interventions>celecoxib; exemestane; exemestane</Interventions><Reference>NCT00201773; OSU-0245</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Dysmenorrhea</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Keratosis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Gout</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Alzheimers disease</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Headache</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Renal cell carcinoma</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Fever</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Inflammatory disease</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Migraine</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Periarthritis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Tenosynovitis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Pancreas tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Arthritis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Non-Hodgkin lymphoma</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Back pain</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Bladder tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Cachexia</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Uterine cervix tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>NADIA</ProtocolAcronym><ProtocolTitle>Non-steroidal drugs and the antiplatelet effects of aspirin</ProtocolTitle><Sponsor>Green Lane Research and Education Fund</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258126"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Blood platelets; Thromboxane B2</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>aspirin; celecoxib; ibuprofen; indomethacin; naproxen; sulindac; tiaprofenic acid</Interventions><Reference>ACTRN12605000371695; ANZCTR392; NADIA</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Single-Dose, Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management</ProtocolTitle><Sponsor>Christiana Care Health Services</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="255438"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>137</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>acetaminophen; celecoxib</Controls><EnrollmentCount>137</EnrollmentCount><Interventions>acetaminophen; celecoxib; gabapentin</Interventions><Reference>603262; NCT02703259</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Celebrex and EPO-906 in Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>University of Southern California Medical School</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="40912"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>43</Patients><Biomarkers>Beta-tubulin; COX-2; E-cadherin; Thymidine phosphorylase (TP); VEGF</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>75</EnrollmentCount><Interventions>EPO-906; EPO-906 + celecoxib; celecoxib</Interventions><Reference>3c-03-19; CEPO906AUS10; NCT00159484</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib bioequivalence</ProtocolTitle><Sponsor>Zydus Pharmaceuticals Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="208963"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>50</Patients><Biomarkers>Body height; Total body mass</Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Cadila Healthcare)</Interventions><Reference>LCPB-13-008CEL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Analgesia after breast cancer</ProtocolTitle><Sponsor>Gifu University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="332803"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Shoulder motion</Biomarkers><Condition>Joint disease</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; tramadol</Interventions><Reference>UMIN000031746</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="43696"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>35</EnrollmentCount><Interventions>celecoxib; celecoxib + irinotecan + cisplatin; cisplatin; irinotecan; radiation therapy (5040 cGy)</Interventions><Reference>01-229; NCT00137852</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Combination Therapy With Celecoxib and Taxotere for the Treatment of Stage D3 Prostate Cancer</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="42652"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>66</Patients><Biomarkers></Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls></Controls><EnrollmentCount>66</EnrollmentCount><Interventions>Taxotere; celecoxib</Interventions><Reference>COXAON-0509-047; GIA16125; NCT00215345</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Prospective, Randomized, Controled Clinical Study of Celecoxib in Combination with Chemotherapy in Patients with Advanced Gastric Cancer</ProtocolTitle><Sponsor>LanZhou University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="100715"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Metastatic stomach cancer</Condition><Controls>5-fluorouracil; cisplatin</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; cisplatin</Interventions><Reference>ChiCTR-TRC-10001158</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>BOXIT</ProtocolAcronym><ProtocolTitle>A Randomized, Phase III, Placebo-controlled Trial Evaluating The Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder</ProtocolTitle><Sponsor>Addenbrookes NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Institute of Cancer Research UK</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="135899"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>433</Patients><Biomarkers></Biomarkers><Condition>Transitional cell carcinoma</Condition><Controls></Controls><EnrollmentCount>475</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>06/Q0104/57; 2006-000687-89; BOXIT; ISRCTN84681538; MREC N: 06/Q0104/57; UKCRN ID: 2074; UR0601</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>BOXIT</ProtocolAcronym><ProtocolTitle>A Randomized, Phase III, Placebo-controlled Trial Evaluating The Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder</ProtocolTitle><Sponsor>Addenbrookes NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Institute of Cancer Research UK</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="135899"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>433</Patients><Biomarkers></Biomarkers><Condition>Bladder cancer</Condition><Controls></Controls><EnrollmentCount>475</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>06/Q0104/57; 2006-000687-89; BOXIT; ISRCTN84681538; MREC N: 06/Q0104/57; UKCRN ID: 2074; UR0601</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Colposcopic Directed Biopsy</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="332629"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>170</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>colposcopic guided biopsy</Controls><EnrollmentCount>170</EnrollmentCount><Interventions>acetic acid; celecoxib; colposcopic guided biopsy</Interventions><Reference>N-2AA6-2018; NCT03464552</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome</ProtocolTitle><Sponsor>UCSF Helen Diller Family Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="24211"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Skin cancer</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000068817; NCI-P01-0190; NCT00023621; UCSF-H473-16531-02B; UCSF-U19-CA81888-BC</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym>AURORAS</ProtocolAcronym><ProtocolTitle>Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury</ProtocolTitle><Sponsor>Kyunghee University Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="213454"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>27</Patients><Biomarkers>Blood pressure; Brachial artery; Flow-mediated dilation</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>36</EnrollmentCount><Interventions>active acupuncture; celecoxib; glibenclamide; sham acupuncture</Interventions><Reference>AURORAS; HI13C0580-2; NCT02255006</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Autism</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="106186"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Autism</Condition><Controls>risperidone</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; risperidone</Interventions><Reference>8144; IRCT138711091556N2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Endo Health Solutions Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="55519"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>143</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>143</EnrollmentCount><Interventions>Lidoderm</Interventions><Reference>EN3220-012; NCT00904605</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Lidocaine Patch Versus Celecoxib in Pain From Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Endo Health Solutions Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="55519"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>143</Patients><Biomarkers>Total body mass</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>143</EnrollmentCount><Interventions>Lidoderm</Interventions><Reference>EN3220-012; NCT00904605</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>TANGO</ProtocolAcronym><ProtocolTitle>Long-Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="257145"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>277</Patients><Biomarkers>Blood pressure; Heart rate</Biomarkers><Condition>Lower back pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>277</EnrollmentCount><Interventions>tanezumab</Interventions><Reference>A4091063; JAPAN CLBP SC STUDY; JapicCTI-163152; NCT02725411; TANGO</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Zhuanggu Joint Capsules in Treatment of Knee Osteoarthritis</ProtocolTitle><Sponsor>China Resources Sanjiu Medical and Pharmaceutical Co Ltd, Shanghai Sixth People’s Hospital</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="244512"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>432</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>432</EnrollmentCount><Interventions>Zhuanggu joint capsule; celecoxib</Interventions><Reference>ChiCTR-IPR-15007267</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of wufuyin on serum level of beta-catenin in the patients of discogenic back pain</ProtocolTitle><Sponsor>Traditional Chinese Medicine Hospital of Zhejiang Province</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="315950"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>beta-Catenin-like protein 1</Biomarkers><Condition>Back pain</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; wufuyin</Interventions><Reference>ChiCTR-INR-17012967</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prospective Study of PD-1 Inhibitor Combined With Liquid Biopsy ctDNA Detection Combined With Targeted Drugs And Hepatic Arterial Chemoembolization for the Treatment of Advanced Unresectable Liver Cancer Patients</ProtocolTitle><Sponsor>The Third Affiliated Hospital of Sun Yat-Sen University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="373945"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Metastatic liver cancer</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Celebrex; Keytruda; Opdivo; TACE; aspirin; lenvatinib; rivoceranib; sirolimus; sorafenib</Interventions><Reference>ChiCTR1900021894</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Trial Assessing the Outcome of Celecoxib Administration Versus Placebo Following Anterior Cruciate Ligament (ACL) Reconstruction</ProtocolTitle><Sponsor>Ottawa Hospital Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="69384"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2006-645; NCT01186887</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine in Patients With Metastatic Breast or Colorectal Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="12978"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>11</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>11</EnrollmentCount><Interventions>capecitabine; celecoxib</Interventions><Reference>2005-0328; CDR0000458042; MDA-2005-0328; MDA-CCC-0326; NCT00305643</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="30185"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>240</Patients><Biomarkers>CRP; Erythrocyte sedimentation rate</Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls>diclofenac</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191348; NCT00762463</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Examination of the Clinical Response of Celecoxib in Dariers Disease and Hailey-Hailey Disease</ProtocolTitle><Sponsor>Juntendo University, Graduate School of Medicine</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="138561"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Keratosis</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>JPRN-UMIN000010191</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Examination of the Clinical Response of Celecoxib in Dariers Disease and Hailey-Hailey Disease</ProtocolTitle><Sponsor>Juntendo University, Graduate School of Medicine</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="138561"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Pemphigus</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>JPRN-UMIN000010191</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63119"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>7-Hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid; COX-2; Cytochrome P450 2C9; Dinoprostone; PTGS2; Prostaglandin G/H synthase 2</Biomarkers><Condition>Adenocarcinoma</Condition><Controls>Paraplatin; gemcitabine; pemetrexed</Controls><EnrollmentCount>313</EnrollmentCount><Interventions>Paraplatin; celecoxib; gemcitabine; pemetrexed</Interventions><Reference>CALGB-30801; CDR0000662707; NCT01041781</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63119"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>7-Hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid; COX-2; Cytochrome P450 2C9; Dinoprostone; PTGS2; Prostaglandin G/H synthase 2</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls>Paraplatin; gemcitabine; pemetrexed</Controls><EnrollmentCount>313</EnrollmentCount><Interventions>Paraplatin; celecoxib; gemcitabine; pemetrexed</Interventions><Reference>CALGB-30801; CDR0000662707; NCT01041781</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63119"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>7-Hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid; COX-2; Cytochrome P450 2C9; Dinoprostone; PTGS2; Prostaglandin G/H synthase 2</Biomarkers><Condition>Large cell lung carcinoma</Condition><Controls>Paraplatin; gemcitabine; pemetrexed</Controls><EnrollmentCount>313</EnrollmentCount><Interventions>Paraplatin; celecoxib; gemcitabine; pemetrexed</Interventions><Reference>CALGB-30801; CDR0000662707; NCT01041781</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Cancer and Leukemia Group B</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="63119"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>7-Hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid; COX-2; Cytochrome P450 2C9; Dinoprostone; PTGS2; Prostaglandin G/H synthase 2</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls>Paraplatin; gemcitabine; pemetrexed</Controls><EnrollmentCount>313</EnrollmentCount><Interventions>Paraplatin; celecoxib; gemcitabine; pemetrexed</Interventions><Reference>CALGB-30801; CDR0000662707; NCT01041781</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Clinical Safety and Efficacy of an Anti-inflammatory Obtained from Active Ingredient of the Brazilian Biodiversity</ProtocolTitle><Sponsor>Apis Flora Industrial E Comercial Ltda, Fundacao De Apoio Ao Ensino, Pesquisa E Assistencia Do Hospital Das Clinicas Da FMRPUSP</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="185292"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>70</Patients><Biomarkers>Cytochrome P450; Dinoprostone; Multidrug resistance protein 1</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>EPP-AF; caffeine; celecoxib; fexofenadine; losartan; metoprolol; midazolam; omeprazole</Interventions><Reference>RBR-9zmfs9; U1111-1131-3520</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prospective Study For PD-1 Inhibitor Combined With Liquid Biopsy ctDNA Detection Combined With Targeted Drugs in the Treatment of Advanced Unresectable Liver Cancer Patients</ProtocolTitle><Sponsor>The Third Affiliated Hospital of Sun Yat-Sen University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="373950"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Circulating tumor DNA</Biomarkers><Condition>Metastatic liver cancer</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Celebrex; Keytruda; Opdivo; aspirin; lenvatinib; rivoceranib; sirolimus; sorafenib</Interventions><Reference>ChiCTR1900021896</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex versus Tramadol in the Treatment of Chronic Lower Back Pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12895"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>791</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>tramadol</Controls><EnrollmentCount>754</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191165; NCT00290901</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Erlotinib in Treating Patients With Liver Cancer</ProtocolTitle><Sponsor>University of California San Francisco</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="39463"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Liver tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib; erlotinib hydrochloride</Interventions><Reference>CDR0000458055; NCT00293436; UCSF-04459; UCSF-H43059-26066-02</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Window of Opportunity Study Targeting the Inflammatory Milieu</ProtocolTitle><Sponsor>University of Colorado at Denver and Health Sciences Center</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="142346"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>42</Patients><Biomarkers>Antigen KI-67</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>42</EnrollmentCount><Interventions>celecoxib; omega-3 fatty acid</Interventions><Reference>08-0104.CC; NCI-2011-02967; NCT01881048</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="266945"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>180</Patients><Biomarkers>Elbow motion; Shoulder motion</Biomarkers><Condition>Pain</Condition><Controls>ibuprofen; tramadol hydrochloride</Controls><EnrollmentCount>180</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>B-1105/128-003; NCT02850211</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="266945"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>180</Patients><Biomarkers>Elbow motion; Shoulder motion</Biomarkers><Condition>Tendon injury</Condition><Controls>ibuprofen; tramadol hydrochloride</Controls><EnrollmentCount>180</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>B-1105/128-003; NCT02850211</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer</ProtocolTitle><Sponsor>Azienda Ospedaliero-Universitaria Consorziale Policlinico</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="220802"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Bladder cancer</Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2401; NCT02343614</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="237996"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>330</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>330</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191099; COXA-0508-247; NCT02528201</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>COX2RCT</ProtocolAcronym><ProtocolTitle>Comparing Postoperative Pain Following COX-2 and Prostanoids Expression</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="324836"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>11b-PGF2a; Dinoprostone; Epoprostenol; Prostaglandin G/H synthase 2; Thromboxane A2</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Celebrex; peritoneal biopsy; single-port laparoscopic surgery</Interventions><Reference>2017-1477; COX2RCT; NCT03391570</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (Europe)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22183"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>388</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>ibuprofen</Controls><EnrollmentCount>388</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191062; NCT00630929</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 99Tc-MDP Treatment for Knee Osteoarthritis</ProtocolTitle><Sponsor>Xinhua Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="282246"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Bone mineral density; Joint stiffness; Lumbar spine bone mineral density; Standardized uptake value</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Yunke</Interventions><Reference>NCT02993029</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib as Adjuvant Biological Therapy in Patients With Head and Neck and Lung Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="49583"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1</Patients><Biomarkers>Ki-67</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>1</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2004-0104; NCT00527982</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib as Adjuvant Biological Therapy in Patients With Head and Neck and Lung Cancer</ProtocolTitle><Sponsor>MD Anderson Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="49583"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1</Patients><Biomarkers>Ki-67</Biomarkers><Condition>Lung tumor</Condition><Controls></Controls><EnrollmentCount>1</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2004-0104; NCT00527982</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>LDMtreatmCRC</ProtocolAcronym><ProtocolTitle>Low-Dose Metronomic Poly-chemotherapy for Metastatic CRC</ProtocolTitle><Sponsor>HaEmek Medical Center</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="214810"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers></Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>capecitabine; celecoxib; cyclophosphamide; methotrexate</Interventions><Reference>0035-14-EMC; LDMtreatmCRC; NCT02280694</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Celecoxib 200 mg Capsule of Liomont, SA de CV versus Celebrex 200 mg Capsule of Pfizer, SA de CV, Research in Healthy Subjects of Both Genders, Under Fasting Conditions</ProtocolTitle><Sponsor>Laboratorios Liomont Sa De Cv</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="185791"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib (Liomont, SA de CV)</Interventions><Reference>P472S034V005</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pilot study to evaluate the bioavailability of celecoxib 200 mg capsule (Liomont, SA de CV) versus Celebrex 200 mg capsule (Pfizer, SA de CV) in healthy subjects of both genders under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Liomont Sa De Cv</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="227717"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>16</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>16</EnrollmentCount><Interventions>celecoxib (Liomont, SA de CV)</Interventions><Reference>P547S012V006</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Safety Trial to Compare Different Analgesics in Combination With Low-Dose Aspirin to Study Their Bleeding Properties and Their Effects on the Stomach</ProtocolTitle><Sponsor>Johnson &amp; Johnson Consumer Products Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="179502"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>92</Patients><Biomarkers>Dinoprostone; Prostaglandin G/H synthase 1; Thromboxane B2</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>92</EnrollmentCount><Interventions>acetaminophen; aspirin; celecoxib; ibuprofen; naproxen sodium; rofecoxib</Interventions><Reference>CR002500; NCT00261586</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>ACE-ICH</ProtocolAcronym><ProtocolTitle>Administration of Celecoxib for Treatment of Intracerebral Hemorrhage : A Pilot Study</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14484"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition>Intracranial hemorrhage</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>12-2007-0084; ACE-ICH; H-0704-028-205; NCT00526214</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Osteopetrosis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Adrenoleukodystrophy</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Fanconi Albertini Zellweger syndrome</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Hurler syndrome</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Hunter syndrome</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Maroteaux-Lamy syndrome</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Sly syndrome</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Alpha mannosidosis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Metachromatic leukodystrophy</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Fucosidosis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Globoid cell leukodystrophy</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Niemann Pick disease type B</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Peroxisome disease</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Rett syndrome</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Niemann Pick disease type C</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Leukodystrophy</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Brain disease</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Leukoencephalopathy</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Allo HCT for Metabolic Disorders and Severe Osteopetrosis</ProtocolTitle><Sponsor>Masonic Cancer Center, University of Minnesota</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198874"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Macrophage colony stimulating factor 1 receptor; Neutrophils</Biomarkers><Condition>Metabolic disorder</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>N-acetylcysteine; Stem cell transplantation; Thymoglobulin; alemtuzumab; alpha lipoic acid; busulfan; celecoxib; fludarabine; peripheral blood stem cells; rituximab; thiotepa; vitamin E</Interventions><Reference>2013LS104; MT2013-31; NCT02171104</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, double-blind, placebo-controlled, randomized, comparative clinical trial to evaluate the safety and efficacy of 200 and 400 mg celecoxib for the treatment of patients with psoriatic arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79072"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>609</Patients><Biomarkers></Biomarkers><Condition>Psoriatic arthritis</Condition><Controls></Controls><EnrollmentCount>609</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191132; N49-01-01-202</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Effect of Periarticular Multi-Drug Regimen on Pain After Partial Hip Replacement</ProtocolTitle><Sponsor>Chung-Ang University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="67748"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>258</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>258</EnrollmentCount><Interventions>cefmetazole; celecoxib; epinephrine; ketorolac; morphine; oxycodone SR; ropivacaine</Interventions><Reference>ChunaAngUH; NCT01112436</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the possible pharmacokinetic interaction between the active substances Celecoxib and Paracetamol contained concomitantly in the test medicine, tablets containing 200 mg of Celecoxib and 500 mg of Paracetamol, prepared by Laboratorios Silanes, SA de CV, and the reference medicines Celebrex ®, capsules containing 200 mg of Celecoxib, manufactured by Pfizer, SA de CV, and Tylenol® Caplets, tablets containing 500 mg of Paracetamol prepared by Janssen Cilag de México, S. de RL de CV</ProtocolTitle><Sponsor>Laboratorios Silanes SA De CV</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="378562"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex; Tylenol, Janssen Cilag de México, S. de RL de CV</Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib + paracetamol</Interventions><Reference>BD-CXP-021/1117</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study To Evaluate Efficacy And Safety Of An Additional Dose Of Celecoxib (YM-177) In Patients With Post-Tooth Extraction Pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="63888"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>122</Patients><Biomarkers>Beta-2-microglobulin; Bilirubin; Blood pressure; Heart rate; N-acetylglucosamine</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>255</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191200; JapicCTI-101023; NCT01062113</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparative pharmacokinetic bioequivalence study drug Dilaksa (celecoxib 200 mg capsules, LLC Krka-Rus, Russia), and the drug Celebrex (celecoxib 200 mg capsules, Pfizer Menyufekchuring Doychlend GmbH, Germany), in healthy volunteers</ProtocolTitle><Sponsor>LLC Krka-Rus</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="169331"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Dilaksa (LLC Krka-Rus, Russia)</Interventions><Reference>13-37 / R</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intravenous Lidocaine in Total Knee Replacement</ProtocolTitle><Sponsor>The University of Hong Kong</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="347286"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>90</Patients><Biomarkers>Arterial oxygen saturation; Blood pressure; Heart rate; Knee motion</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>adrenaline; bupivacaine; celecoxib; fentanyl; ketorolac; lidocaine; morphine; ondansetron; paracetamol; pregabalin; ropivacaine</Interventions><Reference>NCT03597776; UW18-276</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Effects of Celecoxib Augmentation of Olanzapine Treatment In Schizophrenia in a Randomized, Controlled Trial</ProtocolTitle><Sponsor>Chhatrapati Shahuji Maharaj Medical University (ex King George's Medical University)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="299762"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Interleukin-1 beta; Interleukin-6</Biomarkers><Condition>Schizophrenia</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib; olanzapine; olanzapine</Interventions><Reference>CTRI/2017/05/008611</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Onset Time of Brachial Plexus Block Using Local Anesthetic Diluted With 0.9% Saline versus 5% Dextrose</ProtocolTitle><Sponsor>University of Malaya</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="116912"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>55</Patients><Biomarkers></Biomarkers><Condition>Anesthesia</Condition><Controls></Controls><EnrollmentCount>55</EnrollmentCount><Interventions>celecoxib; diclofenac; fentanyl; paracetamol; ropivacaine; tramadol; tramadol</Interventions><Reference>NCT01815944; UMMC883.11</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Robert H Lurie Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29178"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>121</Patients><Biomarkers>CYP2C9; Cyclooxygenase-2; Transforming growth factor (TGF)-beta</Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>121</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00058006; NU 02V2; NU-02V2; PHARMACIA-NU-02V2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Early-Stage Head and Neck Cancer or Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Robert H Lurie Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29178"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>121</Patients><Biomarkers>CYP2C9; Cyclooxygenase-2; Transforming growth factor (TGF)-beta</Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>121</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00058006; NU 02V2; NU-02V2; PHARMACIA-NU-02V2</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="20318"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>662</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>ASA; naproxen</Controls><EnrollmentCount>605</EnrollmentCount><Interventions>ASA; celecoxib; celecoxib + ASA; naproxen + ASA; placebo + ASA</Interventions><Reference>A3191171; NCT00137033</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Vanderbilt-Ingram Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="46348"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>23</Patients><Biomarkers>15-PGDH; COX-2; Collagen alpha-1(XVIII) chain; Cytokines; Prostacyclin synthase; Vascular endothelial growth factors; mPGES; thromboxane</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib; docetaxel; pemetrexed disodium</Interventions><Reference>NCT00520845; P30CA068485; VICC THO 0730; VU-VICC-IRB-070723; VU-VICC-THO-0730</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopedic Trauma Patients</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="195464"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>acetaminophen; aspirin; celecoxib; dexamethasone (Baycadron); gabapentin; heparin; oxycodone (Roxicodone)</Interventions><Reference>13-2669; NCT02160301</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of chemotherapy treatment after completion of standard treatment</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="287597"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>712</Patients><Biomarkers>Thyroid-stimulating hormone</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls>clinical observation</Controls><EnrollmentCount>712</EnrollmentCount><Interventions>celecoxib; methotrexate</Interventions><Reference>CTRI/2017/02/007777; Protocol No 1708 Version</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of chemotherapy treatment after completion of standard treatment</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="287597"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>712</Patients><Biomarkers>Thyroid-stimulating hormone</Biomarkers><Condition>Head and neck tumor</Condition><Controls>clinical observation</Controls><EnrollmentCount>712</EnrollmentCount><Interventions>celecoxib; methotrexate</Interventions><Reference>CTRI/2017/02/007777; Protocol No 1708 Version</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of chemotherapy treatment after completion of standard treatment</ProtocolTitle><Sponsor>Tata Memorial Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="287597"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>712</Patients><Biomarkers>Thyroid-stimulating hormone</Biomarkers><Condition>Mouth tumor</Condition><Controls>clinical observation</Controls><EnrollmentCount>712</EnrollmentCount><Interventions>celecoxib; methotrexate</Interventions><Reference>CTRI/2017/02/007777; Protocol No 1708 Version</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Adjunctive Celecoxib in Improvement of Obsessive-compulsive Disorder</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="250419"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Obsessive compulsive disorder</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>922796; IRCT201512235280N21</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21566"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>249</Patients><Biomarkers>Blood pressure; Pulse rate</Biomarkers><Condition>Osteoarthritis</Condition><Controls>diclofenac</Controls><EnrollmentCount>250</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191103; COXA-0508-261; NCT00174317</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, one-year, double blind, parallel group study to compare the tolerability of celecoxib versus diclofenac for the treatment of elderly patients with osteoarthritis of the hip or knees (coxarthrosis/gonarthrosis)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79890"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>916</Patients><Biomarkers>ALAT; ALP; ASAT; creatinine</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>916</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191006</Reference></Row><Row><ArmCount>12</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Risk of Falling After CFNB Versus ACB</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="288771"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>62</Patients><Biomarkers>Gait; Muscle strength</Biomarkers><Condition>Anesthesia</Condition><Controls></Controls><EnrollmentCount>62</EnrollmentCount><Interventions>Celebrex; acetaminophen; adductor canal block; dexamethasone; femoral nerve block; fentanyl; gabapentine; hydromorphone; lidocaine; midazolam; ondansetron; oxycodone; ropivacaine</Interventions><Reference>820115; NCT02314832</Reference></Row><Row><ArmCount>12</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Risk of Falling After CFNB Versus ACB</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="288771"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>62</Patients><Biomarkers>Gait; Muscle strength</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>62</EnrollmentCount><Interventions>Celebrex; acetaminophen; adductor canal block; dexamethasone; femoral nerve block; fentanyl; gabapentine; hydromorphone; lidocaine; midazolam; ondansetron; oxycodone; ropivacaine</Interventions><Reference>820115; NCT02314832</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression</ProtocolTitle><Sponsor>Lawson Health Research Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="257339"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Bipolar I disorder</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>107775; NCT02726659</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression</ProtocolTitle><Sponsor>Lawson Health Research Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="257339"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Bipolar II disorder</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>107775; NCT02726659</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression</ProtocolTitle><Sponsor>Lawson Health Research Institute</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="257339"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Postnatal depression</Condition><Controls></Controls><EnrollmentCount>56</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>107775; NCT02726659</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colon Cancer</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="377984"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Adenocarcinoma</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; toripalimab; toripalimab</Interventions><Reference>GIHSYSU-14; NCT03926338</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colon Cancer</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="377984"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Colon tumor</Condition><Controls></Controls><EnrollmentCount>10</EnrollmentCount><Interventions>celecoxib; toripalimab; toripalimab</Interventions><Reference>GIHSYSU-14; NCT03926338</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cetuximab and Celecoxib in Treating Patients With Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery</ProtocolTitle><Sponsor>Vanderbilt-Ingram Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="44645"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>17</Patients><Biomarkers>Amphiregulin; EGFR; PGE-2; PGE-M; TGF-alpha</Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>celecoxib; cetuximab</Interventions><Reference>NCT00466505; P30CA068485; VICC GI 0410; VU-IRB-040227; VU-VICC-GI-0410</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of celecoxib in order to prevent spontaneous preterm labor</ProtocolTitle><Sponsor>Qazvin University Of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="292399"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>164</Patients><Biomarkers></Biomarkers><Condition>Premature labor</Condition><Controls></Controls><EnrollmentCount>164</EnrollmentCount><Interventions>celecoxib; magnesium sulfate</Interventions><Reference>28/20/8859; IRCT2015042621947N1</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25105"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Angiogenic peptide; Vascular endothelial growth factor</Biomarkers><Condition>Glioblastoma</Condition><Controls></Controls><EnrollmentCount>55</EnrollmentCount><Interventions>celecoxib; temozolomide; thalidomide</Interventions><Reference>00302; CDR0000257587; CELGENE-2000-P-002521/1; DFCI-00302; NCI-G02-2118; NCT00047294; P30CA006516</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25105"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Angiogenic peptide; Vascular endothelial growth factor</Biomarkers><Condition>Central nervous system tumor</Condition><Controls></Controls><EnrollmentCount>55</EnrollmentCount><Interventions>celecoxib; temozolomide; thalidomide</Interventions><Reference>00302; CDR0000257587; CELGENE-2000-P-002521/1; DFCI-00302; NCI-G02-2118; NCT00047294; P30CA006516</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25105"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>50</Patients><Biomarkers>Angiogenic peptide; Vascular endothelial growth factor</Biomarkers><Condition>Brain tumor</Condition><Controls></Controls><EnrollmentCount>55</EnrollmentCount><Interventions>celecoxib; temozolomide; thalidomide</Interventions><Reference>00302; CDR0000257587; CELGENE-2000-P-002521/1; DFCI-00302; NCI-G02-2118; NCT00047294; P30CA006516</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled, phase III study to determine the safety and efficacy of docetaxel and carboplatin with celecoxib in patients with advanced non-small cell lung cancer</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="58631"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>561</Patients><Biomarkers>Cyclooxygenase-2</Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>540</EnrollmentCount><Interventions>carboplatin; celecoxib; docetaxel</Interventions><Reference>NVALT-4</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Parallel, Control, Post-marketing Study of Transcatheter Arterial Chemoembolization Combined with Lanreotide and Celecoxib in the Treatment for Hepatocellular Carcinoma</ProtocolTitle><Sponsor>Sichuan University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="97571"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>133</Patients><Biomarkers></Biomarkers><Condition>Hepatocellular carcinoma</Condition><Controls></Controls><EnrollmentCount>130</EnrollmentCount><Interventions>Transcathether arterial chemoembolization; celecoxib; celecoxib; lanreotide</Interventions><Reference>ChiCTR-TRC-08000191</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="28739"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>112</Patients><Biomarkers>Adenomatous polyposis coli protein; Apoptotic Index; Bax; Bcl-2; COX-1; COX-2; Cip1; DNA nucleotidylexotransferase; Deoxyuridine triphosphate; Ki-67; Leucine carboxyl methyltransferase 2; Mitotic Index; Ornithine decarboxylase; PGE2; Phospho-Histone H3; Phosphorylated histone H3; Polyamines; Prostaglandin G/H synthase 1; p21 WAF1/Cip1</Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>112</EnrollmentCount><Interventions>celecoxib; celecoxib; eflornithine</Interventions><Reference>CDR0000069278; ID00-109; MDA-ID-00109; N01-CN-95040; N01-CN95040; NCI-2013-00844; NCI-P02-0219; NCT00033371; P30CA016672; P30CA016672</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>University of Washington</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="98737"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>27</Patients><Biomarkers>Carcinoembryonic antigen-related cell adhesion molecule 5; GTPase KRas; K-ras mutation; Mucin-1</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>capecitabine; celecoxib; radiation therapy</Interventions><Reference>7707; NCI-2012-02137; NCT01729923; P30CA015704</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Skin Cancer</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="24214"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Skin cancer</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000068840; CPMC-IRB-9923; CPMC-U19-CA81888-01-UV; NCI-P01-0191; NCT00025051</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial for Pain Relief After Complete Video-Assisted Thoracic surgery. Comparison Between Intercostal Nerve Block Before Wound Closure Followed by Oral Celecoxib and Epidural Anesthesia</ProtocolTitle><Sponsor>Yamaguchi University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="172549"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Intercostal nerve block; celecoxib</Interventions><Reference>JPRN-UMIN000012884</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer</ProtocolTitle><Sponsor>Radiation Therapy Oncology Group</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="49338"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>77</Patients><Biomarkers>Bax; CDK2; H2AX; ICAM2; MMP2; MSH2; PCNA; RAD51; RAD53; Topoisomerase II alpha; VCAM1; adhesion molecules PECAM1; cdc2; cdc25; cdk inhibitor 1; chk1; cyclin D3,; cyclinB1; myc</Biomarkers><Condition>Uterine cervix tumor</Condition><Controls></Controls><EnrollmentCount>84</EnrollmentCount><Interventions>celecoxib; celecoxib + fluorouracil + cisplatin; cisplatin; fluorouracil</Interventions><Reference>CDR0000068849; NCT00023660; RTOG-C-0128</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The effect of Piascledine on lower back pain result from degenerative disc changes</ProtocolTitle><Sponsor>Ahvaz Jundishapur University of Medical Sciences</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="312224"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>Piascledine; celecoxib</Interventions><Reference>IR.AJUMS.REC.1396.250; IRCT2017061234501N1</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Elderly Back Pain: Comparing Chiropractic to Medical Care</ProtocolTitle><Sponsor>Palmer College of Chiropractic</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="168660"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Spinal stiffness</Biomarkers><Condition>Lower back pain</Condition><Controls>celecoxib; naproxen; once-daily naproxen (oral controlled release, pain), Alvogen; valdecoxib</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>High-velocity low amplitude spinal manipulation (HVLA-SM); Low-velocity variable amplitude spinal manipulation (LVVA-SM)</Interventions><Reference>HRSA4; NCT00602901; R18HP01423</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Investigation of the prophylactic effects of lisinopril on chronic migraine</ProtocolTitle><Sponsor>Iranian Center of Neurological Research at Tehran University of Medical Sciences</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="304588"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>112</Patients><Biomarkers></Biomarkers><Condition>Migraine</Condition><Controls>Celebrex</Controls><EnrollmentCount>112</EnrollmentCount><Interventions>Celebrex; lisinopril</Interventions><Reference>IR.TUMS.VCR.REC.1395.1418; IRCT201701089157N5</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparing the effect of acupuncture and medical treatment on subjective symptoms and neuromuscular electrophysiological changes in patients with lumbar disk herniation</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="247750"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>105</Patients><Biomarkers>Compound muscle action potential; Distal motor latency; F wave; Motor nerve conduction velocity</Biomarkers><Condition>Spinal injury</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>Acupuncture; Celebrex; Williams flexion exercise</Interventions><Reference>IR.MUMS.REC.1392.22; IRCT2012122911912N2</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer</ProtocolTitle><Sponsor>Gynecologic Oncology Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="27063"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>51</Patients><Biomarkers></Biomarkers><Condition>Peritoneal tumor</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>celecoxib; paclitaxel</Interventions><Reference>GOG_0126P; NCT00084448</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer</ProtocolTitle><Sponsor>Gynecologic Oncology Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="27063"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>51</Patients><Biomarkers></Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>51</EnrollmentCount><Interventions>celecoxib; paclitaxel</Interventions><Reference>GOG_0126P; NCT00084448</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of Diabetic Nephropathy</ProtocolTitle><Sponsor>National Institute of Diabetes, Digestive and Kidney Diseases</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11411"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Diabetic nephropathy</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00065559; TRMTDN (terminated)</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Celecoxib as Add-on Therapy to Risperidone Versus Risperidone Alone in Patients With Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="36210"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>270</Patients><Biomarkers></Biomarkers><Condition>Schizophrenia</Condition><Controls></Controls><EnrollmentCount>270</EnrollmentCount><Interventions>celecoxib; risperidone; risperidone</Interventions><Reference>A3191105; COXXNT-6570-001; NCT00639483</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>POINT study</ProtocolAcronym><ProtocolTitle>Improving intestinal function after surgery</ProtocolTitle><Sponsor>Flinders Medical Centre</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="258110"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Gastrointestinal disease</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib; diclofenac; pantoprazole</Interventions><Reference>ACTRN12605000299606; ANZCTR315; POINT study</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of COX-2 Selective Inhibitor and Hyaluronan Acid to Prevent Cartilage Degeneration in Patients With Knee Osteoarthritis</ProtocolTitle><Sponsor>National Hospital Organization Chiba Medical Cente, Teikyo University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="122131"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>celecoxib; sodium hyaluronate solution</Interventions><Reference>JPRN-UMIN000005643</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>European Organisation for Research and Treatment of Cancer (EORTC)</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="40684"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>85</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>86</EnrollmentCount><Interventions>capecitabine; celecoxib; fluorouracil; irinotecan; leucovorin calcium</Interventions><Reference>EORTC-40015; EORTC-40015; NCT00064181</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives</ProtocolTitle><Sponsor>Kitov Pharmaceuticals Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="280890"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>104</Patients><Biomarkers>Creatinine; Diastolic blood pressure; Systolic blood pressure; Total body mass; Total body mass</Biomarkers><Condition>Hypertension</Condition><Controls>Norvasc</Controls><EnrollmentCount>104</EnrollmentCount><Interventions>Celebrex; Norvasc</Interventions><Reference>2016-002214-47; KIT-302-03-02; NCT02979197</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients</ProtocolTitle><Sponsor>Medical University of Gdansk</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="42647"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>542</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>542</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>0102 PLCSG; NCT00211952</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pre-emptive Analgesia Following Uterine Artery Embolization</ProtocolTitle><Sponsor>Northwestern University</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="85712"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>23</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib; celecoxib; pregabalin; pregabalin</Interventions><Reference>NCT01555073; STU00004604</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor</ProtocolTitle><Sponsor>Emory University, US Government</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="54278"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>11</Patients><Biomarkers></Biomarkers><Condition>Head and neck tumor</Condition><Controls></Controls><EnrollmentCount>17</EnrollmentCount><Interventions>celecoxib; erlotinib</Interventions><Reference>0596-2004; NCT00314262</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open, crossover, randomized, single dose, two-treatments, two-periods and two-sequences bioequivalence study of two pharmaceutical preparations of Celecoxib 200 mg capsules in healthy Mexican population under fasting conditions</ProtocolTitle><Sponsor>Sanofi-Aventis of Mexico, SA de CV</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="243539"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib (Sanofi)</Interventions><Reference>/A316-15</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>DoCaCel</ProtocolAcronym><ProtocolTitle>A randomized, phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomas</ProtocolTitle><Sponsor>Pfizer Inc, VU University Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="103258"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>196</Patients><Biomarkers>Androgen receptor; COX-2; Estrogen receptor; Estrogen receptor beta; Progesterone receptor</Biomarkers><Condition>Fallopian tube cancer</Condition><Controls></Controls><EnrollmentCount>196</EnrollmentCount><Interventions>carboplatin; celecoxib; celecoxib + docetaxel + carboplatin; docetaxel</Interventions><Reference>2002/241 METC UMCG; DoCaCel; ISRCTN30851756; NTR1491; NTR471</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>DoCaCel</ProtocolAcronym><ProtocolTitle>A randomized, phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomas</ProtocolTitle><Sponsor>Pfizer Inc, VU University Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="103258"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>196</Patients><Biomarkers>Androgen receptor; COX-2; Estrogen receptor; Estrogen receptor beta; Progesterone receptor</Biomarkers><Condition>Peritoneal tumor</Condition><Controls></Controls><EnrollmentCount>196</EnrollmentCount><Interventions>carboplatin; celecoxib; celecoxib + docetaxel + carboplatin; docetaxel</Interventions><Reference>2002/241 METC UMCG; DoCaCel; ISRCTN30851756; NTR1491; NTR471</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>DoCaCel</ProtocolAcronym><ProtocolTitle>A randomized, phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomas</ProtocolTitle><Sponsor>Pfizer Inc, VU University Medical Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="103258"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>196</Patients><Biomarkers>Androgen receptor; COX-2; Estrogen receptor; Estrogen receptor beta; Progesterone receptor</Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>196</EnrollmentCount><Interventions>carboplatin; celecoxib; celecoxib + docetaxel + carboplatin; docetaxel</Interventions><Reference>2002/241 METC UMCG; DoCaCel; ISRCTN30851756; NTR1491; NTR471</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Two Approved Drugs in Patients With Osteoarthritis</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21393"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>395</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>395</EnrollmentCount><Interventions>celecoxib; rofecoxib</Interventions><Reference>0966-219; 2004_070; MK0966-219; NCT00092352</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A comparison between therapeutic effects of between Avocado soya and celecoxib on knee arthrosis</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="302296"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Cartilage oligomeric matrix protein</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>60</EnrollmentCount><Interventions>avocado + soya</Interventions><Reference>IR.MUMS.FM.REC.1395.420; IRCT201612271479N5</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effects of Duloxetine on Post-operative Wound Complication of Total Knee Arthroplasty (TKA) in Central Sensitization Patients</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373885"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers>Hydrocortisone; Knee motion; Norepinephrine; Serotonin</Biomarkers><Condition>Osteoarthritis</Condition><Controls>acetaminophen; celecoxib; oxycodone; pregabalin; tramadol</Controls><EnrollmentCount>80</EnrollmentCount><Interventions>acetaminophen; celecoxib; duloxetine; duloxetine; oxycodone; pregabalin; tramadol</Interventions><Reference>KC18MESI0455; NCT03880916</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Treatment of discogenic low back pain with pricking blood therapy combined with acupoint injection: a randomized controlled trial</ProtocolTitle><Sponsor>Surgical Intensive Care Unit (SICU), First Affiliated Hospital of Sun Yat-sen  University,</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="291261"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="PNA">Phase Not Applicable</DevStatus><Patients>120</Patients><Biomarkers>Interleukin 1; Interleukin-6; Tumor necrosis factor</Biomarkers><Condition>Lower back pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>120</EnrollmentCount><Interventions>acupoint injection; pricking blood therapy</Interventions><Reference>ChiCTR-IPR-17010901</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Compare the Efficacy and Safety of Celbesta and Celebrex in Patients With Rheumatoid Arthritis</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="261586"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>158</Patients><Biomarkers>Erythrocyte sedimentation rate</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>Celebrex</Controls><EnrollmentCount>158</EnrollmentCount><Interventions>Celbesta</Interventions><Reference>CELB_RA_IV; NCT02780323</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Selective COX-2 Inhibitor for the Protection of Intestinal Mucosal Damage in Comparison to NSAID in Rheumatoid Arthritis (Investigation by capsule endoscopy and measurement of biomarkers for rheumatoid arthritis)</ProtocolTitle><Sponsor>Osaka University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="119922"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>16</Patients><Biomarkers>Cytokines</Biomarkers><Condition>Gastric injury</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UMIN000002554</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Tramadol Versus Celecoxib for Reducing Pain During Operative Office Hysteroscopy</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="258085"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>210</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>210</EnrollmentCount><Interventions>celecoxib; tramadol hydrochloride</Interventions><Reference>HYST 8; NCT02736071</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221882"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C0">Phase 0 Clinical</DevStatus><Patients>115</Patients><Biomarkers>Blood cells; Erythrocyte sedimentation rate; Translocator protein</Biomarkers><Condition>Major depressive disorder</Condition><Controls></Controls><EnrollmentCount>115</EnrollmentCount><Interventions>[18F]-FEPPA positron emission tomography; celecoxib; minocycline</Interventions><Reference>NCT02362529; REB056/2014</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of GW-406381 in Treating Adults With Osteoarthritis of the Knee</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="21441"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1340</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>1340</EnrollmentCount><Interventions>GW-406381</Interventions><Reference>2005-000149-12; 62; 839; CXA30007; NCT00120900</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence Study of Two Pharmaceutical Preparations Celecoxib 200 mg capsules. Open, crossover, randomized, single dose, two treatments, two periods and two sequences of fasting study</ProtocolTitle><Sponsor>Hetlabs Mexico, SA de CV</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="165067"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>34</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>/ A240-12</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Opioid-Free Shoulder Arthroplasty</ProtocolTitle><Sponsor>OrthoCarolina Research Institute, Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="341218"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>65</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>65</EnrollmentCount><Interventions>Tora-Dol; acetaminophen; celecoxib; desflurane; gabapentin; lidocaine; liposomal bupivacaine; meloxicam; propofol; rocuronium; sevoflurane; vecuronium</Interventions><Reference>NCT03540030; PRO00021833</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Urinary NGF as A Biomarker for Acute Bacterial Cystitis</ProtocolTitle><Sponsor>Buddhist Tzu Chi General Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="113005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Beta-nerve growth factor; Urinary creatinine; Urinary nerve growth factor</Biomarkers><Condition>Urinary tract infection</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>Baktar; celecoxib</Interventions><Reference>NCT01800799; TCGHUROL007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Urinary NGF as A Biomarker for Acute Bacterial Cystitis</ProtocolTitle><Sponsor>Buddhist Tzu Chi General Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="113005"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>37</Patients><Biomarkers>Beta-nerve growth factor; Urinary creatinine; Urinary nerve growth factor</Biomarkers><Condition>Cystitis</Condition><Controls></Controls><EnrollmentCount>37</EnrollmentCount><Interventions>Baktar; celecoxib</Interventions><Reference>NCT01800799; TCGHUROL007</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical effect of the combined use of celecoxib and gabapentin on analgesia and inflammatory response in patients undergoing lumbar decompression surgery during perioperative period: a randomized controlled trial</ProtocolTitle><Sponsor>Southern Medical University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="322434"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Body temperature; C-reactive protein; Erythrocyte sedimentation rate; Hemoglobin; Leukocyte count</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib; gabapentin</Interventions><Reference>ChiCTR-IOR-17013799</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of celecoxib capsules in post-prandial conditions</ProtocolTitle><Sponsor>Tianjin Yaoyu Bio-Tech Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="361198"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Arthralgia</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Tianjin Jinyao Pharmaceutical Co, Ltd)</Interventions><Reference>CTR20181417; PAE17008M2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of celecoxib capsules in post-prandial conditions</ProtocolTitle><Sponsor>Tianjin Yaoyu Bio-Tech Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="361198"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Tianjin Jinyao Pharmaceutical Co, Ltd)</Interventions><Reference>CTR20181417; PAE17008M2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of celecoxib capsules in post-prandial conditions</ProtocolTitle><Sponsor>Tianjin Yaoyu Bio-Tech Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="361198"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Tianjin Jinyao Pharmaceutical Co, Ltd)</Interventions><Reference>CTR20181417; PAE17008M2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Bioequivalence study of celecoxib capsules in post-prandial conditions</ProtocolTitle><Sponsor>Tianjin Yaoyu Bio-Tech Co Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="361198"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls>celecoxib</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib (Tianjin Jinyao Pharmaceutical Co, Ltd)</Interventions><Reference>CTR20181417; PAE17008M2</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Randomized, Phase II/III Trial of Weekly Cisplatin Chemoradiotherapy +/- Low-Dose Celecoxib For Locoregional Nasopharyngeal Carcinoma</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="131991"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Nasopharyngeal carcinoma</Condition><Controls>5-fluorouracil; cisplatin; radiation therapy (70 Gy)</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; cisplatin; radiation therapy (70 Gy)</Interventions><Reference>86-2664; ACTRN12608000449336; ANZCTR83080</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pre-Surgical Effects of Serms, Anti-COX-2 and Aromatase Inhibitors in Breast Cancer Patients</ProtocolTitle><Sponsor>European Institute of Oncology</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="127257"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>269</Patients><Biomarkers>Body mass index; C-telopeptide; Caspase-3; Cytochrome P450 2D6; Estrogen receptor; Estrogen receptor (ER); Fibrinogen; Human epidermal growth factor receptor Her2/neu; IGF-binding protein-3 (IGFBP-3); Ki-67; PgR; antithrombin III (AT III); estradiol; estrone; estrone-sulphate; globulin; hsCRP; insulin-like growth factor-I (IGF-I); osteocalcin; plasminogen activator inhibitor-I (PAI-I); sex hormone-binding globulin (SHBG); ultrasensitive C-reactive protein (US-CRP)</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>250</EnrollmentCount><Interventions>celecoxib; exemestane; raloxifene; tamoxifen</Interventions><Reference>CC/13/04; IEO S162/303; ISRCTN86894592</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Celecoxib Capsule (200 mg) relative to Celebrex Capsule 200 mg in healthy Thai volunteers under fasting condition</ProtocolTitle><Sponsor>Bio-innova and Synchron.Co.,Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="373461"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>52</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>52</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>TCTR20190306002</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, double-blind, randomized, placebo-controlled, multicenter, parallel-group, comparative clinical trial to evaluate the safety and efficacy of celecoxib for the treatment of patients with osteoarthritis (OA)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="78987"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>293</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>293</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191290; N49-96-02-013</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib for prevention of esophageal stricture after endoscopic treatment in early esophageal cancer/precancerous lesion: a clinical, randomized, controlled trial</ProtocolTitle><Sponsor>Sichuan University, West China Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="212888"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>70</Patients><Biomarkers></Biomarkers><Condition>Esophagus tumor</Condition><Controls></Controls><EnrollmentCount>70</EnrollmentCount><Interventions>celecoxib; endoscopy</Interventions><Reference>ChiCTR-TRC-14005085</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of Analgesic Effect Between Celecoxib and Loxoprofen After Orthopedic Surgery</ProtocolTitle><Sponsor>Sekitetsukai Tanabe Chuou Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="166938"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>56</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>loxoprofen</Controls><EnrollmentCount>56</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>JPRN-JMA-IIA00149</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>INFINITE</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of rAd-IFN  Administered With Celecoxib and  Gemcitabine in Patients With Malignant Pleural Mesothelioma</ProtocolTitle><Sponsor>Trizell Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="357400"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>300</Patients><Biomarkers>Anti-Adenovirus antibodies ; EGF-containing fibulin-like extracellular matrix protein 1; Mesothelin</Biomarkers><Condition>Mesothelioma</Condition><Controls>celecoxib; gemcitabine</Controls><EnrollmentCount>300</EnrollmentCount><Interventions>celecoxib; gemcitabine; rAd-IFN</Interventions><Reference>2017-003169-82; INFINITE; NCT03710876; RAD-IFN-MM-301</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Use of patient controlled analgesics in the management of pain in orthognathic surgery: a randomized, controlled trial, pilot study</ProtocolTitle><Sponsor>Fiona Stanley Hospital, Royal Perth Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265424"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib; ibuprofen; oxycodone (immediate release), Shionogi; paracetamol; tramadol hydrochloride</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; fentanyl; ibuprofen; paracetamol</Interventions><Reference>13/88; ACTRN12616000919415; ANZCTR370417; U1111-1181-3681</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>OPEN STUDY OF TWO TERMS, TWO TREATMENTS, TWO SEQUENCES, CROSS SINGLE DOSE, BIOEQUIVALENCE ASSESSMENT OF TWO ORAL PREPARATIONS (CAPSULES) WITH 200 mg of celecoxib (CELEBREX ® PRODUCT OF SOUTH ATLANTIC LLC ACTAVIS VS., PFIZER CORPORATION CV) FASTING IN HEALTHY VOLUNTEERS</ProtocolTitle><Sponsor>Allergan plc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="176575"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>44</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>Celebrex</Controls><EnrollmentCount>44</EnrollmentCount><Interventions>Celecoxib from South Atlantic ACTAVIS product LLC</Interventions><Reference>CLC-17-ACT</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, double-blind, historical control, parallel assignment, phase II study to compare the safety and efficacy of two creatine combination therapies in amyotrophic lateral sclerosis</ProtocolTitle><Sponsor>Columbia University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="7705"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Motor neurone disease</Condition><Controls></Controls><EnrollmentCount>86</EnrollmentCount><Interventions>Minocin; celecoxib; creatine</Interventions><Reference>AAAB6334; ALSA ID#920; NCT00355576</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>GAIT</ProtocolAcronym><ProtocolTitle>Glucosamine/Chondroitin Arthritis Intervention Trial</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="93367"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>572</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>1588</EnrollmentCount><Interventions>acetaminophen; celecoxib; chondroitin sulfate; chondroitin sulfate; glucosamine; glucosamine</Interventions><Reference>GAIT; GAIT; NCT00010790; NCT00032890</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CELEBRIDO</ProtocolAcronym><ProtocolTitle>Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma</ProtocolTitle><Sponsor>Clinique Universitaires Saint-Luc, Universite Catholique de Louvain</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="375249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Indoleamine 2,3-dioxygenase; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Endometrioid carcinoma</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>celecoxib; endometrial biopsy</Interventions><Reference>CELEBRIDO; LUC19-001; NCT03896113</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>CELEBRIDO</ProtocolAcronym><ProtocolTitle>Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma</ProtocolTitle><Sponsor>Clinique Universitaires Saint-Luc, Universite Catholique de Louvain</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="375249"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>Cytotoxic T-Lymphocytes; Indoleamine 2,3-dioxygenase; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain</Biomarkers><Condition>Adenocarcinoma</Condition><Controls></Controls><EnrollmentCount>48</EnrollmentCount><Interventions>celecoxib; endometrial biopsy</Interventions><Reference>CELEBRIDO; LUC19-001; NCT03896113</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy (SMA)</ProtocolTitle><Sponsor>Childrens Hospital of Eastern Ontario (CHEO)</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="269146"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>12</Patients><Biomarkers>Survival motor neuron protein</Biomarkers><Condition>Spinal muscular atrophy</Condition><Controls></Controls><EnrollmentCount>12</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>15/22E; NCT02876094</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pain Management of ACL Reconstruction</ProtocolTitle><Sponsor>University of California Davis</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="322022"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>60</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>Phenergan; Zofran; acetaminophen; adductor canal nerve block; celecoxib; gabapentin; oxycodone; ropivacaine</Interventions><Reference>1115203; NCT03365908</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis</ProtocolTitle><Sponsor>Severance Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221754"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>106</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>celecoxib</Controls><EnrollmentCount>106</EnrollmentCount><Interventions>naproxen + esomeprazole strontium (rheumatoid arthritis), Hanmi Pharmaceuticals</Interventions><Reference>NCT02355236; Naxozol_P4_1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis</ProtocolTitle><Sponsor>Severance Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="221754"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>106</Patients><Biomarkers></Biomarkers><Condition>Stomach ulcer</Condition><Controls>celecoxib</Controls><EnrollmentCount>106</EnrollmentCount><Interventions>naproxen + esomeprazole strontium (rheumatoid arthritis), Hanmi Pharmaceuticals</Interventions><Reference>NCT02355236; Naxozol_P4_1</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, multicenter, randomized, double-blind, placebo-controlled, parallel-group, outpatient clinical trial to compare the intermittent versus continuous treatment with celecoxib in patients with osteoarthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80049"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib; celecoxib (continuous); celecoxib (intermittent)</Interventions><Reference>A3191096; COXA-0508-239</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>Celebrex - Cervix</ProtocolAcronym><ProtocolTitle>Celecoxib in the Treatment of Patients With Locally Advanced Carcinoma of the Cervix</ProtocolTitle><Sponsor>The University Health Network</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="31477"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>31</Patients><Biomarkers>COX-2; PGE2; Vascular endothelial growth factors</Biomarkers><Condition>Uterine cervix tumor</Condition><Controls></Controls><EnrollmentCount>31</EnrollmentCount><Interventions>celecoxib; cisplatin; radiotherapy</Interventions><Reference>Celebrex - Cervix; NCT00152828; National Cancer Instit.Canada; UHN REB 00-0431-C</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I/II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="28270"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>98-C-0087; 980087; NCT00001693</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Beneficial Antipsychotic Effects of Celecoxib Add-on Therapy Compared to Clozapine Alone in Schizophrenia</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="138643"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Schizophrenia</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; clozapine; clozapine</Interventions><Reference>5508; IRCT201301095280N11</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC)</ProtocolTitle><Sponsor>Chinese Academy of Medical Sciences</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="83730"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Metastatic non small cell lung cancer</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; cisplatin; etoposide</Interventions><Reference>CH-L-025; NCT01503385</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Biliary tumor</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Adenocarcinoma</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Metastatic gastrointestinal cancer</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Metastatic stomach cancer</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Metastatic pancreas cancer</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers</ProtocolTitle><Sponsor>University of Utah</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="213796"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>10</Patients><Biomarkers></Biomarkers><Condition>Appendix adenoma</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-fluorouracil; celecoxib; leucovorin; oxaliplatin; pembrolizumab</Interventions><Reference>HCI76239; MK-3475 GI; NCT02268825</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines</ProtocolTitle><Sponsor>Roswell Park Comprehensive Cancer Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="228379"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers>C-C motif chemokine 22; C-C motif chemokine 3; C-C motif chemokine 4; C-C motif chemokine 5; C-X-C motif chemokine 10; C-X-C motif chemokine 11; C-X-C motif chemokine 9; CA-125 antigen; CD3 Antigens; Cytotoxic T-Lymphocytes; Dendritic cells; Forkhead box protein P3; Granzyme B; Indoleamine 2,3-dioxygenase; Integrin alpha-M; Integrin alpha-X; Interferon gamma; Interleukin-10; Macrophages; Myeloid-derived suppressor cells; Natural killer cells; Nitric oxide; Prostaglandin G/H synthase 2; Regulatory T-Lymphocytes; Stromal cell-derived factor 1; T-Helper Lymphocytes; T-cell surface glycoprotein CD4; T-cell surface glycoprotein CD8 alpha chain; Th1 cells</Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>alpha-type-1 polarized dendritic cell vaccine (peritoneal cancer), University of Pittsburgh; celecoxib; cisplatin; interferon alpha-2b; rintatolimod</Interventions><Reference>11-128; 5P01CA132714; NCT02432378</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer</ProtocolTitle><Sponsor>City of Hope</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="36145"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Fallopian tube cancer</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>celecoxib; cyclophosphamide</Interventions><Reference>03092; CDR0000567043; NCI-2009-01597; NCT00538031</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer</ProtocolTitle><Sponsor>City of Hope</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="36145"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Peritoneal tumor</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>celecoxib; cyclophosphamide</Interventions><Reference>03092; CDR0000567043; NCI-2009-01597; NCT00538031</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer</ProtocolTitle><Sponsor>City of Hope</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="36145"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>celecoxib; cyclophosphamide</Interventions><Reference>03092; CDR0000567043; NCI-2009-01597; NCT00538031</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Eastern Cooperative Oncology Group</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="13007"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Cancer pain</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000389434; ECOG-E1Z02; NCT00093678</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>STAMP</ProtocolAcronym><ProtocolTitle>Selective Treatment According to Molecular Subtype of Prostate Cancer</ProtocolTitle><Sponsor>Second Hospital of Tianjin Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="355416"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>300</Patients><Biomarkers>Alpha-type platelet-derived growth factor receptor; Beta-type platelet-derived growth factor receptor; Epidermal growth factor receptor; HER2; Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform; Prostate-specific antigen; RAC-alpha serine/threonine-protein kinase; Solute carrier family 45 member 3/Serine/threonine-protein kinase B-raf fusion gene</Biomarkers><Condition>Hormone refractory prostate cancer</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>abiraterone; carboplatin; celecoxib; docetaxel; everolimus; gefitinib; goserelin; lapatinib; olaparib; prednisone; sunitinib; vemurafenib</Interventions><Reference>NCT03696186; STAMP</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer</ProtocolTitle><Sponsor>Tanta University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="351226"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>50</Patients><Biomarkers></Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls>Eloxatin; fluorouracil; leucovorin</Controls><EnrollmentCount>50</EnrollmentCount><Interventions>Eloxatin; celecoxib; fluorouracil; leucovorin</Interventions><Reference>CELECOXIB; NCT03645187</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, parallel-control, open-label, post-marketing study to assess the efficacy of preventive anti-inflammatory and analgesia treatment with celecoxib in patients who underwent endoscopic nasal surgery</ProtocolTitle><Sponsor>People's Hospital Peking University, Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="97182"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>120</Patients><Biomarkers>PGE2; TXA2/PGI2</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ChiCTR-TRC-10000783</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="178412"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>25</Patients><Biomarkers>Cellular tumor antigen p53; Prostaglandin E2 receptor EP3 subtype; Prostaglandin G/H synthase 2</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>N01-CN-85183-STEP-1-EXT; N01CN85183; NCI-2014-00524; NCI-2014-00524; NCT02090933; RSRB#10077</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Decreasing Narcotics in Advanced Pelvic Surgery (Pain)</ProtocolTitle><Sponsor>Hartford Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="181574"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>138</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>138</EnrollmentCount><Interventions>Celebrex; Dilaudid CR; Percocet; Vicodin; Zofran; acetaminophen (Tylenol); dexamethasone; gabapentin; hydrocodone; ibuprofen; oxycodone; pelvic surgery</Interventions><Reference>NCT02110719; REAG00414HU</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>OSCARE</ProtocolAcronym><ProtocolTitle>Effect Of Celecoxib On Hip Osteoarthritis (OA) Progression</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="21502"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>23</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>666</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191068; NCT00163241; OSCARE</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib for preterm birth</ProtocolTitle><Sponsor>Kyoto University Hospital</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="292706"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Amniotic fluid; Peak systolic velocity</Biomarkers><Condition>Premature labor</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UMIN000026304</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib (Celebrex) in the Management of Acute Renal Colic</ProtocolTitle><Sponsor>University of Minnesota</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="32778"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>53</Patients><Biomarkers></Biomarkers><Condition>Urolithiasis</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>0405M60562; 3485B; NCT00304317</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib (Celebrex) in the Management of Acute Renal Colic</ProtocolTitle><Sponsor>University of Minnesota</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="32778"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>53</Patients><Biomarkers></Biomarkers><Condition>Renal colic</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib</Interventions><Reference>0405M60562; 3485B; NCT00304317</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect Of COX-2 Selective Inhibitors On Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery</ProtocolTitle><Sponsor>Jinling Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="152516"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>164</Patients><Biomarkers>Catecholamine; Glucocorticoid; IL-4; IL-6; TNF-alpha</Biomarkers><Condition>Insulin resistance</Condition><Controls></Controls><EnrollmentCount>164</EnrollmentCount><Interventions>celecoxib; parecoxib; parecoxib; tramadol hydrochloride</Interventions><Reference>NCT01930318; PTP-IR-EEN-1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib for Thyroid Eye Disease</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="266681"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>40</Patients><Biomarkers></Biomarkers><Condition>Thyroid associated ophthalmopathy</Condition><Controls>artificial tears</Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>IRB00094787; NCT02845336</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study On The Analgesic Efficacy Of A 4-Week Combination Of Nsaids Patch And Celecoxib In Patients With Knee Osteoarthritis Who Responded Poorly To Monotherapy With Nsaids Patch (A Randomized, Open-Label, Parallel-Group, Controlled Study Compared To Home Based Exercise Therapy)</ProtocolTitle><Sponsor>Sapporo Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="126509"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>72</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>72</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>JPRN-UMIN000007719</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>The Impact of Genotype on Plasma and Cerebral Spinal Fluid Pharmacokinetics of Celecoxib in Children</ProtocolTitle><Sponsor>Childrens Hospital of Eastern Ontario (CHEO)</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="76981"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Cytochrome P450 2C9</Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>09/09E; NCT01344200</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Barbara Ann Karmanos Cancer Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="40738"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>27</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>27</EnrollmentCount><Interventions>celecoxib; gefitinib; gefitinib + celecoxib</Interventions><Reference>CDR0000327805; NCT00068653; P30CA022453; WSU-C-2563; ZENECA-1839US/0252</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation Of Adding Celecoxib To Treatment Of Mood Disorder Patients Receiving Electroconvulsive Therapy</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="125774"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>48</Patients><Biomarkers>C-reactive protein; High-sensitivity c-reactive protein; Interleukin-1 beta (IL-1beta); Interleukin-6 (IL-6); Tumour necrosis factor-alpha (TNF-alpha)</Biomarkers><Condition>Mood disorder</Condition><Controls></Controls><EnrollmentCount>50</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>89-02-33-10809-44959; IRCT201201247202N2</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>CONDOR</ProtocolAcronym><ProtocolTitle>Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="15495"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>4484</Patients><Biomarkers>Alanine Aminotransferase; Aspartate Aminotransferase; C-Reactive Protein; Ferritin; Gamma Glutamyl-Transferase; Hemoglobin; cytochrome P450 (CYP) 2C9</Biomarkers><Condition>Osteoarthritis</Condition><Controls>diclofenac; omeprazole</Controls><EnrollmentCount>4484</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191084; CONDOR; NCT00141102</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>CONDOR</ProtocolAcronym><ProtocolTitle>Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="15495"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>4484</Patients><Biomarkers>Alanine Aminotransferase; Aspartate Aminotransferase; C-Reactive Protein; Ferritin; Gamma Glutamyl-Transferase; Hemoglobin; cytochrome P450 (CYP) 2C9</Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>diclofenac; omeprazole</Controls><EnrollmentCount>4484</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191084; CONDOR; NCT00141102</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small-Cell Lung Cancer</ProtocolTitle><Sponsor>Groupe Cooperateur Multidisciplinaire en Oncologie</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="44067"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers></Biomarkers><Condition>Non-small-cell lung cancer</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000454352; EU-20572; GERCOR-B03-1; NCT00274898; PFIZER-GERCOR-B03-1; SANOFI-GERCOR-B03-1</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IV, one year, double-blind, parallel-group clinical trial to compare the tolerability of celecoxib versus diclofenac  for the treatment of elderly patients with osteoarthritis of the hip or knees</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80136"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>67</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>67</EnrollmentCount><Interventions>celecoxib; diclofenac</Interventions><Reference>A3191025</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer</ProtocolTitle><Sponsor>Dana-Farber Cancer Institute Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="30108"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>85</Patients><Biomarkers>COX-2; Vascular endothelial growth factor (VEGF)</Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>85</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>02-193; COXAON-0509-125; NCT00136487</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="42442"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>23</Patients><Biomarkers></Biomarkers><Condition>Pancreas tumor</Condition><Controls></Controls><EnrollmentCount>23</EnrollmentCount><Interventions>celecoxib; irinotecan</Interventions><Reference>02-128; NCT00177853</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="17201"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>278</Patients><Biomarkers></Biomarkers><Condition>Arthralgia</Condition><Controls>Non-selective NSAIDS (diclofenac)</Controls><EnrollmentCount>278</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191332; NCT00446797</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Open-Label Comparative Study On Celecoxib Efficacy And Safety Versus Non-Selective NSAID In Acute Pain Due To Ankle Sprain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="17201"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>278</Patients><Biomarkers></Biomarkers><Condition>Injury</Condition><Controls>Non-selective NSAIDS (diclofenac)</Controls><EnrollmentCount>278</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191332; NCT00446797</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Medical Treatment of 'High-Risk' Neurofibromas</ProtocolTitle><Sponsor>Spectrum Health Hospitals</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="47159"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>20</Patients><Biomarkers>Tumor mass</Biomarkers><Condition>Neurofibromatosis</Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>celecoxib; pegylated interferon alpha-2b; temozolomide; vincristine sulfate</Interventions><Reference>2008-260; 2008-260; NCT00846430</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of analgesic efficacy of celecoxib and acetaminophen in pediatric tonsillectomy</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="303776"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>acetaminophen</Controls><EnrollmentCount>200</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>IRCT2015080919470N29; Ir.sums.rec.1394.s946</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma</ProtocolTitle><Sponsor>HaEmek Medical Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="90383"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>80</Patients><Biomarkers>PDGF; TSP-1; Vascular endothelial growth factors</Biomarkers><Condition>Metastatic colorectal cancer</Condition><Controls></Controls><EnrollmentCount>80</EnrollmentCount><Interventions>capecitabine; celecoxib; methotrexate</Interventions><Reference>EMC-0047-11; NCT01668680</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Molecular mechanism of celecoxib on inflammatory cytokines and loss of apoptosis in respiratory papilloma</ProtocolTitle><Sponsor>Beijing Tongren Hospital</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="372185"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers>Apoptosis regulator BAX; Apoptosis regulator Bcl-2; Caspase-3; Prostaglandin G/H synthase 2</Biomarkers><Condition>Papillomavirus infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>ChiCTR1900021567</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Etoposide and Celecoxib in Patients With Advanced Cancer</ProtocolTitle><Sponsor>Beckman Research Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="42025"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>58</Patients><Biomarkers></Biomarkers><Condition>Solid tumor</Condition><Controls></Controls><EnrollmentCount>58</EnrollmentCount><Interventions>celecoxib; etoposide</Interventions><Reference>01036; CDR0000570381; CHNMC-01036; NCT00551005; P30CA033572</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A 6-Week Study Of The Pain Relieving Effects Of Celecoxib 200 mg Twice Daily Compared To Tramadol 50 mg Four Times Daily In Patients With Chronic Low Back Pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12816"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>792</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls>tramadol</Controls><EnrollmentCount>802</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191338; NCT00662558</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study to Verify the Efficacy of YM-177 (Celecoxib) in Postoperative Pain Patients</ProtocolTitle><Sponsor>Astellas Pharma Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66166"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>616</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>etodolac</Controls><EnrollmentCount>616</EnrollmentCount><Interventions>YM-177</Interventions><Reference>177-CL-102; JapicCTI-184528; JapicCTI-R140636; NCT01118572</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer</ProtocolTitle><Sponsor>Case Comprehensive Cancer Center</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="29241"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>6</Patients><Biomarkers></Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>6</EnrollmentCount><Interventions>celecoxib; vinorelbine</Interventions><Reference>CWRU-ICC-3102; GSK-CWRU-ICC-3102; ICC3102; NCT00075673; P30CA043703</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>CAAN</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Celecoxib in Combination with Exemestane for locally advanced breast cancer</ProtocolTitle><Sponsor>UCB SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="152029"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>82</Patients><Biomarkers></Biomarkers><Condition>Metastatic breast cancer</Condition><Controls></Controls><EnrollmentCount>82</EnrollmentCount><Interventions>celecoxib; exemestane; exemestane; letrozole</Interventions><Reference>CAAN</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, multicenter clinical trial to compare the effects of celecoxib versus rofecoxib and dietary sodium on blood pressure in osteoarthritis (OA) subjects with treated systolic hypertension</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="79829"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>55</Patients><Biomarkers>ALT; AST; alkaline phosphatase</Biomarkers><Condition>Hypertension</Condition><Controls></Controls><EnrollmentCount>65</EnrollmentCount><Interventions>celecoxib; rofecoxib</Interventions><Reference>A3191121; N49-01-02-145</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, multicenter clinical trial to compare the effects of celecoxib versus rofecoxib and dietary sodium on blood pressure in osteoarthritis (OA) subjects with treated systolic hypertension</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="79829"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>55</Patients><Biomarkers>ALT; AST; alkaline phosphatase</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>65</EnrollmentCount><Interventions>celecoxib; rofecoxib</Interventions><Reference>A3191121; N49-01-02-145</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Lipidomics Screening of Celecoxib in Ex Vivo Human Whole Blood Assay - Part B</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="227584"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>20</Patients><Biomarkers>Lipids</Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>20</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>818658-PART B; NCT02413203</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis</ProtocolTitle><Sponsor>National Health and Family Planning Commission, P R China</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="249389"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers>C-reactive protein; Cervical motion; Erythrocyte sedimentation rate; Erythrocytes</Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib; etanercept; sulfasalazine</Interventions><Reference>2015117183344589; NCT02638896</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>CHIP</ProtocolAcronym><ProtocolTitle>Trial in Pediatric Patients with Familial Adenomatous Polyposis (FAP)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="23666"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>106</Patients><Biomarkers>Adenomatous polyposis coli protein  </Biomarkers><Condition>Familial adenomatous polyposis</Condition><Controls></Controls><EnrollmentCount>106</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>2006-002228-40; A3191193; CDR0000508797; CHIP; MDA-2006-0040; NCT00393016; NCT00534040; NCT00585312; PFIZER-A3191193</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A randomized, controlled trial to evaluate the effectiveness of celecoxib versus placebo as an additional treatment for depression in outpatients of Colombo North Teaching hospital Ragama</ProtocolTitle><Sponsor>University of Kelaniya</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="351165"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>120</Patients><Biomarkers></Biomarkers><Condition>Depression</Condition><Controls></Controls><EnrollmentCount>120</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>SLCTR/2018/027; U1111-1213-0256</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, double-blind, parallel-group clinical trial to compare the incidence of gastroduodenal ulcer associated with celecoxib with that of naproxen for the treatment of patients with osteoarthritis or rheumatoid arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79933"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>537</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>537</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>A3191305; N49-97-02-062</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, multicenter, double-blind, parallel-group clinical trial to compare the incidence of gastroduodenal ulcer associated with celecoxib with that of naproxen for the treatment of patients with osteoarthritis or rheumatoid arthritis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79933"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>537</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls></Controls><EnrollmentCount>537</EnrollmentCount><Interventions>celecoxib; naproxen</Interventions><Reference>A3191305; N49-97-02-062</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>CombinaiR3</ProtocolAcronym><ProtocolTitle>First-line Treatment of Ewing Tumors With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years</ProtocolTitle><Sponsor>Institut Curie</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="284335"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Circulating Tumor Cells; Standardized uptake value</Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>Temcad; celecoxib; cyclophosphamide; doxorubicine; etoposide; ifosfamide; irinotecan; peripheral blood stem cells; radiotherapy; surgical excision; vinblastine; vincristine</Interventions><Reference>2016-000981-46; CombinaiR3; IC 2015-13 COMBINAIR3; IC2015-13; NCT03011528</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>CombinaiR3</ProtocolAcronym><ProtocolTitle>First-line Treatment of Ewing Tumors With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years</ProtocolTitle><Sponsor>Institut Curie</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="284335"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Circulating Tumor Cells; Standardized uptake value</Biomarkers><Condition>Ewing sarcoma</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>Temcad; celecoxib; cyclophosphamide; doxorubicine; etoposide; ifosfamide; irinotecan; peripheral blood stem cells; radiotherapy; surgical excision; vinblastine; vincristine</Interventions><Reference>2016-000981-46; CombinaiR3; IC 2015-13 COMBINAIR3; IC2015-13; NCT03011528</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis</ProtocolTitle><Sponsor>Sun Yat-Sen University</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="154024"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>celecoxib; celecoxib; etanercept; etanercept</Interventions><Reference>NCT01934933; [2013]2-93</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>12-Week No-Rofecoxib Plus Aspirin Endoscopy Study</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="5260"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>49</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>Enteric-coated aspirin</Controls><EnrollmentCount>49</EnrollmentCount><Interventions>MK-0782; celecoxib</Interventions><Reference>2007_636; NCT00543465</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>12-Week No-Rofecoxib Plus Aspirin Endoscopy Study</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="5260"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>49</Patients><Biomarkers></Biomarkers><Condition>Rheumatoid arthritis</Condition><Controls>Enteric-coated aspirin</Controls><EnrollmentCount>49</EnrollmentCount><Interventions>MK-0782; celecoxib</Interventions><Reference>2007_636; NCT00543465</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex Short Versus Long Therapy In Ostheoarthritis Of The Knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="16954"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>218</Patients><Biomarkers>alanine aminotransferase (ALT); blood urea nitrogen; gamma GT; hematocrit; total protein (TP)</Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Celebrex; Celebrex (arm 1); Celebrex (arm 2)</Interventions><Reference>635-IFL-0508-015; A3191091; NCT00137410</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Erector Spine Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="342038"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>7</Patients><Biomarkers></Biomarkers><Condition>Bone injury</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>Celebrex; bupivacaine; erector spinae plane block; gabapentin; ketamine; lidocaine; paravertebral nerve block; ropivacaine</Interventions><Reference>NCT03540095; PRO18040578</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Erector Spine Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="342038"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>7</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>7</EnrollmentCount><Interventions>Celebrex; bupivacaine; erector spinae plane block; gabapentin; ketamine; lidocaine; paravertebral nerve block; ropivacaine</Interventions><Reference>NCT03540095; PRO18040578</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>carbo-cox2</ProtocolAcronym><ProtocolTitle>Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-Treated Recurrent Ovarian Cancer Patients</ProtocolTitle><Sponsor>Catholic University of the Sacred Heart</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="66480"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>45</Patients><Biomarkers>Ca-125; Endostatin; VEGF (vascular endothelial growth factor)</Biomarkers><Condition>Ovary tumor</Condition><Controls></Controls><EnrollmentCount>45</EnrollmentCount><Interventions>carboplatin; celecoxib</Interventions><Reference>935/03; NCT01124435; carbo-cox2</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Effect of celecoxib and ibuprofen versus placebo on pain after laparotomy in drug dependence</ProtocolTitle><Sponsor>Hamadan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="217673"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>114</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>114</EnrollmentCount><Interventions>celecoxib; ibuprofen</Interventions><Reference>D/P/16/35/9/87; IRCT201411269014N50</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>GROUP</ProtocolAcronym><ProtocolTitle>Gabapentin Reduces Opioid Use Post-operatively</ProtocolTitle><Sponsor>Mount Sinai Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="282970"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>47</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>acetaminophen; celecoxib; gabapentin</Interventions><Reference>16-0262-A; GROUP; NCT02999724</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>GROUP</ProtocolAcronym><ProtocolTitle>Gabapentin Reduces Opioid Use Post-operatively</ProtocolTitle><Sponsor>Mount Sinai Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="282970"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>47</Patients><Biomarkers></Biomarkers><Condition>Surgical procedure</Condition><Controls></Controls><EnrollmentCount>44</EnrollmentCount><Interventions>acetaminophen; celecoxib; gabapentin</Interventions><Reference>16-0262-A; GROUP; NCT02999724</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex With Preoperative Chemoradiation - Rectal Cancer</ProtocolTitle><Sponsor>The University Health Network</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="25448"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>39</Patients><Biomarkers></Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>39</EnrollmentCount><Interventions>5-FU; celecoxib</Interventions><Reference>NCT00188565; Ontario Cancer ResearchNetwork; UHN REB 02-0130-C</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase IIIb, 12-week, randomized, double-blind, placebo-controlled multicenter study to evaluate the  analgesic efficacy of celecoxib compared to placebo for the treatment of patients with chronic low back pain</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="80172"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>374</Patients><Biomarkers></Biomarkers><Condition>Lower back pain</Condition><Controls></Controls><EnrollmentCount>374</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>COXA-0508-245</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparison of efficacy of adding Gabapentin, or Celecoxib or combination of them to analgesic method in knee and shoulder arthroscopy</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="125801"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>104</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>104</EnrollmentCount><Interventions>celecoxib; celecoxib; gabapentin; gabapentin</Interventions><Reference>1910051508; IRCT201205217274N5</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Prospective, open, randomized, comparative, crossover, pharmacokinetics and bioavailability study of the drug celecoxib, capsules, 200 mg (Protech Biosystems Ltd., India) compared with the preparation Celebrex, capsules, 200 mg (Pfizer Pharmaceuticals, Puerto Rico, USA)</ProtocolTitle><Sponsor>LLC "Vial"</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="225178"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>38</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls>celecoxib</Controls><EnrollmentCount>38</EnrollmentCount><Interventions>celecoxib (Protech Biosystems Ltd)</Interventions><Reference>CXB001</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study Of 'Continuous Use' Of Celecoxib Versus 'Usual or Intermittent Use'</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="15494"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>858</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>875</EnrollmentCount><Interventions>celecoxib; celecoxib (continuous use); celecoxib (intermittent use)</Interventions><Reference>A3191173; NCT00139776</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A pilot study of the analgesia after laparoscopic inguinal hernia repair</ProtocolTitle><Sponsor>Aichi Medical University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="276113"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>celecoxib; celecoxib; diclofenac sodium; transverse abdominis plane (TAP)</Interventions><Reference>UMIN000021842</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer</ProtocolTitle><Sponsor>NSABP Foundation Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="41686"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>18</Patients><Biomarkers>COX-2; Mitogen-activated protein kinase 1; RAC-alpha serine/threonine-protein kinase; Sarcoplasmic/endoplasmic reticulum calcium ATPase 1</Biomarkers><Condition>Colorectal tumor</Condition><Controls></Controls><EnrollmentCount>18</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00087256; NSABP P-3; NSABP-P-3</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Incidence of Esophagitis, Peptic Ulcers and Small Intestinal Mucosal Lesions Induced by Loxoprofen, Etodolac and Celecoxib in Healthy Volunteers: A Prospective, Randomized, Comparative Trial</ProtocolTitle><Sponsor>Osaka Medical College</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="129586"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>33</Patients><Biomarkers></Biomarkers><Condition></Condition><Controls></Controls><EnrollmentCount>33</EnrollmentCount><Interventions>celecoxib; etodolac; famotidine; loxoprofen</Interventions><Reference>JPRN-UMIN000009475</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celebrex Premedication in Teeth With Symptomatic Irreversible Pulpitis</ProtocolTitle><Sponsor>Cairo University</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="319297"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>46</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>46</EnrollmentCount><Interventions>Celebrex</Interventions><Reference>CELEBREX PREMEDICATION; NCT03339544</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy of Celecoxib 200 mg in Relieving Pain and Walking Dysfunction in Osteoarthritis of the Knee</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="13066"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>NCT00597415; Pfizer walking model; UH IRB 06-04-41</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-opioid analgesia after rotator cuff repair</ProtocolTitle><Sponsor>Henry Ford Health System</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="367994"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>hydrocodone-acetaminophen</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>Celebrex; Neurontin; acetaminophen; diazepam; ketorolac</Interventions><Reference>123191; NCT03818919</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pre-Prostatectomy Celecoxib or Placebo</ProtocolTitle><Sponsor>OHSU Knight Cancer Institute</Sponsor><TrialStatus>Suspended</TrialStatus><Trial id="266164"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>28</Patients><Biomarkers>Androgen receptor; Dinoprostone; Prostaglandin G/H synthase 2; Prostate-specific antigen</Biomarkers><Condition>Prostate tumor</Condition><Controls></Controls><EnrollmentCount>34</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>HOR-01019-L; IRB00001004; NCT02840162</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II Trial of Anastrozole With Celecoxib as First-Line Therapy for Postmenopausal Women With Hormone Receptor Positive Breast Cancer</ProtocolTitle><Sponsor>Central Adelaide Local Health Network Inc</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="131251"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>43</Patients><Biomarkers>Hormone receptor</Biomarkers><Condition>Breast tumor</Condition><Controls></Controls><EnrollmentCount>43</EnrollmentCount><Interventions>anastrozole; celecoxib</Interventions><Reference>ACTRN12605000498695</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>COREA</ProtocolAcronym><ProtocolTitle>Effects of Celecoxib After Percutaneous Coronary Intervention</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12643"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>271</Patients><Biomarkers></Biomarkers><Condition>Coronary arteriosclerosis</Condition><Controls></Controls><EnrollmentCount>260</EnrollmentCount><Interventions>aspirin; celecoxib; clopidogrel</Interventions><Reference>134-가-37 (sic); COREA; NCT00292721</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis</ProtocolTitle><Sponsor>Columbia University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="333488"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Spondylarthritis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib; diclofenac; indomethacin; meloxicam; omeprazole</Interventions><Reference>AAAR3505; NCT03473665</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis</ProtocolTitle><Sponsor>Columbia University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="333488"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Ankylosing spondylitis</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>celecoxib; diclofenac; indomethacin; meloxicam; omeprazole</Interventions><Reference>AAAR3505; NCT03473665</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym>MAST</ProtocolAcronym><ProtocolTitle>Multi-modal Analgesic Strategies in Trauma</ProtocolTitle><Sponsor>University of Texas Health Science Center Houston</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="333255"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1616</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>1616</EnrollmentCount><Interventions>Celebrex; acetaminophen; gabapentin; ketorolac; lidocaine; naproxen; opiod therapy; pregabalin; regional anesthesia therapy; tramadol</Interventions><Reference>HSC-MS-18-0036; MAST; NCT03472469</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="266215"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>DNA (cytosine-5)-methyltransferase 1; Probable ATP-dependent RNA helicase DDX53; Regulatory T-Lymphocytes</Biomarkers><Condition>Metastasis</Condition><Controls>5-fluoro-2-deoxycytidine; celecoxib; decitabine</Controls><EnrollmentCount></EnrollmentCount><Interventions>5-fluoro-2-deoxycytidine; celecoxib; decitabine; pulmonary metastasectomy</Interventions><Reference>16-C-0146; 160146; NCT02839694</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="266215"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>DNA (cytosine-5)-methyltransferase 1; Probable ATP-dependent RNA helicase DDX53; Regulatory T-Lymphocytes</Biomarkers><Condition>Sarcoma</Condition><Controls>5-fluoro-2-deoxycytidine; celecoxib; decitabine</Controls><EnrollmentCount></EnrollmentCount><Interventions>5-fluoro-2-deoxycytidine; celecoxib; decitabine; pulmonary metastasectomy</Interventions><Reference>16-C-0146; 160146; NCT02839694</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="266215"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>DNA (cytosine-5)-methyltransferase 1; Probable ATP-dependent RNA helicase DDX53; Regulatory T-Lymphocytes</Biomarkers><Condition>Melanoma</Condition><Controls>5-fluoro-2-deoxycytidine; celecoxib; decitabine</Controls><EnrollmentCount></EnrollmentCount><Interventions>5-fluoro-2-deoxycytidine; celecoxib; decitabine; pulmonary metastasectomy</Interventions><Reference>16-C-0146; 160146; NCT02839694</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="266215"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>DNA (cytosine-5)-methyltransferase 1; Probable ATP-dependent RNA helicase DDX53; Regulatory T-Lymphocytes</Biomarkers><Condition>Germ cell and embryonic cancer</Condition><Controls>5-fluoro-2-deoxycytidine; celecoxib; decitabine</Controls><EnrollmentCount></EnrollmentCount><Interventions>5-fluoro-2-deoxycytidine; celecoxib; decitabine; pulmonary metastasectomy</Interventions><Reference>16-C-0146; 160146; NCT02839694</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="266215"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients></Patients><Biomarkers>DNA (cytosine-5)-methyltransferase 1; Probable ATP-dependent RNA helicase DDX53; Regulatory T-Lymphocytes</Biomarkers><Condition>Lung tumor</Condition><Controls>5-fluoro-2-deoxycytidine; celecoxib; decitabine</Controls><EnrollmentCount></EnrollmentCount><Interventions>5-fluoro-2-deoxycytidine; celecoxib; decitabine; pulmonary metastasectomy</Interventions><Reference>16-C-0146; 160146; NCT02839694</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase I, Randomized, Parallel, Double-blind, Placebo-controlled Trial of Celecoxib added to Sertraline in Patients with Moderate to Severe Depression</ProtocolTitle><Sponsor>National Iranian Oil Company Health Organization, Tehran University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="106710"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>40</Patients><Biomarkers>Serum IL-6</Biomarkers><Condition>Major depressive disorder</Condition><Controls></Controls><EnrollmentCount>40</EnrollmentCount><Interventions>celecoxib; sertraline</Interventions><Reference>5402; IRCT138903124090N1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29188"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>COX-2; IL-10; IL-12; IL-6; basic fibroblast growth factor (bFGF); interferon (IFN)-gama; thyroglobulin; vascular endothelial growth factor (VEGF)</Biomarkers><Condition>Metastasis</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000302439; NCT00061906; OSU-0239; OSU-0239; OSU-2003C0003</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Celecoxib in Treating Patients With Progressive Metastatic Differentiated Thyroid Cancer</ProtocolTitle><Sponsor>Ohio State University Comprehensive Cancer Center</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="29188"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>32</Patients><Biomarkers>COX-2; IL-10; IL-12; IL-6; basic fibroblast growth factor (bFGF); interferon (IFN)-gama; thyroglobulin; vascular endothelial growth factor (VEGF)</Biomarkers><Condition>Thyroid tumor</Condition><Controls></Controls><EnrollmentCount>25</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>CDR0000302439; NCT00061906; OSU-0239; OSU-0239; OSU-2003C0003</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ERLO-XIB</ProtocolAcronym><ProtocolTitle>Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective, Randomized Study</ProtocolTitle><Sponsor>Tata Memorial Centre, Tata Memorial Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259032"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Cellular tumor antigen p53; Epidermal growth factor receptor; Prostaglandin G/H synthase 2; Tumor mass; Vascular endothelial growth factors</Biomarkers><Condition>Squamous cell carcinoma</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>celecoxib; celecoxib; erlotinib; erlotinib</Interventions><Reference>830; CT-Drugs/206/2011; CTRI/2012/07/002828; ERLO-XIB; NCT02748707; TMC IRB project no 830</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>ERLO-XIB</ProtocolAcronym><ProtocolTitle>Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective, Randomized Study</ProtocolTitle><Sponsor>Tata Memorial Centre, Tata Memorial Hospital</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="259032"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>64</Patients><Biomarkers>Cellular tumor antigen p53; Epidermal growth factor receptor; Prostaglandin G/H synthase 2; Tumor mass; Vascular endothelial growth factors</Biomarkers><Condition>Mouth tumor</Condition><Controls></Controls><EnrollmentCount>64</EnrollmentCount><Interventions>celecoxib; celecoxib; erlotinib; erlotinib</Interventions><Reference>830; CT-Drugs/206/2011; CTRI/2012/07/002828; ERLO-XIB; NCT02748707; TMC IRB project no 830</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer</ProtocolTitle><Sponsor>Tel Aviv Sourasky Medical Center</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="43301"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients></Patients><Biomarkers></Biomarkers><Condition>Pancreas tumor</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>celecoxib; curcumin; gemcitabine</Interventions><Reference>NCT00486460; TASMC-07-NA-132-CTIL</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="22224"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>386</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls>ibuprofen</Controls><EnrollmentCount>393</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191063; NCT00620867</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase III Study of CG-100649 in Osteoarthritis Patients</ProtocolTitle><Sponsor>CrystalGenomics Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="104488"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>362</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate</Biomarkers><Condition>Osteoarthritis</Condition><Controls>celecoxib</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>polmacoxib</Interventions><Reference>CG100649-3-01; NCT01765296</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II/III, multicenter, double-blind, placebo-controlled, parallel-group clinical trial to evaluate the efficacy and tolerability of two doses of celecoxib in treating the signs and symptoms of osteoarthritis of the knee</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79913"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>715</Patients><Biomarkers></Biomarkers><Condition>Osteoarthritis</Condition><Controls></Controls><EnrollmentCount>715</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191251; N49-98-02-087</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>NSAID#8 Study</ProtocolAcronym><ProtocolTitle>Celecoxib versus Naproxen for prevention of recurrent ulcer bleeding in arthritis patients</ProtocolTitle><Sponsor>Chinese University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8680"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>514</Patients><Biomarkers></Biomarkers><Condition>Bleeding</Condition><Controls>esomeprazole; naproxen</Controls><EnrollmentCount>514</EnrollmentCount><Interventions>aspirin; celecoxib; esomeprazole</Interventions><Reference>8N Study; CONCERN; NCT00153660; NSAID#8 Study</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>NSAID#8 Study</ProtocolAcronym><ProtocolTitle>Celecoxib versus Naproxen for prevention of recurrent ulcer bleeding in arthritis patients</ProtocolTitle><Sponsor>Chinese University of Hong Kong</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="8680"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>514</Patients><Biomarkers></Biomarkers><Condition>Cardiovascular disease</Condition><Controls>esomeprazole; naproxen</Controls><EnrollmentCount>514</EnrollmentCount><Interventions>aspirin; celecoxib; esomeprazole</Interventions><Reference>8N Study; CONCERN; NCT00153660; NSAID#8 Study</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Efficacy Of Pretreatment By Medicines On Post Endodontic Pain</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="135457"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>Gelofen; celecoxib</Interventions><Reference>705; IRCT201106306926N1</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled, parallel, multiple-dose clinical trial to compare the effects of celecoxib and placebo for the treatment of patients with ulcerative colitis in remission</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Status not specified</TrialStatus><Trial id="79883"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>221</Patients><Biomarkers></Biomarkers><Condition>Ulcerative colitis</Condition><Controls></Controls><EnrollmentCount>221</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191128; N49-01-02-198</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Laser and Medical Treatment of Diabetic Macular Edema</ProtocolTitle><Sponsor>National Eye Institute</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="96978"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Blood pressure; Cholesterol; Hemoglobin A1C; Lipids</Biomarkers><Condition>Diabetic macular edema</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>celecoxib; vitamin E</Interventions><Reference>02-EI-0063; 020063; NCT00027287</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Compare Celecoxib and Ibuprofen Sr In The Management Of Acute Pain Post Orthopedic Or Gynecological Surgery</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12942"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>146</Patients><Biomarkers></Biomarkers><Condition>Pain</Condition><Controls>ibuprofen SR</Controls><EnrollmentCount>132</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>A3191086; NCT00150280</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of antiinflammatory agent effect for TMD (myalgia of the masticatory muscle and arthralgia of the temporomandibular joint)</ProtocolTitle><Sponsor>Saga University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="319302"></Trial><Drug id="12135">celecoxib</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Temporomandibular joint syndrome</Condition><Controls>Mazuren; loxoprofen</Controls><EnrollmentCount>100</EnrollmentCount><Interventions>celecoxib</Interventions><Reference>UMIN000029972</Reference></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>